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Executive Summary 
 
Behavioural sensitisation is a progressive enhancement of stereotypic or 
locomotor behaviour following repeated intermittent administration of a 
psychostimulant or stress. It is a phenomenon thought to underlie many 
neuropsychiatric disorders (e.g. schizophrenia, addiction, depressive disorders, 
dyskinesia, and psychosis) although its own mechanism remains contentious. In 
this thesis a multidisciplinary approach was used to investigate the role of 
dopamine in behavioural sensitisation. Different in vivo and ex vivo techniques 
were used to assess and elucidate putative changes in dopaminergic 
neurotransmission of behaviourally sensitised animals. If so, this improved 
understanding of behavioural sensitisation could provide a better understanding 
of the pathophysiologies of neuropsychiatric disorders and provide more insight 
into why existing pharmacotherapies for these disorders are able to confer only 
modest benefit. Moreover, this improved understanding can lead to development 
of new medication and more effective therapies to treat neuropsychiatric 
disorders and therapies that address the specific problems associated with them. 
Previously, an oversimplified view of neurotransmitter release was used for the 
development of current available drugs, i.e. stabilising either the attenuated or 
increased release of neurotransmitters without considering the involvement of 
synaptic plasticity. Therapies being used with modest effectiveness regulate 
dopamine transmission levels, suggesting a putative role for dopamine. The 
present study used chronic intermittent nicotine administration in rodents to 
induce behavioural sensitisation which was monitored behaviourally by 
measuring locomotor activity. Further studies were performed ex vivo assessing 
receptor binding, intracellular cAMP accumulation and electrically stimulated 
dopamine release. Prior to the pharmacological assessments, a novel LC-MS/MS 
method to measure (cyclic-) nucleotides was developed and a fast cyclic 
voltammetry (FCV) technique was established to measure real-time 
neurotransmitter release. Specific pharmacological tools were used to identify the 
role of dopaminergic neurotransmission in behavioural sensitisation. Finally, the 
ex vivo findings using tissue from sensitised and non-sensitised animals were 
compared to those findings obtained in vivo. 
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Abstract 
 
OBJECTIVES: Extensive research efforts have provided insights into 
understanding the aetiology of neuropsychiatric disorders, however remains still 
not fully understood. Herein it is hypothesised that understanding the mechanism 
underlying the behavioural sensitisation can help to elucidate the responsible 
mechanism(s) underlying certain neuropsychiatric disorders, and eventually could 
lead to improved (pharmaco) therapies. The present study investigated the role of 
the dopamine D1 receptor in the mechanism underlying behavioural sensitisation. 
METHODS: Rats were chronically (5 days) treated with nicotine to induce 
behavioural sensitisation. Following a withdrawal period, rats were pre-treated 
with SCH-23390 and/or given a final nicotine challenge. Subsequent ex vivo 
cAMP accumulation was determined using a 96-well filterplate method and LC-
MS/MS analyses, and binding affinities were assessed ex vivo using a 96-well 
filterplate method and [3H]-SCH-23390. Electrically stimulated dopamine release 
was determined using the fast cyclic voltammetry (FCV) technique. A selection of 
specific pharmacological tools was tested across all assays. 
RESULTS: The intermittent treatment regime produced a robust expression of 
sensitisation, showing it is a long lasting phenomenon. The nicotine induced 
sensitisation was dose dependently antagonised by the dopamine D1 receptor 
antagonist SCH-23390. FCV experiments showed that the frequency dependent 
electrical modulation of dopamine release can be altered by nicotine and 
moreover, for the first time, it was shown that this effect can be altered by 
dopamine D1 receptor ligands. The developed LC-MS/MS method was validated 
and applied in vitro to determine cAMP accumulation in cell cultures and brain 
tissue samples. Behavioural sensitisation increased the efficacy of dopamine for 
the dopamine D1 receptor, and decreased the potency of D1 agonists on cAMP 
accumulation ex vivo, however, did not affect the affinity of the tested 
dopaminergic ligands for the dopamine D1 receptor. 
CONCLUSIONS: The present study showed that selective antagonism of the 
dopamine D1 receptor blocks the expression of nicotine induced behavioural 
sensitisation in vivo, and suggests that this is a result of the enhanced response 
of neurones in the dorsal striatum to dopamine D1 receptor activation. This thesis 
 Abstract 
 
 
xvi 
 
presents a successful multidisciplinary approach which resulted in additional 
information about the mechanism underlying behavioural sensitisation and 
showed an important role for the dopamine D1 receptor. Furthermore, the 
described approach provides a successful framework to study behavioural 
sensitisation which also can be used for future studies and ultimately the 
elucidation of the mechanism(s) underlying neuropsychiatric disorders. 
 
Keywords: Behavioural sensitisation, nicotine, dopamine D1 receptor, cAMP, 
neuropsychiatric disorders 
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Chapter 1. General Introduction 
 
Abstract.  
OBJECTIVES: Behavioural sensitisation is a phenomenon which can be 
developed following repeated intermittent stimulation by administration of a 
psychostimulant or stress. Its mechanism is suggested to play an important role 
in the underlying mechanism of neuropsychiatric disorders like schizophrenia, 
addiction, depressive disorders, dyskinesia, and psychosis. Therefore, the 
understanding of behavioural sensitisation could help to characterise these 
neuropsychiatric disorders and improve therapies to treat these major health and 
social problems. The objective of this chapter was to provide an introduction and 
literature review of the extensive research efforts into behavioural sensitisation 
and the current status of this research, in particular in relation to putative 
mechanisms underlying neuropsychiatric disorders. 
CONCLUSIONS: Behavioural sensitisation is a well described and characterised 
phenomenon supported by preclinical studies (i.e. behavioural, cellular, and 
molecular) and clinical evidence, in control and disease models. A large number 
of reports suggest a common mechanism underlying neuropsychiatric disorders 
and point towards behavioural sensitisation as the putative mechanism. A better 
understanding of the mechanism(s) underlying behavioural sensitisation might 
give new insights to improve currently available (pharmaco-) therapies for the 
treatment of neuropsychiatric disorders. Preclinical studies suggest a deficiency 
in dopaminergic neurotransmission to be responsible for behavioural sensitisation. 
However, more advanced in vivo behavioural studies and ex vivo mechanistic 
studies are required to elucidate the exact role of dopamine in this phenomenon. 
In addition to the dopaminergic hypothesis, it has been shown that different 
aspects of the cAMP pathway are involved in behavioural sensitisation and can 
be used as a marker or target in the discovery of putative mechanisms underlying 
behavioural sensitisation.  
 
 
Keywords: Behavioural sensitisation, nicotine, dopamine D1 receptor, cAMP, 
neuropsychiatric disorders 
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1.1 INTRODUCTION 
 
Psychostimulants administered to humans or animals can induce different 
behaviours including locomotor activation and stereotypic behaviours. Repeated 
intermittent administration of psychostimulants can develop behavioural 
sensitisation (Downs and Eddy, 1932), a phenomenon characterised by either a 
progressive enhancement in behavioural activity or an enduring behavioural 
hypersensitivity to these drugs (Utena, 1966; Robinson and Becker, 1986; 
Tadokoro and Kuribara, 1986). The origin of stimulation can vary from 
psychological factors such as stress, trauma or reward, and environmental 
stressors, or by chemical factors during prolonged drug use. The prolonged 
neurological stimulation can evolve in behavioural sensitisation with symptoms 
such as increased stereotypical behaviour or locomotor activity.  
 
Dopamine, serotonin and noradrenaline are all monoamine neurotransmitters and 
can be released peripherally as well as in the brain where they play an important 
role in emotion, cognition and motor activities. Currently, most of the available 
drugs to treat neuropsychiatric disorders like anxiety, depression and 
schizophrenia mainly target the synthesis or the rate of release of these 
monoaminergic neurotransmitters. Additionally, preclinical findings including 
neurochemical, electrophysiological, molecular and morphological changes are 
reported following psychostimulant induced behavioural sensitisation (Robinson 
and Berridge, 1993; Robinson and Becker, 1986; Sato et al., 1992). Furthermore, 
the dopaminergic pathway is shown to be important in behavioural sensitisation 
(Kalivas and Stewart, 1991). The observation of symptoms following drug 
administration or psychosocial stressors has led to the hypothesis that processes 
homologous to behavioural sensitisation may underlie the development and 
expression of chronic and recurrent affective disorders (in animals; sensitisation 
to repeated stress, Doherty and Gratton, 1992). More recently, in addition to the 
preclinical observations, clinical evidence supports these findings and also 
suggests an important role for behavioural sensitisation in humans. For example, 
Post and colleagues described the importance of the behavioural sensitisation 
model to give additional rationale to the development of bipolar disorders in 
humans (Post et al., 2001). Strakowski and colleagues reported behavioural 
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sensitisation following amphetamine challenges in humans (Strakowski et al., 
1996), and observed that patients with schizophrenic psychosis, in contrast to 
healthy volunteers, did not show a progressive increase in symptoms after an 
amphetamine challenge, meaning that they were already sensitised or do not 
sensitise (Strakowski et al., 1997). Additionally, significantly lower dopamine D1 
receptor binding in the ventral striatum and caudate of chronic smokers was 
observed (Dagher et al., 2001). Significantly lower striatal dopamine D2 receptor 
availability has been observed in patients with cocaine (Volkow et al., 1997) and 
methamphetamine (Volkow et al., 2001) dependence. Recently, more evidence 
of behavioural sensitisation as a model of stress induced psychosis in humans 
was shown by van Os and colleagues (Myin-Germeys et al., 2005; Lataster et al., 
2010). 
Based on these findings, and the association of behavioural sensitisation with 
addiction, a few hypotheses to explain behavioural sensitisation are proposed 
and strongly point towards an important role for the neurotransmitter dopamine. 
Dopamine is an endogenous neurotransmitter in the brain which is involved in the 
neurobiology and symptoms of many neuropsychiatric disorders (for review see 
Marsden, 2006). In this chapter (Chapter 1) a brief overview will be presented on 
dopaminergic signalling. However, despite all the available information, little is 
known about the functionality and the exact mechanisms of how dopamine 
signalling is involved in behaviour. The future challenge remains to understand 
how dopamine is exactly involved in neuropsychiatric disorders and their 
behaviours. 
 
The dopamine pathway can be triggered by binding of its endogenous ligand (i.e. 
dopamine) or synthesised ligand to its cognate receptor (Figure 1-1). This 
specific receptor, also called the dopamine receptor, is a member of the 7-
transmembrane domain receptor family and consists of different subtypes, i.e. D1 
to D5 (Neve and Neve, 1997). These subtypes can be grouped into two receptor 
families: the dopamine D1-like receptors (which include the D1 and D5 receptors 
subtypes) and the dopamine D2-like receptors (including the D2, D3 and D4 
receptors subtypes) (Garau et al., 1978; Kebabian and Calne, 1979). The 
dopamine receptor subtypes can enhance (D1-like) or inhibit (D2-like) through 
activity of adenylate cyclase, coupling to stimulatory (Gas) or inhibitory (Gai) G 
proteins, respectively. Upon the binding of a ligand to the corresponding receptor 
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protein, the conformation of this protein will change and activate intracellular 
guanine nucleotide binding proteins, and therefore the dopamine receptor is also 
a member of the G-protein coupled receptor (GPCR) family. The G-protein 
(guanine nucleotide-binding protein) is a heterotrimer with an alpha (α), beta (β) 
and gamma (γ) subunit. Receptor activation will displace the guanosine 
diphosphate (GDP) from the alpha subunit by guanosine triphosphate (GTP) and 
subsequently release the alpha-subunit and beta-gamma dimmer from the G-
protein heterotrimer. GTP is catalysed back to GDP via an enzymatic 
autoregulation process, by the alpha-subunit itself and re-joined by the beta-
gamma dimer. There are 4 main subtypes known for the alpha unit of the G-
protein: Gs, Gi, Gq and Go. There are also distinct families for the beta and 
gamma subunits, but they will not be discussed here. Receptors are not 
specifically coupled to a single G-protein subtype and the wide variety of receptor 
subtypes and G-protein subtypes can result in many possible pathways. 
Moreover, not only the alpha subunit but also the beta-gamma dimer can affect 
enzymes like adenylate cyclase (Bayewitch et al., 1998) and, in addition, several 
families of proteins have been characterised that act as “accessory” G-protein 
signal regulators (AGS: Berman and Gilman, 1998; Blumer and Lanier, 2003), 
revealing even more possible pathways for controlling downstream GPCR effects. 
Previous studies have shown that behavioural sensitisation can affect G-proteins 
(Nestler et al., 1990; Terwilliger et al., 1991; Striplin and Kalivas, 1993; for review 
see Nestler, 2001a), and Bowers and colleagues showed that the regulatory 
protein AGS3 was strongly elevated in PFC and nucleus accumbens following 
chronic cocaine treatment (Bowers et al., 2004) and involved in addiction 
associated behaviours (Bowers et al., 2003). 
G-proteins can also affect ion-channels directly or by targeting one of the 
following three enzymes: Adenylate Cyclase, Phospholipase C and 
Phospholipase A (Figure 1-1). To add to the complexity of GPCR signalling, 
these specific enzymes and their subtypes can also differ widely among cells. 
These enzymes typically activate a diffusible second messenger which can 
trigger a cascade of biochemical reactions that ultimately can alter neuronal 
function. Theoretically, the actions of neurotransmitters (including dopamine) are 
mainly mediated through the activation or inhibition of the catalytic unit of 
adenylate cyclase by Gαs or Gαi, respectively (Gilman, 1989; Neer, 1995). The 
adenylate cyclase (AC; EC 4.6.1.1) family consists of at least 10 distinct 
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adenylate cyclase isoforms (see Patel et al., 2001 for review). All of these 
isoforms are integral transmembrane proteins (except for one that is found to be 
soluble, sAC) and consist of two sets of six transmembrane domains. In the last 
few decades, Vogel‟s laboratory has performed extensive studies to adenylate 
cyclase and shown a distinct role for the specific isozymes of adenylate cyclase 
in the effects of chronic treatment with opioids (Avidor-Reiss et al., 1995a; 1995b; 
1996; 1997; Kato et al., 1998) or cannabinoids (Rhee et al., 2000) in transfected 
cells. 
An important biological function of adenylate cyclase is the cyclisation of 
adenosine triphosphate (ATP) to adenosine-3‟,5‟-cyclic monophosphate (cAMP) 
(Sutherland et al., 1962). cAMP, discovered by Rall and Sutherland (Rall et al., 
1958; Sutherland and Rall, 1958) is one of the most important second 
messengers in biology. The second domain of adenylate cyclase contains two 
catalytic domains which can form an intramolecular hetrodimer which activates 
the formation of cAMP (Krupinski et al., 1989). Subsequently, adenylate cyclase 
will attack the 3‟-OH group of the α-phosphate of ATP which will result in the 
release of cAMP and pyrophosphate (Tesmer et al., 1997; Zhang et al., 1997). 
Following its synthesis and release, cAMP can target different effectors (Figure 
1-1). A key signalling pathway is activation of protein kinases. cAMP can bind to 
the homodimerised regulatory subunits of the cAMP-dependent protein kinase 
(PKA; EC 2.7.1.37) and phosphorylates serine/threonine (Meinkoth et al., 1993) 
which will cause dissociation from the catalytic subunit homodimer and results in 
phosphorylation of substrate proteins including enzymes, ion channels and 
transcription regulators. The key effector protein, protein kinase A (PKA), is also 
found downstream of the dopamine D1-like and D2-like receptors intracellular 
pathways and is essential for their effects (Flores-Hernandez, et al., 2000). 
Psychostimulants are also able to activate the cAMP-pathway which 
subsequently activates a wide variety of downstream signalling pathways 
(Svenningsson et al., 2003). Activation of PKA can further modulate the 
phosphorylation state of DARPP-32. It has been shown that dopamine D1 and D2 
receptor activation may result in opposite and phosphorylation site specific 
regulation of DARPP-32 levels (Hamada et al., 2004; Svenningsson et al., 2004). 
The effect of systemic nicotine on dopamine levels in the nucleus accumbens is 
also mediated through PKA (Inoue et al., 2007) and increases phosphorylation of 
DARPP-32 at both Thr34 and Thr75 (Zhu et al., 2005), which could be a direct 
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effect on DARPP-32 signalling through α4 nAChRs (Hamada et al., 2005) or 
through nicotine induced dopamine release, as activation of nAChRs can result in 
the release of dopamine, particularly in the striatum (Westfall, 1974). Furthermore, 
nicotine can stimulate release of serotonin (5HT) in the striatum (Reuben and 
Clarke, 2000) and subsequently produce an increase in phospho-Thr34-DARPP-
32 and a decrease in phospho-Thr75-DARPP-32 (Svenningsson et al., 2002), 
similar to dopamine D1 receptor mediated activation. 
Long term changes in the cAMP pathway (for example increase in PKA activity) 
have been reported following chronic cocaine exposure (Terwilliger et al., 1991; 
Unterwald et al., 1996; Miserendino and Nestler, 1995). cAMP can directly bind to 
and regulate a subtype of ion channel and early physiological studies have 
shown that cyclic nucleotides can directly control their opening (Fesenko et al., 
1985). It became evident that these channels contain an intracellular cyclic 
nucleotide binding domain that gated the opening of the channels upon binding 
cAMP or cGMP (reviewed by Zagotta and Seigelbaum, 1996; Zufall et al., 1997; 
Kaupp and Seifert, 2002; Mansuy, 2004; Dremier et al., 2003). These channels 
are now known as cyclic nucleotide gated (CNG) channels. 
 
cAMP is removed by a group of enzymes called phosphodiesterases (PDE; EC 
3.1.4.17) (Butcher et al., 1962). There are at least 19 subtypes of 
phosphodiesterase (Conti et al., 1999) but only a limited number are known to 
specifically catalyze the  hydrolysis of the 3‟-carbon phosphoester bond of cAMP 
to the corresponding 5‟-monophosphate, AMP (e.g. PDE4). Using selective PDE 
inhibitors it has been shown that PDEs are also involved in behavioural 
sensitisation (e.g. PDE4, Knapp et al., 2001; Thompson et al., 2004). 
Guanosine-3‟,5‟-cyclic monophosphate (cGMP) together with cAMP are the two 
most important cyclic nucleotide second messengers in biology. cGMP was 
originally isolated from urine (Price et al., 1967) but later also found in many 
tissues including brain tissue (Goldberg et al., 1969; Ishikawa et al., 1969). Like 
cAMP, cGMP is synthesised by a specific enzyme, in this case guanylate cyclase 
(GC; EC 4.6.1.2) (Hardman et al., 1969; Schultz et al., 1969) and like adenylate 
cyclase is found in different subtypes (i.e. soluble forms (sGC) and 
transmembrane isoforms (tmGC)). 
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Figure 1-1 Signalling pathways of the dopamine D1 and D2 receptors 
Schematic representations of hypothesized dopamine D1 and D2 receptor 
activation-induced signalling pathways. Dopamine, or dopamine receptor ligands, 
can activate either or both D1 or D2 receptors and subsequently activate AC-
cAMP-PKA-CREB signaling and CRE-mediated gene expression. D1R/D2R, 
dopamine receptor 1/2; AC, adenylate cyclase; PLC, phospholipase C; DAG, 
diacylglycerol; GC, guanylate cyclase; PDE, phosphodiesterase; PKA/C/G, 
phosphokinase A/C/G; MAPK, mitogen activated protein kinase; PP-1, protein 
phosphatase-1; IP3, inositolphosphate3; ATP, adenosine triphosphate; cAMP, 
cyclic adenosine monophosphate; GTP, guanosine triphosphate; cGTP, cyclic 
guanosine monophosphate; CREB, cAMP response element-binding; CNGC, 
cyclic nucleotide gated channels. References used, Hopf et al., 2003; Neve et al., 
2004; Hyman et al., 2006; McClung and Nestler, 2008; Nishi et al., 2011, and 
references herein. 
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Psychostimulants like cocaine or amphetamine affect dopamine release directly 
by dopamine receptor activation or dopamine uptake transporters. However, 
systemically administered nicotine will activate nicotinic acetylcholinergic 
receptors (nAChRs) prior to other systems. The acetylcholinergic receptor family 
(AChRs) are transmembrane receptors which can be divided into two sub-
classes: the nicotinic (ionotropic, nAChRs) and muscarinic (metabotropic, 
mAChRs) acetylcholinergic receptors. The nAChR‟s are members of the 
superfamily of ligand-gated ion channels and are composed of a diversity of 
subtypes (Dani, 2001). To date eight alpha subunits (α2 – α9) and three beta 
subunits (β2 - β4) are known and are found in many different combination (Conroy 
and Berg, 1995; Colquhoun and Patrick, 1997; Lukas, 1998; Lukas et al., 1999). 
The three properties of these receptors that contribute to their physiological 
effects include activation, desensitisation, and upregulation following activation. 
Each of these phenomena is likely to be involved in behavioural sensitisation to 
nicotine, but the relative importance of each is still unknown (Picciotto et al., 
2008). Different subtypes of the nAChR are reported to be involved in the nicotine 
elicited effect on locomotor activity (e.g. α6, Le Novere et al., 1999; α4β2, Goutier 
et al., manuscript in preparation). nAChR antagonists are potential 
antidepressants (a hypercholinergic hypothesis, Shytle et al., 2002) and, 
moreover, nAChR (partial-) antagonists also have been shown to attenuate 
behavioural sensitisation, for example varenicline blocks nicotine induced 
sensitisation (Goutier et al., manuscript in preparation).  
nAChRs are widely expressed on dopaminergic cell bodies and terminals, 
neighbouring afferents and interneurones (Gotti et al., 2007; 2009; 2010). 
nAChRs are specifically located in midbrain dopaminergic neurones that project 
to the dorsal striatum, nucleus accumbens and prefrontal cortex. These 
projections are correlated to specific behaviours, notably motor control, „reward‟ 
and executive function, respectively. Dopamine is an important neurotransmitter 
and once released by the cell, and extracellularly available in the synapse, it can 
bind and activate dopamine receptors. Therefore, the actual synaptic 
concentration of dopamine is of great importance. In the dorsal striatum, a brain 
area with relatively high dopamine levels, synaptic dopamine levels are regulated 
by i) the efflux of dopamine from intra-cellular vesicles, and ii) the function of 
uptake transporters like the dopamine transporter (DAT) and vesicular 
monoamine transporter (VMAT). Dopaminergic neurotransmission in subcortical 
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regions like the basal ganglia, including the striatum, is synaptic and the uptake 
transporters are of great importance. In cortical regions there are only a few 
transporters and dopamine is allowed to diffuse away from the synapse, a 
phenomenon called “volume transmission”. The mechanisms through which 
nAChRs modulate the activity of dopaminergic neurones and ascending 
pathways, is extensively reviewed by Livingstone and Wonnacott (2009). 
 
Specific reuptake inhibitors, including psychostimulants (e.g. cocaine and 
amphetamine) and antidepressants have their mode of action by inhibition of 
reuptake thus increasing the extracellular dopamine levels. It is also suggested 
that the DAT is involved in cocaine sensitisation (Cass et al., 1993; Alburges et 
al., 1993; Zahniser et al., 1995) and the DAT mRNA levels are upregulated 
following amphetamine sensitisation (Shilling et al., 1997). Daily administration of 
cocaine decreased [3H]-dopamine uptake (24 h after last injection), increased 
receptor affinity (Km) and had no change on the maximum binding rate (Vmax) in 
rat nucleus accumbens, although it had no effect on uptake in the striatum 
(Izenwasser and Cox, 1990). This study also showed that the potency of cocaine 
to inhibit [3H]-dopamine uptake was increased following chronic cocaine 
treatment compared to saline. In contrast, it was shown that after 3 days of 
withdrawal following chronic cocaine administration (14 days) DAT density (Bmax) 
or affinity (Kd) were not affected in the nucleus accumbens, using [
3H]-GBR-
12935 as the radioligand, however the density of the DAT was increased in the 
striatum (Claye et al., 1995).  
Moreover, previous results suggests that nicotine can inhibit DAT indirectly 
through nAChR (Wonnacott, 1997), although contradictory results are reported 
on the effect of nicotine on the mRNA expression of DAT following chronic 
nicotine administration in vivo (Ferrari et al., 2002; Li et al., 2004). In humans, 
striatal uptake of [18F]-fluoro-dopa (fluoro-3,4-dihydroxyphenylalanine, a 
dopamine precursor) was 16-29% higher in regular smokers compared to non-
smoking subjects (Salokangas et al., 2000), which also supports a role for 
nicotine in dopamine uptake. 
 
The basal ganglia circuit plays a key role in the regulation of voluntary 
movements as well as in behavioural control and cognitive functions (Graybiel et 
al., 1994). The mesocorticolimbic dopamine pathway, which arises in the ventral 
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tegmental area and innervates the nucleus accumbens among other regions, has 
been implicated in mechanisms underlying neuropsychiatric disorders and 
behavioural sensitisation. The basal ganglia contains many different types of 
neurones which are modulated by numerous neurotransmitter systems including 
gamma-aminobutyric acidergic (GABAergic), dopaminergic, noradrenergic, 
glutamatergic, cholinergic, and peptidergic afferents. Changes or dysfunction 
between these different neurotransmitter systems in the basal ganglia can result 
in changes in behavioural responses. Previous reports have shown that nAChRs 
are located at neurones facilitating GABA and dopamine transmission within 
different brain areas, e.g. prefrontal cortex, thalamus, ventral tegmental area, 
substantia nigra, nucleus accumbens, and striatum (Clarke et al., 1984; Clark and 
Pert, 1985; Picciotto and Corrigall, 2002; Wonnacott et al., 2005). Like other 
psychostimulants, nicotine can also induce the release of dopamine in these 
areas (Clarke and Pert, 1985; Grady et al., 1992; Pontieri et al, 1996). Evidence 
from several studies suggests that dopamine D1 receptors in the cerebral cortex 
are primarily localised on GABAergic interneurones, and to a lesser degree on 
pyramidal excitatory amino acid neurones (Al-Tikriti et al, 1992). The dopamine 
D2 receptor is primarily localised on pyramidal cells and to a lesser degree on 
GABAergic interneurones (Al-Tikriti et al, 1992; Vincent et al., 1995). 
The striatum is known to be involved in inhibitory as well as excitatory 
neurotransmission pathways, i.e. indirect inhibitory: Cx (D2 MSN)  STr  GPe 
 STN  GPi  Thal  Cx, and direct excitatory: Cx (D1 MSN)  STr  GPi 
 Thal  Cx, respectively. The striatum is important in linking the neuronal 
pathways of different brain areas and „filters‟ these signals as shown in Figure 1-2, 
although, it is important to recognise that this is an extremely oversimplified view 
of the anatomy and function of the basal ganglia and other neurotransmitters and 
neuromodulators (e.g. choline, histamine, serotonin) are involved as well.  
 
Nicotine is one of the most extensively abused drug in society and yet despite the 
enormous amount of literature about nicotine, only a limited number of studies on 
nicotine induced sensitisation are documented. Most studies report on the 
addictive properties, socioeconomic and health problem of nicotine. However, as 
behavioural sensitisation is considered a putative mechanism underlying 
addiction it is important to understand its own mechanism of action. Nicotine is of 
particular interest for studying dopaminergic mechanisms putatively underlying 
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behavioural sensitisation. Most studies to date have investigated the effect of 
direct acting dopaminergic drugs (e.g. cocaine and amphetamine) on behavioural 
sensitisation. However, the ability of indirect dopaminergic drugs to induce 
sensitisation is also of great interest for the development of novel 
pharmacotherapies. 
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Figure 1-2 Dopaminergic signalling complex of the basal ganglia 
Schematic showing the signalling complex of the basal ganglia including the 
established dopaminergic pathways: Mesolimbic (VTA (pc)  Nac); Mesocortical 
(VTA (pf)  PFCx); Nigrostriatal (SNc  CPu); Striatonigral (STr  SNc/SNr); 
and Striatopallidal (STr  GPe/GPi). VTA, ventral tegmental area; including PF, 
parafascicular; and PC, paracentral; STr, striatum; including NAc, nucleus 
cccumbens; and CPu, caudate putamen; GP; globus pallidus; including GPe, 
globus pallidus-external; and GPi, globus pallidus-internal; STN, subthalamic 
nucleus; SN, substantia nigra; including SNc, substantia nigra pars compacta; 
and SNr, substantia nigra pars reticulata; Thal, Thalamus. References used, 
Fallon and Moore, 1978; Johnson and North, 1992; Koob, 1992; DeLong, 2000; 
Hummel and Unterwald, 2002; Marsden, 2006; and Vezina et al., 2007.  
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Nicotine administered intra-nucleus accumbens induced behavioural sensitisation 
in rat (Kita et al., 1992). The nicotine induced sensitisation could be antagonised 
by systemic administration of SCH-23390 (Chapter 2). However, in addition intra-
accumbens infusion of SCH-23390 did not alter cocaine induced locomotor 
activity, despite occupying 40-60% of the dopamine D1-like receptors in the 
anterior nucleus accumbens core and shell (Neisewander et al., 1998). This 
suggests that regions other than the nucleus accumbens are involved in 
locomotor activity produced by intra-accumbens infusion of cocaine and that 
stimulation of dopamine D1 receptors in the nucleus accumbens is possibly 
important but not necessary for this behaviour. 
 
On the basis of previous findings, the present study investigated the role of 
dopamine in nicotine induced behavioural sensitisation at a behavioural, cellular, 
and molecular level in the rat dorsal striatum. With regards to the scope of the 
performed research, this thesis distinguishes five result chapters based on the 
techniques used.  
 
 
HYPOTHESES AND AIMS 
 
Hypothesis: Alterations in dopaminergic neurotransmission, particularly dopamine 
D1 receptor mediated, plays an important role in the mechanism underlying the 
expression of nicotine induced behavioural (i.e. locomotor) sensitisation. 
 
Aims: 
- Investigate the involvement of the dopamine pathway in nicotine induced 
locomotor sensitisation.  
- Characterize the interaction of the dopamine D1 with D2 receptors and nicotine 
on dopamine release. 
- Examine putative changes in dopamine D1 and D2 mediated cAMP 
accumulation and receptor binding pharmacology following chronic nicotine 
induced locomotor sensitisation. 
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Chapter 2. The effect of dopamine D1 receptor 
blockade on nicotine induced behavioural 
sensitisation 
 
Abstract. 
OBJECTIVES: Behavioural sensitisation is a phenomenon which can occur after 
repeated intermittent administration of a drug. It is also suggested as a putative 
mechanism underlying many neuropsychiatric disorders and therefore, 
understanding of its mechanism is of great importance. Intermittent chronic 
psychostimulant administration has been shown to induce behavioural 
sensitisation in the rat. This study investigated whether the expression of nicotine 
induced sensitisation could be blocked by a dopamine D1 receptor antagonist.  
METHODS: Rats were chronically (5 days), intermittently treated with vehicle or 
nicotine and ambulatory locomotor activity was measured using a photobeam 
system. Following different withdrawal periods (5 or 17 days), chronic nicotine 
treated animals were pre-treated with SCH-23390 (a dopamine D1 receptor 
antagonist) or vehicle and 30 min later challenged with nicotine. 
RESULTS: Acute nicotine (0.4 mg/kg, s.c.) significantly increased locomotor 
activity.  Subsequently, intermittent chronic nicotine administration for 5 days 
induced the development of locomotor sensitisation. Moreover, a nicotine 
challenge given after 5 or 17 days of withdrawal produced a robust sensitised 
response (i.e. expression of sensitisation) showing that sensitisation is a long 
lasting phenomenon. The expression of nicotine induced sensitisation was dose 
dependently antagonised by the dopamine D1 receptor antagonist SCH-23390. 
CONCLUSIONS: An in vivo locomotor activity paradigm was successfully 
validated to assess nicotine induced behavioural sensitisation in the rat. The 
present findings suggest a role for the dopaminergic D1 receptor in the underlying 
mechanism of the expression of nicotine induced behavioural sensitisation. This 
model can now be used for future ex vivo experiments investigating molecular 
mechanisms of behavioural sensitisation. 
 
Keywords: Locomotor activity, behavioural sensitisation, nicotine, SCH-23390 
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2.1 INTRODUCTION 
 
Impairment of dopaminergic neurotransmission in the mesolimbic, mesocortical 
and nigrostriatal pathways has been suggested to contribute to the pathogenesis 
of e.g. schizophrenia, tardive dyskinesia, psychoses, Parkinson‟s disease 
including L-DOPA (L-3,4,-dihydroxy phenylalanine) induced dyskinesia, and (drug) 
addiction (see Chapter 1). Each of these pathologies has their own hypothesis for 
underlying molecular mechanisms, although, they share one specific hypothesis 
explaining the pathologies by dysfunction of dopaminergic neurotransmission. 
Altered dopaminergic neurotransmission can be studied in the laboratory by 
using several different animal models, where the pathology can be (partially) 
mimicked by using different pharmacological tools. Psychostimulants are known 
to alter dopaminergic neurotransmission, and psychomotor stimulant drugs have 
been associated with different behavioural effects in rats depending on the 
administration regimen. With respect to locomotor behaviour, repeated 
intermittent daily injections of psychostimulants produces behavioural 
sensitisation, a gradual increase in drug induced locomotor activity or other 
behaviours (e.g. conditioned place preferences). In contrast to continuous 
infusion using a minipump leads to the development of behavioural tolerance, in 
which the locomotor behaviour is suppressed over time (Post, 1980; Burger et al., 
1994). Given this fact, one is able to study reversal, attenuation or blockade of 
the induced pathogenesis by examining novel hypotheses or drugs in these 
models. 
 
The first report to describe behavioural sensitisation was that of Tatum and 
colleagues (Tatum et al., 1929). However, behavioural sensitisation using 
psychostimulants was first described by Downs and Eddy (1932). Around the 
same time it was shown that daily cortical stimulation kindling showed 
progressive development of motor seizures (Watanabe, 1936), which was later 
found to induce long-term sensitisation (Goddard, 1969). Many years later 
behavioural sensitisation was proposed as a model for stimulant induced 
psychosis (Segal et al., 1983; Post et al., 1984; Robinson and Becker, 1986) and 
has been extensively linked to drug addiction (Robinson and Berridge, 1993).  
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Behavioural sensitisation is a significant focus of research in behavioural 
pharmacology. Sensitisation can translate in many different responses, although, 
the most commonly studied drug responses showing sensitisation are different 
forms of motor activation, i.e. locomotor activity, stereotyped and rotational 
behaviours (Post and Rose, 1976; Kalivas and Stewart, 1991; Robinson and 
Becker, 1986; Wise and Leeb, 1993). Sensitisation can be induced by stress, 
punishment/reward, chemically (by local potassium administration), by 
administration of a drug (systemically or locally through a cannula), or by 
electrical stimulation of specific brain regions (e.g. Le Merrer and Stephens, 2006, 
Vezina et al., 2007). 
Behavioural locomotor activity sensitisation is the enhanced motor-stimulant 
response that occurs with repeated exposure to psychostimulants. To develop 
sensitisation, it is crucial to administer the challenge intermittently (Volkow, 2006). 
For example, daily intermittent injections of cocaine produced behavioural 
sensitisation to the locomotor response in rats, whereas continuous cocaine 
infusions produced behavioural tolerance (Burger et al., 1994). The development 
of sensitisation can also be dependent on the environment, which might depend, 
at least to some extent, on the fact that different drug evoke behaviours 
depending on the environment (Einat and Szechtman, 1993a, 1993b). 
Furthermore, extensive research has shown that behavioural sensitisation can 
occur and be studied in several different stages, i.e. the acquisition (or 
development) of sensitisation, a withdrawal period, reversal treatment period, and 
an (re-) expression phase of sensitisation following a challenge. Previous reports 
showed that these stages are temporally, anatomically, and neurochemically 
distinct, suggesting they consist of different pharmacology (e.g. Kalivas et al., 
1993). These conclusions are made on the basis that some drugs selectively 
target (i.e. induce, block, stimulate or reverse) the development or expression 
phase of behavioural sensitisation. Reversal treatment is studied by a regime 
consisting of the development of sensitisation by psychostimulants, followed by 
chronic treatment with a drug (reversal treatment) and a withdrawal period after 
which a challenge with the psychostimulant only was given (e.g. Li et al., 2000; 
Moro et al., 2007). Furthermore, it has been shown that after the development of 
behavioural sensitisation with a certain drug, the same subject can express 
behavioural sensitisation following a withdrawal period and exposure to another 
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drug. This phenomenon is called cross-sensitisation (DiFranza and Wellman, 
2007). 
 
For this reason numerous studies have been performed which assessed the role 
of dopamine in behavioural sensitisation over the last few decades. In keeping 
with its ability to modulate dopaminergic neuronal function in the brain, 
behavioural sensitisation is currently considered as a behavioural model to 
improve treatments of neuropsychiatric disorders related to dopaminergic 
neuronal dysfunction, such as depression, schizophrenia, Parkinson‟s disease, 
anxiety, obsessive compulsive disorder, dyskinesia, bipolar disorder (Post et al., 
2001), and drug addiction. Behavioural sensitisation can be induced by 
psychostimulants which share the ability to increase synaptic dopamine levels 
directly (e.g. cocaine or amphetamine) or indirectly (e.g. nicotine or PCP). 
Although the exact mechanism underlying behavioural sensitisation is not fully 
understood yet, several mechanisms are proposed. Most of these include the 
dopaminergic system, i.e. the mesolimbic and/or nigrostriatal dopaminergic 
systems (Robinson and Becker, 1986; Kalivas and Stewart, 1991; Wolf et al., 
1994). Behavioural sensitisation to psychostimulants (e.g. cocaine or 
amphetamine) involves changes in dopaminergic transmission, particularly in the 
mesolimbic dopamine system. These include augmentation of nucleus accumbus 
and striatal extracellular dopamine levels in response to a challenge with the 
sensitising drug (Kalivas and Duffy, 1993; Wolf et al., 1993), a transient increase 
in the basal activity, or supersensitivity, of dopaminergic neurones in the VTA, 
and a subsensitivity of VTA dopamine D2 autoreceptors (Henry et al., 1998). 
More enduring cellular changes include supersensitivity of nucleus accumbens 
dopamine D1 receptors, an effect that can persist for at least 1 month following 
withdrawal from cocaine (Henry and White, 1995). Over time, repeated exposure 
to drug that alters the activity and metabolism of cells, can alter the properties of 
individual cells and their circuitries. Subsequently, this can result in complex and 
changed behaviours (e.g. sensitisation, tolerance, dependence, craving: Koob 
2000; Nestler and Aghajanian, 1997; Vezina, 2004).  
Previous studies have suggested a role for the dopamine D1 receptor in the 
striatal brain region. Increased inhibitory response of neurones in the nucleus 
accumbens to D1 receptor agonists following chronic cocaine (Henry and White, 
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1991), and repeated administration of SKF-38393 enhanced the sensitivity of 
neurones in the nucleus accumbens and caudate putamen to D1 receptor 
agonists (White et al., 1990; Henry and White, 1991; and other work by White‟s 
laboratory). Like other psychostimulants, daily systemic administration of nicotine 
is known to sensitise ambulatory stimulant effect in rats (Clarke, 1987).  
 
However considered as a psychostimulant, nicotine does differ in mechanism of 
action at a molecular level compared to other psychostimulants. Cocaine and 
amphetamine act directly on dopaminergic neurotransmission by blocking 
dopamine uptake and stimulate release, respectively, whereas nicotine binds to 
nAChR‟s and indirectly affects dopaminergic neurones (see for review Mash and 
Staley, 1997). Moreover, nicotine effects on behaviour are often much weaker 
compared to cocaine or amphetamine. Earlier studies indirectly implicated a role 
for dopamine D1 receptors in psychostimulant induced locomotor sensitisation as 
it has been shown that systemic SCH-23390 can block, or at least attenuate, 
sensitisation to amphetamine (e.g. Vezina and Stewart, 1989; Drew and Glick, 
1990), cocaine (e.g. McCreary and Marsden, 1993; Kuribara and Uchihashi, 1993; 
Mattingly et al., 1996), 3,4-methylenedioxymethylamphetamine (MDMA: e.g. 
Ramos et al., 2004), and other dopaminergic agonists. However, the effect of 
nicotine on behavioural sensitisation is less well understood and the effect of 
SCH-23390 on nicotine induced behavioural sensitisation has not been 
investigated yet. Therefore present study investigates the effect of the dopamine 
D1 antagonist SCH-23390 on the expression of nicotine induced sensitisation. 
 
 
HYPOTHESES AND AIMS 
 
Hypothesis: 
The dopamine D1 receptor is suggested to be involved in the underlying 
mechanism of behavioural sensitisation. Herein it is hypothesised that a 
dopamine D1 receptor antagonist will block the expression of nicotine induced 
locomotor sensitisation. 
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Aims: 
- Induce behavioural locomotor activity sensitisation by chronic intermittent 
nicotine administration. 
- Show that the sensitised response is a relatively long lasting phenomenon by 
examination of sensitisation following a relative short and relative long withdrawal 
period. 
- Investigate if a dopamine D1 antagonist blocks the expression of nicotine 
induced locomotor sensitisation. 
- Establish a robust in vivo behavioural (locomotor) sensitisation model which can 
be used in future studies investigating putative molecular changes which occur as 
a result of locomotor sensitisation (see Chapter 5, cAMP accumulation and 
Chapter 6, receptor binding). 
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2.2 MATERIALS AND METHODS 
 
The described in vivo behavioural experiments were performed at Abbott 
Healthcare Products, the Netherlands. 
 
2.2.1. Drugs 
(-)-Nicotine dihydrate ditartrate and saline were purchased from Acros Organics 
(Geel, Belgium). (-)-Nicotine dehydrate tartrate (1.228 mg/mL) was dissolved in 
0.9% sterile saline and adjusted to pH 5.0 with NaOH/HCl. The final dose for 
administration was 0.4 mg/kg (-)-nicotine (measured as the freebase). SCH-
23390 was purchased from Sigma-Aldrich (Amsterdam, the Netherlands), 
dissolved in saline and adjusted to pH 6.6 with NaOH/HCl. 
(-)-Nicotine and saline were administered subcutaneously (s.c.) and SCH-23390 
and corresponding vehicle were given by intraperitoneal (i.p.) administration. All 
nicotine injections were in volumes of 1 mL/kg body weight, drugs and 
corresponding vehicles were administered in volumes of 2 mL/kg. 
 
2.2.2 Animals 
Subjects were naïve adult male Wistar rats (HsdCpb:WU, Harlan, Horst, the 
Netherlands) weighing between 250-270 g at delivery. Animals were housed 2 
rats/cage in a temperature (21 ± 1 °C) and humidity (40-50 %) controlled 
environment, and were habituated for 1 week prior to experimentation. The rats 
had ad libitum access to food (RM1 (E) pellets, SDS Special Diet Service, 
England) and tap-water, except during experimental sessions. Lighting was 
maintained under a 12 h light-dark cycle (lights on 06:00-18:00 h). All 
experimental procedures were performed between 08:00 and 16:00 h. The 
methodology was approved by the animal ethics committee of Abbott Healthcare 
Products, the Netherlands, and is in accordance with all local laws. 
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2.2.3 Locomotor activity measurements 
Animals were matched for body weight and randomly assigned to treatment 
groups. Locomotor activity measurements were performed using 24 transparent 
perspex cages (21 x 36 x 18 cm) which were placed between 7 photobeams. 
Locomotor activity (ambulatory movement) was monitored and quantified using 
“Photobeam Activity System” software (PAS; San Diego Instruments, San Diego, 
CA, USA). 
 
2.2.4. Experimental designs 
All experiments in this study used a dose of 0.4 mg/kg nicotine (s.c.) as previous 
studies in this laboratory and previous literature have shown that this dose is 
optimal to induce behavioural sensitisation (e.g. Domino, 2001). One day prior to 
each experiment (day 0), all animals were habituated to the activity cages for one 
h followed by a saline injection and locomotor activity was recorded. 
 
Experiment 1. – Effect of acute and chronic nicotine administration on locomotor 
activity. 
To assess the ability of nicotine to induce development of behavioural 
sensitisation, three groups of naïve rats (n = 8 rats/group) were habituated as 
described above. On the testing days (day 1 and 5) the rats were habituated for 
60 min to the test apparatus, before administration of either saline (s.c., 2 groups) 
or (-)-nicotine (0.4 mg/kg, s.c., 1 group). After receiving the injections, the rats 
were directly placed back in the test apparatus and locomotor activity was 
measured for 45 min, in 5 min time epochs. This first time dose of nicotine was 
considered the acute dose. On day 2, 3 and 4 all groups received the same 
treatment as the day before and were directly placed back in their home cage. 
After a 16 day withdrawal period (day 22), all groups received a saline injection 
(s.c.) and locomotor activity was measured to assess if the response was 
context-dependent. On day 23 (i.e. after a 17 day withdrawal period), rats were 
habituated for 60 min to the test apparatus prior to administration of either a 
saline (s.c., 1 vehicle group) or (-)-nicotine challenge (0.4 mg/kg, s.c., 1 vehicle 
group and 1 nicotine group). The rats were directly placed back in the test 
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apparatus and locomotor activity was measured for 45 min, in 5 min time epochs. 
See Table 2-1 for study design. 
 
Table 2-1 Study design chronic nicotine administration 
Group Pre-treatment 
(development) 
Pre-challenge Challenge 
(expression) 
VEH – VEH 5 Saline injections 1 Saline injection 7th dose of Saline 
VEH – NIC 5 Saline injections 1 Saline injection 1st dose of Nicotine 
NIC – NIC 5 Nicotine injections 1 Saline injection 6th dose of Nicotine 
VEH, vehicle; NIC, nicotine 
 
 
Experiment 2. – Effect of a nicotine challenge after chronic nicotine followed by a 
5 days withdrawal period. 
In a second experiment, three groups of naïve rats (n = 12 rats/group) rats were 
treated following the same protocol as described in „Experiment 1‟. However, in 
this experiment a shorter withdrawal period was investigated and rats received a 
saline injection at day 9, and the nicotine challenge at day 10 (i.e. after 5 days of 
withdrawal). See Figure 2-1 for the treatment scheme. 
 
60 min 45 min 60 min
LocomotorLocomotor
HabituationHabituation
VEH VEH/
SCH
NIC
DAY 0 DAY 1
Repeated DAY 1 - 5 
(locomotor test only at day 1 and 5)
45 min 5 days 60 min 45 min 30 min 30 min 45 min
Locomotor
Habituation
DAY 9
Locomotor
Habituation
DAY 10
NICVEH
 
Figure 2-1 Treatment scheme to induced locomotor sensitisation  
To study habituation, development and expression (including pretreatment) of 
locomotor sensitisation the following paradigm was used as described in this 
figure. VEH, vehicle; NIC, nicotine; SCH, SCH-23390. 
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Experiment 3. – Effect of SCH-23390 on spontaneous locomotor activity and the 
expression of nicotine induced locomotor sensitisation. 
Six groups of naïve rats (n = 8 rats/group) were habituated to the activity cages 
one day prior to the experiment (day 0). On the testing days (day 1 and 5) the 
rats were habituated for 60 min to the test apparatus, before administration of 
either saline (s.c., 2 groups) or (-)-nicotine (0.4 mg/kg, s.c., 4 groups). After the 
injections, the rats were directly placed back in the test apparatus and locomotor 
activity was measured for 45 min. On day 2, 3 and 4 all groups received the 
same injections as given on day 1 and were directly placed back in the home 
cage. 
After a 16 day withdrawal period (day 22), all groups received a saline injection 
(s.c.) and locomotor activity was measured. After a 17 day withdrawal period (day 
23), rats were habituated for 60 min to the test apparatus before administration of 
a pre-challenge of either saline (s.c., 2 vehicle groups and 1 nicotine group) or 
SCH-23390 (0.003, 0.01 or 0.03 mg/kg, i.p., to the 3 nicotine groups respectively). 
The rats were directly placed back in the test apparatus and locomotor activity 
was measured for 30 min. After 30 min of either saline or SCH-23390 
administration, one of the saline groups received another saline challenge and all 
other groups were challenged with 0.4 mg/kg (-)-nicotine (s.c.). Locomotor activity 
was measured for another 45 min, as previously described. 
 
Experiment 4. – Effect of SCH-23390 (0.03 mg/kg) on the expression of nicotine 
induced sensitisation. 
In this experiment, four groups of naïve rats (n = 12 rats/group) were treated 
following the same protocol as described in “Experiment 2.” to develop nicotine 
sensitisation. After 4 days of withdrawal, rats were given a saline injection and 
locomotor activity was assessed as previously described. On day 10, rats were 
habituated for 60 min to the test apparatus before administration of a pre-
challenge of either saline (s.c., 1 vehicle group and 2 nicotine groups) or SCH-
23390 (0.03 mg/kg, i.p., third nicotine group). The rats were directly placed back 
in the test apparatus and locomotor activity was measured for 30 min. After 30 
min of either saline or SCH-23390 administration, the Vehicle - Vehicle group 
was challenged with saline and all other groups were challenged with 0.4 mg/kg 
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(-)-nicotine (s.c.). Locomotor activity was measured for another 45 min, as 
previously described. See Table 2-2 for study design.  
 
Table 2-2 Study design chronic nicotine with SCH-23390 pretreatment 
Group Pre-treatment 
(development) 
Pre-challenge Challenge 
(expression) 
VEH - VEH 5 Saline injections 1 Saline injection 7th dose of Saline 
VEH - NIC 5 Saline injections 1 Saline injection 1st dose of Nicotine 
NIC - NIC 5 Nicotine injections 1 Saline injection 6th dose of Nicotine 
NIC - SCH/NIC 5 Nicotine injections 1 SCH injection 6th dose of Nicotine 
VEH, vehicle; NIC, nicotine; SCH, SCH-23390 
 
2.2.5. Data analyses 
Data were analysed and presented as mean total amount of ambulant 
movements (beam breaks) over a period of 30 min (pretreatment) or 45 min 
(challenge) after injection ± standard error of the mean (s.e.m.). Data was taken 
from all animals regardless of their behavioural (sensitised) response and mean 
values were calculated. Graphs and statistical analyses were performed using 
Prism graphing software (GraphPad, USA). The main effects of drug treatments 
were analysed using one-way analyses of variance (ANOVA): [F (dfb, dfw) = x; P 
= x]. When a significant difference among the treatments was obtained using an 
ANOVA, this was followed by a post hoc Bonferroni‟s multiple comparison test 
analyses where appropriate. Differences between day 1 vs. day 5 were analysed 
using an unpaired two-tailed t-test. Data with P < 0.05 were considered as 
significant. 
 
Methodological considerations: Statistics 
The experimental design of pre-treatment of animals to induce sensitisation 
before administration of a challenge was considered as a 2 factor (i.e. a within-
subjects factor of day and between-subjects factor of treatment) and would 
require a two-way ANOVA. However, the factor of day was not quantitative and 
therefore a one-way ANOVA was performed. 
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2.3 RESULTS 
 
One day prior to each experiment (day 0), all animals were given a subcutaneous 
(s.c.) saline injection to assess the basal response to injection in addition to 
habituate the rats to the experimental conditions (e.g. test apparatus, handling 
and injections). There was no significant difference found in locomotor activity 
between the experimental and control groups in response to saline on day 0 ([F 
(2, 20) = 1.175; P = 0.3293]), and therefore all animals were used to perform this 
study. 
Experiment 1. – Effect of acute and chronic nicotine administration on locomotor 
activity. 
The effect of acute nicotine on locomotor activity in Wistar rats was investigated. 
Two groups received saline (s.c.) and one group nicotine (0.4 mg/kg, s.c.), and 
locomotor activity was measured for 45 min (Figure 2-2A). There was a 
significant treatment effect ([F (2, 20) = 12.46; P = 0.0003]), and post hoc testing 
demonstrated that acute nicotine produced a significant (P < 0.01), but modest, 
increase in locomotor response compared to vehicle groups (see Figure 2-2B). 
 
The two saline groups and the nicotine group all received their treatment 
intermittently, ones a day for five consecutive days. Statistical analysis using 
ANOVA showed a significant treatment effect ([F (2, 20) = 46.12; P < 0.0001]).  
Post hoc testing demonstrated that the groups which received chronic saline did 
not showed any change in locomotor activity after 5 days of treatment, however, 
the animals which received chronic nicotine (0.4 mg/kg, s.c.) for five days showed 
an increased locomotor response which is consistent with the development of 
behavioural sensitisation (Figure 2-2C and D). This effect was only observed in 
the nicotine group and was well established by the 5th (challenge) dose.  
 
To demonstrate that behavioural sensitisation was not conditioned to the test 
apparatus, all groups (both vehicle and nicotine groups) were given a saline 
injection (s.c.) after a 16 days withdrawal period (day 22). There was no 
significant difference in locomotor activity between the treatment groups after the 
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saline injection [F (2, 20) = 0.09662; P = 0.9083], see Figure 2-3A and B. This 
suggests that there was no evidence of a conditioned response (i.e. it was a 
context-independent response) from the repeated pairing of nicotine with the 
injection or test cage. 
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Figure 2-2 Effect of acute and chronic nicotine on locomotor activity in rats 
A. Effect of acute nicotine administration in naïve rats. Changes in locomotor 
activity over time (min) in response to an acute dose of nicotine (see Table 2-1 
for study design). Data represent mean ± s.e.m., n = 8 animals per group. B. 
Mean locomotor activity ± s.e.m. of 45 min after acute nicotine administration (0.4 
mg/kg, s.c.). C. Effect of a nicotine challenge after chronic nicotine pretreatment 
on locomotor activity. D. Chronic nicotine administration significantly increased 
locomotor activity compared to vehicle (P < 0.001). Moreover, the response after 
chronic nicotine treatment was increased (i.e. sensitisation) compared to acute 
nicotine (unpaired t-test day 1 vs day 5, $ P < 0.001). Post hoc Bonferroni‟s, ** P 
< 0.01, *** P < 0.001. n = 8 animals/group. 
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Figure 2-3 Effect of a challenge injection after a 17 days withdrawal period  
A. Effect of a saline challenge on locomotor activity after chronic nicotine 
treatment followed by a 17 day withdrawal period. B. Mean locomotor activity ± 
s.e.m. of 45 min after a saline challenge. No significant difference between the 
groups was observed. C. Locomotor activity of a saline injection followed by a 
nicotine challenge. D. Effect of a nicotine challenge after chronic nicotine 
treatment followed by a 17 day withdrawal period [F (2, 20) = 37.86; P < 0.0001]. 
Post hoc Bonferroni‟s, ** P < 0.01, *** P < 0.001. n = 8 animals/group. 
 
After the development of nicotine sensitisation, followed by a 17 day withdrawal 
period, all groups received a challenge: The chronic vehicle group received saline 
(s.c.), the second vehicle group received for the first time nicotine (0.4 mg/kg, 
s.c.), and the chronic nicotine group received a nicotine challenge (0.4 mg/kg, 
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s.c.). The vehicle and acute nicotine groups gave equal responses compared to 
vehicle and acute nicotine at day 1 (Figure 2-3D vs. Figure 2-2B). The chronic 
nicotine treated group showed equal response compared to day 5 (Figure 2-3D 
vs. Figure 2-2D); i.e. expression of behavioural sensitisation. These data show 
that the behavioural sensitised response is a long lasting phenomenon. 
 
Experiment 2. – Effect of a nicotine challenge after chronic nicotine followed by a 
5 days withdrawal period. 
A second experiment was performed using the exact same treatment as 
described in “Experiment 1.”, but this time using a shorter (i.e. 5 days) withdrawal 
period. Thirty six rats were randomly divided into three groups of 12 rats each. 
Locomotor sensitisation was developed by daily nicotine administration for 5 
consecutive days and was comparable to previous findings („Experiment 1‟). The 
development of sensitisation was followed by a relative short withdrawal period, 
and all groups received a saline injection at day 9. One-way ANOVA showed a 
significant effect [F (2, 33) = 7.342; P < 0.0023] and post hoc Bonferroni‟s 
analysis revealed that the chronic nicotine group was modest but significantly 
increased compared to only one of the vehicle groups (P < 0.01, Figure 2-4A). 
After 5 days of withdrawal (i.e. day 10), one vehicle group received saline and the 
other vehicle and nicotine groups received a nicotine challenge (0.4 mg/kg, s.c.). 
One-way ANOVA analysis showed that there was a statistical difference [F (2, 33) 
= 37.74; P < 0.0001] and post hoc Bonferroni‟s showed that all groups were 
significantly different to each other Figure 2-4B. Locomotor activity was 
significantly enhanced after acute nicotine administration (P < 0.001 vs vehicle) 
and after chronic nicotine treatment (P < 0.001 vs vehicle) (Figure 2-4B). 
Furthermore, the nicotine challenge showed a larger response in rats sub-
chronically preatreated with nicotine, compared to rats which received nicotine for 
the first time (pretreated vs. acute, P < 0.01), which represents the expression of 
nicotine sensitisation. 
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Figure 2-4 Effect of acute and chronic nicotine on locomotor activity  
A. Effect of a saline injection to all treatment groups after a 4 day withdrawal 
period. The nicotine pretreated group showed a significant increase compared to 
only 1 vehicle group. B. Effect of a nicotine challenge after 5 days of withdrawal. 
Post hoc Bonferroni‟s, ** P < 0.01, *** P < 0.001. n = 12 animals/group. 
 
Statistical comparison of the nicotine sensitised responses after 5 and 17 days of 
withdrawal showed that the responses were not different to each other (unpaired 
t-test, P > 0.05). The observed effects of nicotine induced sensitisation were 
found very robust during this study where the experiment was repeated 13 times 
(for behavioural characterisation and in order to obtain tissue for ex vivo studies, 
see Table 5-1 and Chapter 5) and showed high reproducibility. 
 
Experiment 3. – Effect of SCH-23390 on spontaneous locomotor activity and the 
expression of nicotine induced locomotor sensitisation. 
Nicotine sensitisation was developed with the same results as described in 
“Experiment 1.”, P < 0.001 (data not shown). 
On day 23, i.e. after 17 days of withdrawal, the three additional chronicnicotine 
treated groups were pretreated with different doses of SCH-23390 (0.003, 0.01 
and 0.03 mg/kg, i.p.) and the effect of SCH-23390 on spontaneous activity was 
investigated. No significant treatment effect of SCH-23390 was observed using 
one-way ANOVA [F (5, 41) = 0.7219; P = 0.6108], see Figure 2-5A and Figure 
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2-5B. These results show that SCH-23390 does not cross-sensitise with nicotine. 
Furthermore, the effect of SCH-23390 pretreatment on the expression of nicotine 
induced sensitisation after 17 days (day 23) of withdrawal was studied. When 
SCH-23390 was pre-administered 30 min prior to the nicotine challenge, SCH-
23390 induced a dose dependent attenuation of nicotine sensitisation (Figure 
2-5B). 
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Figure 2-5 Effect of SCH-23390 pretreatment on the expression of nicotine 
induced sensitisation after 17 days (day 23) of withdrawal  
A/B. The first three groups were given saline and the last three groups SCH-
23390 (0.003, 0.01, 0.03 mg/kg) was given 30 min prior to nicotine. One-way 
ANOVA showed no significant effect of either saline or the three tested dose of 
SCH-23390. C/D. All groups were given a nicotine challenge, except from one 
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vehicle group [F (5, 41) = 18.27; P < 0.0001]. Acute and sub-chronic nicotine 
control groups showed a significant increase and sensitised response, 
respectively. The three SCH-23390 pre-treated groups were significantly different 
compared to vehicle (P < 0.001), but were not significantly different compared to 
acute or chronic nicotine. Post hoc Bonferroni‟s, *** P < 0.001. n = 8 
animals/group. 
 
Experiment 4. – Effect of SCH-23390 (0.03 mg/kg) on the expression of nicotine 
induced sensitisation. 
In a separate experiment, the effect of SCH-23390 pretreatment on the 
expression of nicotine induced sensitisation after 5 days of withdrawal was 
studied. 48 animals were randomly assigned to four groups: vehicle - vehicle 
(pre-treated and challenged with saline); vehicle - nicotine (pre-treated with saline 
and challenged with nicotine); nicotine - nicotine (pre-treated and challenged with 
nicotine) and, nicotine – SCH/NIC (pre-treated with nicotine and challenged with 
SCH-23390 followed by nicotine challenge), see Table 2-2 for study design. 
Nicotine induced locomotor sensitisation was developed following 5 days of 
chronic nicotine treatment with similar results compared to previous experiments 
(“Experiment 1.”). After a withdrawal period of 5 days, rats were given a pre-
challenge of saline (vehicle) or SCH-23390 30 min prior to the nicotine challenge. 
After the nicotine challenge to the nicotine - nicotine group, a statistically 
significant increase in locomotor activity was observed [F (3, 44) = 34.15; P < 
0.0001]. Furthermore, it was found that SCH-23390 pretreatment (0.03 mg/kg, 
i.p.) significantly blocked the expression of nicotine sensitisation (post hoc 
Bonferroni‟s, ** P < 0.01), see Figure 2-6. 
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Figure 2-6 Effect of SCH-23390 pretreatment on the expression of nicotine 
induced sensitisation after 5 days of withdrawal  
Effect of SCH-23390 (0.03 mg/kg, i.p.) pretreatment on the expression of nicotine 
induced locomotor sensitisation after 5 days of withdrawal (i.e. day 10). SCH-
23390 pre-treated group was significantly different to vehicle *** P < 0.001. Post 
hoc Bonferroni‟s, ** P < 0.01, *** P < 0.001. n = 12 animals/group. 
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2.4 DISCUSSION 
 
This study investigated the effect of repeated intermittent nicotine administration 
on locomotor activity and the effect a dopamine D1 antagonist on the expression 
of nicotine induced behavioural sensitisation. This study demonstrated for the first 
time that SCH-23390 (a selective dopamine D1 receptor antagonist) dose 
dependently blocked the expression of nicotine induced behavioural locomotor 
sensitisation in the rat. 
 
Nicotine is a non-specific agonist of nicotinic acetylcholinergic receptors (nAChR; 
see Chapter 6). In rodents, nicotine alters locomotor activity (Clarke and Kumar, 
1983; Ksir et al., 1985). The present results demonstrated that acute nicotine 
increased locomotor activity. However, some previous studies also did report 
opposing effects, i.e. increasing, decreasing, or no effect on locomotor activity 
after acute nicotine (Domino, 2001; Palmatier and Bevins, 2002). These 
contradictory results may be due to methodological differences between studies. 
Different environmental experience (i.e. habituation) to the animal prior to nicotine 
injection can give opposing observations. For example, nicotine induced highly 
reproducible, but modest, hyperactivity in rats that had been habituated to the 
test cage; however, it produced only a small increase in locomotion in animals 
not previously exposed to the test environment (O‟Neill et al., 1991). In the 
present study, the animals were habituated (including saline injection) one day 
before acute nicotine treatment (i.e. Day 0) and at the beginning of each 
experimental day. The animals showed an increased locomotor activity in the first 
30 min, this is probably due exploratory behaviour of a novel environment. 
Chronic nicotine and saline treated animals showed equal exploratory activity in 
the first 30 min when exposed to the test cage and was the same for all days (i.e. 
day 1, day 5 or after withdrawal), indicating no significant effect on habituation or 
no conditioning effect of the test environment. On treatment days 2, 3, and 4 the 
animals received the treatment in their home cage instead of in a test cage. As 
discussed before, the development of sensitisation can be dependent on the test 
environment. Therefore, it should be noted that, in this case, both the test cages 
and homecages were of the same design. It is therefore unlikely that appreciable 
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differences in the test and home cage environment contribute tot “differential 
conditioning” of the two environments. Nonetheless, behavioural sensitisation 
following repeated intermittent nicotine administration was observed regardless of 
the observed first-time (acute) effect of nicotine (Domino, 2001). 
 
In the present study, nicotine induced locomotor activity sensitisation was used 
as a model for behavioural sensitisation. Chronic (i.e. 5 days intermittent) nicotine 
administration increased ambulatory locomotor activity in rats in a time-
dependent manner. After 5 days of treatment a plateau of locomotor sensitisation 
development was achieved. Another aspect of behavioural sensitisation is the 
expression phase. A phenomenon that is characterised by expression of the 
same sensitised response to a challenge after a certain withdrawal period.  
Behavioural sensitisation is known to be a long lasting phenomenon and present 
study examined the expression of sensitisation after two withdrawal periods, i.e. a 
relative long 17-days and relative short 5-days period. The first expression 
experiments performed in this study used a 17 day withdrawal period and 
nicotine sensitisation was shown long lasting (e.g. as shown in “Experiment 1.”). 
Although the chronic nicotine administration was shown to be a robust paradigm, 
a shorter withdrawal period was assessed and as expected nicotine sensitisation 
was also expressed after 5 days of withdrawal (as shown in “Experiment 2.”). 
Moreover, the 5 days paradigm showed an even greater magnitude (i.e. more 
locomotor activity counts) of the expression phase of sensitisation, showing that 
the induced sensitisation is a long lasting phenomenon however is attenuating 
over time. 
 
This study investigated the hypothesis that the dopamine D1 receptor is involved 
in expression of behavioural sensitisation. First, it was shown that SCH-23390 at 
different doses did not alter basal locomotor activity (Figure 2-5B) which was in 
agreement with previous publications (O‟Neill et al., 1991). However, it should be 
noted that present data did not include the effect of SCH-23390 on nicotine 
induced locomotor activity in experimentally naïve animals, but only chronic 
nicotine treated animals. Previous literature, however, showed that SCH-23390 
(0.001, 0.01 and 0.1 mg/kg) dose dependently blocked the effect of acute 
nicotine administration on locomotor activity (O‟Neill et al., 1991). Furthermore, it 
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has been reported that SCH-23390 blocks the acquisition of amphetamine 
induced locomotor sensitisation (e.g. Vezina and Stewart, 1989) but not cocaine 
induced locomotor sensitisation (e.g. Mattingly et al., 1996) in the rat. No data is 
available for nicotine induced sensitisation. Together with other examples not 
mentioned inhere, the effect of SCH-23390 on the development of behavioural 
sensitisation is not consistent and therefore its effect on nicotine induced 
sensitisation should be determined empirically. Although SCH-23390 blocks the 
effect of acute nicotine, it is hypothesised that SCH-23390 will also block the 
development of nicotine induced locomotor sensitisation. 
The effect of the dopamine D1 receptor antagonist SCH-23390 on the expression 
of nicotine sensitisation after different periods of withdrawal was examined.  After 
a relative long withdrawal period of 17-days, SCH-23390 pretreatment did not 
significantly blocked the expression of nicotine induced sensitisation, although it 
was shown that SCH-23390 attenuated the expression of sensitisation 
(“Experiment 3.”). This could be explained by the chronic nicotine treated group 
which was not significant different from the acute nicotine group, which is 
normally significant as showed in “Experiment 1” and “Experiment 2”. There was 
only a small pharmacological window to significantly block the sensitised nicotine 
response by SCH-23390, and the expression of nicotine sensitisation was more 
evident after 5 days of withdrawal compared to 17 days (“Experiment 1 and 2”). 
Therefore the expression study using SCH-23390 was repeated with a high dose 
of SCH-23390 (0.03 mg/kg) and assessed after 5 days of withdrawal. After a 
shorter withdrawal period of 5 days, SCH-23390 (0.03 mg/kg, i.p.) did 
significantly block the expression of nicotine sensitisation (“Experiment 4.”). 
 
This study describes SCH-23390 as a selective dopamine D1 antagonist although 
in vitro SCH-23390 also showed high affinity for the serotonin 5HT2 receptor 
subtype (Millan et al., 2001; see Chapter 7 for more discussion). However, the 
doses required to induce a similar response in vivo are greater than 10-fold 
higher than those required to induce a dopamine D1 mediated response (for 
review see Bourne, 2001). Interestingly, 5HT2 receptor agonists do also block 
nicotine induced sensitisation. For example, 2,5-dimethoxy-(4-chlorophenyl)-
isopropylamine (DOI: a selective 5HT2 agonist) blocks the expression but not the 
acquisition of nicotine sensitisation (Olausson et al., 2001) and Ro-60-0175 (a 
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5HT2C agonist) blocks the acquisition of nicotine induced sensitisation (Grottick et 
al., 2001). And 5HT2C agonists Ro-60-0175 and WAY-163,909, but not 5HT2C 
antagonist SB-242,084, attenuated the expression of nicotine induced 
sensitisation after a 5 day withdrawal period following a 5 day intermittent nicotine 
administration (Zaniewska et al., 2007). Although unlikely, it should be kept in 
mind that activation of 5HT2 receptors by SCH-23390 may contribute to its 
behavioural properties both in animals as well as in human. 
 
 
Conclusions 
In conclusion, the present study showed that repeated nicotine administration 
can develope sensitisation to behavioural locomotor activity in the rat and is a 
long lasting phenomenon. The present results provide evidence for the 
pharmacological attenuation of the expression of nicotine induced behavioural 
sensitisation by SCH-23390, therefore suggesting a role for the dopamine D1 
receptor and potential dopamine D1 ligand pharmacotherapies. However, due to 
the complexity of brain signalling it is likely that other neurotransmitter systems 
(e.g. serotonergic, noradrenergic, and cholinergic) can play a role as well, and 
other classes of ligands may also be considered as potential pharmacotherapies. 
Nonetheless, it is clear from this study and supportive available literature that 
dopamine and dopamine D1 receptors play a particularly important role in 
behavioural sensitisation. This model is now ready for further studies 
investigating the molecular mechanisms of behavioural sensitisation. 
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Chapter 3. The effect of nicotine and dopamine D1 
ligands on ex vivo dopamine release in the dorsal 
striatum 
 
Abstract. 
OBJECTIVES: The exact molecular mechanism of behavioural sensitisation is 
still yet unknown, however it is suggested that dopamine release plays an 
important role. Extensive research have been carried out to investigate the role of 
dopamine D2 receptor mediated dopamine release, however the role of the 
dopamine D1 receptor is less well studied. As shown in Chapter 2, nicotine 
induced behavioural sensitisation can be blocked by a dopamine D1 receptor 
antagonist. This study investigated the effect of nicotine and dopamine D1 
receptor ligands on electrically evoked dopamine release ex vivo in corticostriatal 
slices. 
METHODS: In this study, ex vivo fast cyclic voltammetry (FCV) was used to 
examine the effect of nicotine, SCH-23390 (D1 antagonist) and SKF-38393 (D1 
agonist) on electrically evoked dopamine release. The release of dopamine was 
measured following stimulations at different frequencies, in dorsal striatal slices. 
RESULTS: Nicotine induced a decrease in dopamine efflux at low frequency and 
an increase at high frequency electrical field stimulation. Neither SCH-23390 nor 
SKF-38393 altered single pulse or multiple pulse stimulated dopamine release on 
their own. However, both D1 ligands blocked the nicotine induced decrease in 
dopamine release at single pulse, but not multiple pulse electrical stimulation. 
CONCLUSIONS: These results showed that the frequency dependent electrical 
modulation of dopamine release can be altered by nicotine and moreover, for the 
first time, showed that this effect can be altered by dopamine D1 ligands. These 
findings suggest a potential role of frequency dependent signalling by nicotine, 
which may contribute to identify the mechanism of behavioural sensitisation. 
 
 
Keywords: FCV, fast cyclic voltammetry, dopamine release, nicotine, dopamine 
D1 receptor, SCH-23390, SKF-38393, dorsal striatum, ex vivo 
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3.1 INTRODUCTION 
 
Nicotine, like other psychostimulants, can induce behavioural sensitisation as 
previously discussed in Chapters 1 and 2. Moreover, nicotine, like other 
psychostimulants, is able to increase extracellular dopamine levels in the brain of 
rats after systemic administration, as measured by in vivo microdialysis 
(Anderson et al., 1981; Imperato et al., 1986; Robinson et al., 1988; Brazell et al., 
1990) and by in vivo electrochemistry (Stamford et al., 1984; Stamford, 1985; 
Robinson et al., 2003; Robinson and Wightman, 2007). There is also evidence for 
increased extracellular dopamine levels in rats sensitised to amphetamine as 
measured in vivo and ex vivo (Jones et al., 1996; Domino and Tsukada, 2009). It 
is suggested that repeated administration of a psychostimulant or contextual 
stimuli exposure (for example in the case of stress) affects brain neurochemistry 
and is mediated by increased dopamine release (Martin-Iverson et al., 1993). 
More specifically, ex vivo studies have shown that nicotine, like other 
psychostimulants, can also induce dopamine release in striatal brain slices (i.e. 
superfusion using [3H]-dopamine (Rowell et al., 1987; Grady et al., 1992; el-Bizri 
and Clarke, 1994), or by using fast cyclic voltammetry, FCV (Zhou et al., 2001; 
Zhang et al., 2009). 
 
Dopamine transmission in the brain has an autoregulatory system by which 
dopamine D2-like receptor activation will inhibit the further release of dopamine 
from the presynaptic cell. The effect of dopamine D2 receptor stimulation or 
inhibition is well described as it is functionally coupled to presynaptic dopamine 
release and uptake. In contrast to the dopamine D2-like receptors, the post 
synaptically located dopamine D1-like receptors are not autoreceptors and 
therefore activation of the dopamine D1 receptor will not directly regulate the 
release of dopamine. For example, neither the dopamine D1 agonist 6-Cl-APB 
nor D1 antagonist SCH-23390 altered single pulse dopamine release on their own, 
using ex vivo striatal slices (O‟Neill et al., 2007). Neither could the inhibitory effect 
of quinpirole (a selective D2-like receptor agonist) on electrically stimulated 
dopamine release be antagonised by SCH-23390 (Palij et al., 1990). Another 
study using electrically stimulated [3H]-dopamine release from guinea pig brain 
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slices showed that the dopamine D1 agonist SKF-38393 did not affect dopamine 
release. (-)-Sulpiride (a selective dopamine D2-like receptor antagonist) reversed 
the inhibition induced by quinpirole, while SKF-38393 did not have any effect on 
quinpirole (Kondo et al., 1986). A more detailed description of the dopamine D1 
receptor and intracellular signalling is given in Chapter 1.  
 
As previously shown, psychostimulants are able to increase dopamine levels and 
induce behavioural sensitisation. However, only a limited number of studies 
investigated the putative correlation between these two phenomena ex vivo. One 
example is the examination of cocaine induced behavioural sensitisation on 
dopamine release, studied ex vivo in brain slices using superfusion and 
radiolabeled ligands. Bowyer and colleagues showed that in striatal slices from 
native animals, bath applied amphetamine evoked the release of [3H]-dopamine 
and inhibited subsequent K+-stimulated [3H]-dopamine release (Bowyer et al., 
1987). A study by Yi and Johnson showed that chronic administration of cocaine 
abolished the stimulatory effect that amphetamine normally has on the efflux of 
[3H]-dopamine from striatal synaptosomes, but K+-stimulated release was not 
affected (Yi and Johnson, 1990). However, chronically administered cocaine, plus 
acute challenge with cocaine potentiated the effect of amphetamine on the K+ 
induced release of [3H]-dopamine (Yi and Johnson, 1990). In a study reported by 
Risso and colleagues, it was shown that chronic (-)-nicotine continuously 
administered through osmotic mini-pumps for 10 days did not affect K+ (15 mM) 
stimulated [3H]-dopamine release in rat striatum (Risso et al., 2004) which is in 
consensus with behavioural data (as discussed in Chapter 2). In another study it 
was shown that chronic nicotine treatment (0.4 mg/kg, 14 days) neither affected 
basal nor electrically stimulated (20 mA, 2 Hz, 4 min) [3H]-dopamine release in rat 
VTA slices (Amantea, 2004). However, the inhibitory effect of baclofen (GABAB 
agonist) on [3H]-release was abolished after chronic nicotine treatment. These 
studies have shown that dopaminergic neurotransmission is affected after chronic 
psychostimulant administration. However, more evidence is needed to prove the 
importance of dopamine release in chronic psychostimulant induced behavioural 
sensitisation. 
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Stimulation of neurones by depolarisation using a high concentration potassium 
(K+) as a stimulus is a common method to induce neurotransmitter release for in 
vivo and ex vivo studies (van der Werf et al., 1987; Schlicker et al., 1989; 
Hoffman et al., 1998; Hoffman and Gerhardt, 1999; Molchanova et al., 2004; 
Nickell et al., 2005). However, this method does not represent the physiological 
temporal resolution of physiological stimulations in the intact brain. 
Neurotransmission is changed by normal experience or neuropathology and the 
actual neurotransmission operates on a millisecond timescale, and it is 
suggested that higher cognitive function and motor movement are regulated by 
the firing frequency of neurones. These neurones fire at different frequencies and 
can be categorised into tonic and phasic rhythms. Tonic regular firing of 
dopamine neurones occur at a rate of 2 – 5 Hz, and can increase to bursts of 
action potentials having a frequency of 15 – 100 Hz (Hyland et al., 2002). These 
fast temporal processes can be mimicked by electrical stimulation using a bipolar 
stimulation electrode, and stimulations at specific frequencies. Additionally a 
technique to measure these signals with a high temporal resolution (i.e. 
subsecond) is required, for example fast electrochemical techniques (see below). 
 
Constant potential amperometry, high-speed chronoamperometry, fast cyclic 
voltammetry (FCV) and differential pulse voltammetry (DPV) are the most 
common electrochemical techniques used to detect monoamine 
neurotransmitters (i.e., serotonin, dopamine, noradrenaline, adenosine, and 
histamine). Each method has its advantages and disadvantages; however the 
technique of FCV is superior when chemical selectivity and high spatial as well as 
high temporal resolution are required. FCV is a potential sweep technique in 
which the background subtracted voltammogram gives additional information 
about the electrolysed species. The current response is measured over a range 
of potentials in which FCV is a better technique to discern additional current 
contributions from other electroactive species (e.g. 3,4-Dihydroxyphenylacetic 
acid or DOPAC, pH, and serotonin). FCV is a relatively fast technique with single 
scans typically recorded every 100 ms (i.e. 10 Hz). For more background 
information and limitation of the technique see the review by Wightman and 
colleagues (Robinson et al., 2008). In particular, electrochemical detection using 
the technique of FCV in combination with a carbon fiber microelectrode has been 
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successfully demonstrated to characterise dopamine release and uptake in vivo 
and in vitro (Stamford et al., 1988a; Robinson et al., 2008).  
In vitro brain slice preparations are often used to study processes involved in 
synaptic plasticity and to evaluate the role of native receptor subtypes in 
neurotransmission (Shankaranarayana Rao and Raju, 2004). Receptors capable 
of modulating dopamine release in the striatum are not exclusively expressed on 
dopaminergic terminals within the striatum. Therefore, in vitro approaches using 
more intact tissue preparations, like brain slices, allow recordings from semi-
intact neural circuits and neighbouring influences with the advantage of 
mechanical stability and control over the extracellular environment. This study 
has focused on a specific area of the brain, the dorsal striatum, in isolated 
corticostriatal slices, and must not be seen as a single unit but as part of many 
inter brain pathway connections. Furthermore, this study focused on the dorsal 
striatal area. As mentioned before, there are important differences between the 
dorsal striatum and nucleus accumbens (and within the nucleus accumbens), 
also with respect to dopamine release probability as shown using FCV (Stamford 
et al., 1988a; Zhang et al., 2009). 
 
In addition to the radiolabelled superfusion studies which were mentioned before, 
there are some reports which investigated ex vivo dopamine release following 
behavioural sensitisation using FCV. For example, Muscat and colleagues 
studied the effect of quinpirole- and amphetamine induced behavioural 
sensitisation on ex vivo dopamine release after 3 days of withdrawal, as 
measured by fast cyclic voltammetry (Muscat et al., 1993). They showed that 
single pulse evoked dopamine release in rat nucleus accumbal slices was not 
different after behavioural sensitisation, but that multiple pulse stimulated 
dopamine release was enhanced in quinpirole- and attenuated in amphetamine 
sensitised rats. Furthermore, it was shown that the potency of quinpirole to inhibit 
single pulse stimulated dopamine was significantly increased in quinpirole 
sensitised, but decreased in amphetamine sensitised rats. Also behavioural 
sensitisation induced by repeated stress can increase extracellular dopamine 
concentrations in the nucleus accumbens and striatum, as determined by high-
speed chronoamperometry (Doherty and Gratton, 1992). 
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In contrast to the number of studies assessing the effect of the dopamine D2 
receptor activation or inhibition on dopamine release, considerably less attention 
has been paid to the role of the dopamine D1 receptor. Nonetheless, the 
dopamine D1 receptor is still very important in dopaminergic neurotransmission. 
As shown in Chapter 2 of this thesis, dopamine D1 ligands can alter behavioural 
sensitisation suggesting an important role for dopamine D1 receptor mediated 
neurotransmission in the mechanism underlying behavioural sensitisation. The 
experiments in this study have examined the contribution of dopamine D1 
receptor activation or inhibition and the effect of nicotine on dopamine release in 
the dorsal striatum using FCV. 
 
 
HYPOTHESES AND AIMS 
 
Hypotheses: 
Nicotine induced behavioural locomotor sensitisation results from impairment in 
the dopaminergic system in the dorsal striatum, specifically by the dopamine D1 
receptor. 
 
Aims: 
- Study putative changes of basal and electrically stimulated dopamine release in 
corticostriatal slices. 
 
- Studying the cellular and synaptic mechanisms by assessing the effect of 
dopamine D1 receptor ligands on stimulated dopamine release, which might 
underlie nicotine induced behavioural sensitisation. 
 
 Chapter 3 The effect of nicotine and dopamine D1 ligands on ex vivo dopamine 
release in the dorsal striatum 
 
 
42 
 
3.2 MATERIALS AND METHODS 
 
The described technique of fast cyclic voltammetry (FCV) was established, and 
experiments were performed at the Department of Chemistry, National University 
of Ireland, Maynooth (NUIM), Ireland. 
 
3.2.1. Drugs 
The following ligands and chemicals were used: D(+)-glucose, dopamine, (-)-
quinpirole.HCl (L-171555), GBR-12909.2HCl, (±)-SKF-38393.HCl, and R-(+)-
SCH-23390.HCl were purchased from Sigma Aldrich (Zwijndrecht, the 
Netherlands). Calcium chloride (CaCl2) was obtained from Baker (Deventer, the 
Netherlands). (-)-Nicotine ditartrate dihydrate from Acros Organics (Geel, 
Belgium). 
3 mM K+ Krebs-Ringer Buffer (KRB, Gibco-Invitrogen) contained (in mM): 121 
NaCl, 2 KCl, 25 NaHCO3, 1.2 MgSO4, 11 D-(+)-glucose, 1.2 KH2PO4, with 
modifications as used during whole experiment: CaCl2 (2.4 mM) and D(+)-
glucose (22 mM). The buffers were freshly prepared on each test day, kept at 
37 °C and gassed with 5 % CO2/95 % O2 (BOC gasses, Dublin, Ireland) for at 
least 30 min before use. 
 
3.2.2. Animals and tissue preparation 
Naïve adult male Wistar Unilever Harlan (WUH) rats, 100-150 g (Harlan, United 
Kingdom) were used. All experimental procedures were carried out according to 
the regulations of the Animal Research Ethics Committee of NUIM and national 
legislation. The rats were killed by decapitation, without anaesthetics (see 
methodological considerations below), using a guillotine. Brains were removed 
and dissected (according to Paxinos and Watson, 1998) as quickly as possible. 
Directly after preparation, the tissue was placed in ice-cold Krebs-Ringer Buffer 
gassed with 95 % O2/5 % CO2 before commencing the slicing procedure. 
For striatal recordings, the brain was blocked sagittally to split both hemispheres. 
The cut was made along the midline between coordinates +1.7 – +0.2 mm 
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relative to Bregma (Paxinos and Watson, 1998), using a razor blade. 
Hemispheres were glued, midline side up, to the plate of the vibratome 
(Campden Instruments, Loughborough, UK). The tissue block was sliced in 350 
µm thick slices till 2-3 slices around +1.7 – +0.2 mm relative to Bregma (Paxinos 
and Watson, 1998) were obtained. The slices were kept in Krebs-Ringer Buffer at 
room temperature and gassed with 95 % O2/5 % CO2 for 0.5 h before starting the 
experiment. 
 
 
 
Figure 3-1 Schematic of coronal brain slice including CPu  
The vertical line in the sagittal schematic (inset) indicates the coordinate where 
the coronal schematic was taken (between coordinates +1.7 – +0.2 mm relative 
to Bregma (Paxinos and Watson, 1998). CPu indicates the caudate putamen in a 
coronal section. The electrode indicates the position of recording. Diagrams were 
modified from Paxinos and Watson (1998). 
 
Methodological considerations: Tissue preparation 
Although some studies use anaesthetics before decapitation of the experimental 
animals, in house experience and previous published studies (e.g. Hiramatsu et 
al., 1994; Mantz et al., 1994) showed that the use of anaesthetics can affect the 
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results of neurochemical experiments. Therefore all experiments in this study 
were performed using decapitation without the use of anaesthetics. 
 
3.2.3. Fast Cyclic Voltammetry (FCV) 
Extracellular recordings were made in slices using a custom-made interface-type 
chamber. Slices were perfused with Krebs-Ringer buffer (KRB) at 29-30 °C and 
gassed with 95 % O2/5 % CO2. A three-electrode setup was used consisting of a 
commercially available carbon fiber glass electrode (Ø 5 µm x length 30-60 µm, 
KationScientific, USA) for current recordings, an auxillary electrode (an Ag/AgCl 
wire in a 100 uL-pipet tip with KRB), and a reference electrode (Ag/AgCl wire). All 
electrodes were connected to a headstage (Millar voltammeter probe, 2x 
amplification). Fast cyclic voltammetry was performed using a Millar-potentiostat 
(PD systems, West Moseley, UK, kindly donated by Dr. Julian Millar). A triangular 
waveform from 0 to -1.0 to +1.4 to -1.0 and back to 0 V vs. Ag/AgCl was used at 
a scan rate of 480 V/s. The sampling rate was 4 Hz and data was digitalised 
using an A/D-converter (Powerlab 4/20, ADInstruments, Oxford, UK). A standard 
PC with Chart software (v5.2, AD Instruments) was used for data acquisition and 
analysis. The faradaic current of the electrode was monitored using a digital 
oscilloscope (Nicolet 310).  
Dopamine release was electrically evoked by a monophasic stimulation pulse 
(100 µs width, 10 V amplitude) which was generated by a NeuroLog stimulator 
(NeuroLog NL-800, Digitimer, Hertfordshire, UK). The NeuroLog was connected 
to a Stimulus Isolation Unit (radio frequency transformer isolation unit, SIU5, 
Grass Technologies) to minimise artefacts. The electrical pulse(s) were applied 
using bipolar tungsten electrodes (100 µm apart; 0.1 MΩ, Molecular Probes Inc, 
USA). The stimulation pulse had a calculated current of 0.1 µA, according to 
Ohm‟s law (i.e. I = V /R; where I is current (A), V is potential (V) and R is 
resistance (Ω)). Both stimulating and recording electrodes were placed in the 
dorsal striatum, approximately 100 µm apart. The shape of the waveform was 
recorded by the A/D-converter and analysed using Scope software (v3.7.3, 
ADInstruments). 
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Methodological considerations: Electrodes 
Despite the good quality of home-made carbon fiber microelectrodes, their 
manufacturing is a very labour intensive process and can provide poor 
reproducibility. Therefore this study used commercially available carbon fiber 
microelectrodes (Ø 5 µm, 50 µm exposed, glass sealed; Kation Scientific, USA). 
The electrodes were manufactured according to the protocol described by Budai 
and Molnár (2001) using spark etching (Armstrong-James and Millar, 1979; 
Armstrong-James et al., 1980; Millar, 1992). Electrodes with a diameter of 5 µm 
were chosen as the capacitance (the ability of the electrode to hold an electrical 
charge) of smaller electrodes was found to be much larger, resulting in a lower 
signal to noise ratio (Wipf et al., 1989), and to minimise tissue damage by the 
electrode. Additionally, the use of smaller electrodes would result in less tissue 
damage. 
 
3.2.4. Experimental protocol 
The carbon-fiber microelectrode was placed into the CPu where transient 
dopamine release was monitored, and its position was adjusted to a site where 
single pulse electrical stimulated dopamine release was achieved. Single pulse 
electrical stimulation (0.1 ms, 10V) at 5 min intervals elicited reliable dopamine 
release detected in the range 0.05 to 0.15 µM. Peak release was reached within 
1 s and returned to baseline between 1 and 2 s. Stable release was maintained 
for 25 min before experiments with drug perfusion were initiated. 
 
<8 min
Pre-incubation of
slice in buffer
Dissection &
slice preparation
45 min
Stabilize release
25 min
Control
25 min
Incubation with
Drug A
25 min
Incubation with
Drug B
25 min
Electrical stimulation  
Figure 3-2 Experimental scheme of a typical release experiment 
Experimental scheme showing the actions and their respective time frames. 
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After preparation, the brain slice was pre-incubated at 32°C in the slice bath. 
Experiments were started after achieving a stable single pulse signal for at least 
25 min. At the end of the control period (i.e. incubation without test compound) 
different types of electrical stimulations were examined with 5 min recovery 
periods between each stimulation. Then the incubation was repeated in the 
presence of a test compound (i.e. Drug A or Drug B). 
 
3.2.5. Data analyses 
Chart software (ADInstruments) was used to evaluate the voltage-time potential 
traces obtained by averaging data in a 10 mV window centred on the peak 
oxidation potential for dopamine. Data were analysed using Chart software to 
detect peak amplitudes. Amplitudes (voltages, V) were converted to currents 
(amperage, A) to correct for gain settings. 
Graphs and statistical analyses were performed using PRISM graphing software 
(GraphPad, USA). The main effects of treatments were analysed using a one-
way analysis of variance (ANOVA): [F (dfb, dfw) = x; P = x]. When a significant 
difference was observed, the ANOVA was followed by a post hoc Bonferroni‟s 
multiple comparison test analysis where appropriate. Or using an unpaired two-
tailed t-test (all data with P < 0.05 were considered as significant) where 
indicated. The correlation (r2) value was calculated from the Pearson correlation 
coefficient using PRISM software. 
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3.3 RESULTS 
 
Prior to studing the interactions between nicotine and changes in dopamine 
functionality, a system for fast cyclic voltammetric measurements was 
successfully established (as previously described by e.g. Millar et al., 1985; Millar 
and Barnett, 1988; Palij et al., 1990; Kruk and O‟Connor, 1995; O‟Neill et al., 
2007).  
To investigate the quality of the commercially available carbon fiber 
microelectrodes (KationScientific, USA), a comparison of faradaic currents was 
made between custom-made and commercial carbon fiber microelectrodes. The 
measured faradaic current showed a clear representation of the applied triangular 
waveform by first a negative potential followed by a positive and negative 
potential, respectively. It was found that the commercial electrodes had 
comparable faradaic currents to the home made electrodes (Figure 3-3). 
Furthermore, the sensitivity of the commercial electrodes was determined by 
measuring different concentrations of dopamine in a physiologically relevant 
range, perfused through the experimental slice-bath. The signal-to-noise ratios 
and sensitivity of the commercial electrodes to the dopamine standard solutions 
(Figure 3-4) were comparable to the home-made electrodes. 
A 
 
B 
 
Figure 3-3 Faradaic current commercial vs custom-made electrode 
Representative faradaic currents of a carbon fiber microelectrode (Ø 5 µm) in a 
perfusing Krebs-Ringer Buffer salt solution, using a triangular waveform 
(superimposed linear grey-line) as described in the methods section. A.) A 
commercial available carbon fiber microelectrode (KationScientific). B.) A 
custom-made carbon fiber microelectrode (kindly donated by Dr. Carmel O‟Neill). 
y-axis, potential (V); x-axis, time (min). 
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Figure 3-4 Calibration curve of dopamine  
Increasing concentrations of dopamine were applied to the perfusion bath using a 
complete wash-out between each concentration. Mean ± s.e.m. of n = 4 
experiments on individual days using different electrodes. Dotted lines represent 
95 % confidence interval. r2 = 0.9952, y= 0.0114x + 0.0579. 
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In order to validate the FCV technique in a biological system, rat cortico-striatal 
brain slices were prepared as described in the methods section. After inserting 
the microelectrode into the slice, the presence of dopamine transients and 
stimulated release confirmed that the electrode was placed in a 
microenvironment with functional dopaminergic terminals that release dopamine. 
To validate the system, the effect of single pulse and multiple pulse (4 pulses at 1 
Hz, 4p@1Hz) electrical stimulation on dopamine release in rat striatal slices were 
examined. It was shown that 4p@1Hz induced twice as much dopamine release 
compared to a single pulse stimulation (Figure 3-5). The experiment was 
performed in the presence of GBR-12909, a dopamine transporter inhibitor, 
which explains the relative long decay time (indicated by a relative large half 
width) and is in consensus with previous literature (e.g. Palij et al., 1990). 
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Figure 3-5 Effect of single pulse and 4 pulses at 1 Hz stimulation on the 
release of striatal dopamine release  
A.) Representative example of dopamine overflow after single pulse and 
4p@1Hz electrical stimulation. B.) Effect of single pulse and 4 pulses at 1 Hz on 
dopamine release. Unpaired two-tailed t-test showed a significant increase of 
4p@1Hz in transient amplitude compared to single pulse (** P < 0.01). n = 2 
slices tested individual days from separate rats, in the presence of GBR-12909 (1 
µM). 
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Pharmacological validation of the FCV setup was achieved by examination of the 
effect of quinpirole on single- and multiple pulse stimulation in rat striatal slices. A 
test concentration of quinpirole (1 µM) was incubated for 60 min, reaching its 
maximal effect by 15 - 20 min. Therefore further concentrations were incubated 
for 25 min before stimulation. Quinpirole inhibited dopamine release at single 
pulse and 4p@1Hz electrical stimulation in a concentration dependent manner 
(Figure 3-6). However, quinpirole had a lower potency at 4p@1Hz stimulation 
compared to single pulse stimulation (pEC50 6.7 ± 0.1 vs. 7.5 ± 0.1, respectively).  
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Figure 3-6 Effect of quinpirole on electrically stimulated dopamine release  
A.) Quinpirole was tested at a concentration range from 1E-05 to 1E-10 M. Single 
pulse (■) and 4p@1Hz (▲). pEC50 and Emax (at 10 µM) values of quinpirole were; 
single pulse (7.4 ± 0.2 and 80%, respectively) and 4p@1Hz (6.8 ± 0.1 and 55 %, 
respectively). B.) Representative measured current of sample-and-hold trace at 
+600 mV potential (i.e. dopamine oxidation potential). Effect of 0, 0.1 and 10 µM 
quinpirole on single pulse induced dopamine release. n = 2 experiments at two 
individual days from two separate rats, in the presence of GBR-12909 (1 µM). 
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The effect of nicotine on dopamine release was investigated. After equilibration of 
the slice in the superfusion bath for 1 hr, the carbon fiber electrode was 
positioned into the dorsal striatum and dopamine release was evoked by single 
pulse electrical stimulation. Single pulse stimulation was repeated every 5 min 
and after a 20 min stable release, nicotine (500 nM) was added to the bath. 
Nicotine decreased single pulse induced dopamine release by 32 ± 7 %. The 
effect of nicotine (500 nM) on dopamine release was rapid and its maximal effect 
(Emax) was achieved by 10 min (Figure 3-7). 
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Figure 3-7 Effect of nicotine on single pulse induced dopamine release in 
time  
Single pulse stimulation was repeated every 5 min and after a 20 min stable 
release, nicotine (500 nM) was added to the bath (horizontal bar). Results of 4 
individual experiments performed on four different days (n = 2-4). 
 
Neurotransmission is highly dependant on the firing frequency of neurones. Using 
FCV it was shown that dopamine release produced by low frequency (5p@10Hz) 
or high frequency (5p@100Hz) electrical stimulation was not significantly different 
compared to single pulse stimulation in the absence of a dopamine reuptake 
inhibitor (Figure 3-8). Addition of nicotine (500 nM) to the slice bath for 25 min did 
significantly decrease dopamine release at single pulse and at low frequency 
stimulation. Interestingly, the presence of nicotine increased dopamine release at 
high frequency stimulation (Figure 3-8). 
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Figure 3-8 Representative sample and hold measurements of the dopamine 
signal following addition of nicotine  
The effect of different electrical stimulation frequencies (single pulse, 5 pulses at 
10 Hz and at 100 Hz) on dopamine release in corticostriatal slices (350 µm) in 
the absence (black lines) or presence (grey lines) of nicotine (500 nM). Insert: 
Vertical bar indicates current (A) and horizontal bar represents time (s). 
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These experiments were repeated for quantification and statistical assessment of 
this biphasic effect of nicotine (Figure 3-9). There was no significant effect found 
between the different stimulation parameters in the absence of nicotine (control 
group [F (2,8) = 2.044; P = 0.1918]), but did show a significant difference in the 
presence of nicotine compare to its respective control group (Nicotine group [F 
(2,9) = 52.58; P < 0.001]). Further post hoc Bonferroni‟s analysis showed that 
addition of nicotine significantly decreased single pulse stimulated dopamine 
release (100 % vs. 64 ± 8%, P < 0.01), and also significantly decreased low 
frequency multiple pulse, 5p@10Hz (128 ± 12 % vs. 48 ± 14 %, P < 0.01). 
However, interestingly, addition of nicotine significantly increased dopamine 
release at high frequency multiple pulse stimulation, 5p@100Hz (116 ± 13 % vs. 
215 ± 15 %, P < 0.01). 
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Figure 3-9 Effect of nicotine on electrically stimulated dopamine release at 
different frequencies 
The effect of nicotine (500 nM) on electrically evoked dopamine in dorsal striatal 
slices with single pulse or multiple pulses (5p@10Hz or 5p@100Hz). [DA]0, 
extracellular dopamine concentration. [DA]0, extracellular dopamine 
concentration. Unpaired two-tailed t-test, ** P < 0.01. Data of 4 individual 
experiments (n = 4). 
 
 
As previously shown in Chapter 2, nicotine induced behavioural sensitisation can 
be attenuated by dopamine D1 ligands. Therefore the effect of dopamine D1 
ligands on electrically stimulated dopamine release, at different frequencies, was 
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investigated. Firstly, the effect of the dopamine D1 receptor agonist SKF-38393 
on electrically stimulated dopamine release was examined.  
Rat corticostriatal slices were incubated with SKF-38393 (1 µM) for 25 min and 
dopamine release was induced by a single pulse and multiple pulse (5p@10Hz 
or 5p@100Hz) stimulation, followed by incubation of SKF-38393 in the presence 
of nicotine (500 nM) for another 25 min. Statistical analysis using a one-way 
ANOVA showed no significant treatment effect of SKF-38393 in the absence or 
presence of nicotine on single pulse stimulated dopamine release ([F (2, 8) = 
0.8763; P = 0.4528], Figure 3-10). Following 5p@10Hz stimulation there was a 
significant treatment effect observed, [F (2, 8) = 30.84; P = 0.0002], and post-hoc 
Bonferroni‟s analysis showed a significant decrease of dopamine release 
following SKF-38393 in the presence of nicotine (P < 0.01, Figure 3-10). The 
same effect was observed at 5p@100Hz: Following 5p@100Hz stimulation there 
was a significant treatment effect observed, [F (2, 7) = 18.39; P = 0.0016], and 
post-hoc analysis showed a significant decrease of dopamine release following 
SKF-38393 in the presence of nicotine (P < 0.01, Figure 3-10). Compared to 
nicotine alone, SKF-38393 fully antagonised the effect of nicotine on single pulse 
release but not at multiple pulse (5p@10Hz and 5p@100Hz) stimulated release 
(Figure 3-9 vs Figure 3-10). 
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Figure 3-10 Effect of a D1 agonist and combination with nicotine on 
electrically stimulated dopamine release 
The effect of the dopamine D1 receptor agonist SKF-38393 on dopamine release 
and pre-incubation of SKF-38393 (1 µM) on the effect of nicotine. Dotted-line 
represents nicotine control level (Figure 3-9). Post hoc Bonferroni‟s, ** P < 0.01, 
*** P < 0.001. Data from 4 individual experiments (n = 4). 
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The effect of the prototypical dopamine D1 receptor antagonist SCH-23390 on 
electrically stimulated dopamine was examined.  
Rat corticostriatal slices were incubated with SCH-23390 (1 µM) for 25 min and 
dopamine release was induced by a single pulse and multiple pulse (5p@10Hz 
or 5p@100Hz) stimulation, followed by incubation of SCH-23390 in the presence 
of nicotine (500 nM) for another 25 min. Statistical analysis using a one-way 
ANOVA showed no significant treatment effect of SCH-23390 in the absence or 
presence of nicotine on single pulse stimulated dopamine release ([F (2, 9) = 
3.610; P = 0.0706], Figure 3-11A). Following 5p@10Hz stimulation there was a 
significant treatment effect observed, [F (2, 8) = 19.55; P = 0.0008], and post-hoc 
Bonferroni‟s analysis showed that SCH-23390 significant reversed the effect of 
nicotine on decrease of dopamine release (P < 0.05, Figure 3-11A). The same 
effect was observed at 5p@100Hz: Following 5p@100Hz stimulation there was a 
significant treatment effect observed, [F (2, 3) = 8.370; P = 0.0109], and post-hoc 
analysis showed a significant decrease of dopamine release following SCH-
23390 in the presence of nicotine (P < 0.05, Figure 3-11A). Compared to nicotine 
alone, SCH-23390 fully antagonised the effect of nicotine on single pulse release 
but did not alter the effect of nicotine at multiple pulse (5p@10Hz and 5p@100Hz) 
stimulated release (Figure 3-9 vs Figure 3-11A). 
Furthermore, the effect of SCH-23390 following pre-incubation with nicotine was 
assessed. SCH-23390 blocked the inhibitory effect of nicotine on single pulse 
induced dopamine release, but not the multiple pulse induced release (Figure 
3-11B vs Figure 3-9). No significant effect of treatments was observed compared 
to their respective controls (unpaired two-tailed t-test, P > 0.05). These results 
are comparable to those obtained after pre-incubation of SCH-23390 followed by 
nicotine, although the reversal effect of SCH-23390 on single pulse stimulated 
dopamine release was not as efficacious compared to pre-incubation of SCH-
23390. 
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Figure 3-11 Effect of a D1 antagonist and nicotine on electrical stimulated 
dopamine release 
A. The effect of the dopamine D1 receptor antagonist SCH-23390 (1 µM) alone 
on dopamine release and the effect of nicotine in the presence of SCH-23990. 
Dotted-line represents nicotine control level (Figure 3-9). Post hoc Bonferroni‟s, * 
P < 0.05; *** P < 0.001. Data from 4 individual experiments (n = 4). B. The effect 
of SCH-23390 (1 µM) after nicotine pre-incubation. Data from 3 individual 
experiments, unpaired two-tailed t-test showed P > 0.05 for all groups (n = 3). 
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3.4 DISCUSSION 
 
This study showed that nicotine affects stimulated dopamine release in slices of 
rat caudate putamen ex vivo and that its effect is dependent on the frequency of 
the electrical stimulation. Furthermore, this study showed for the first time that 
dopamine D1 ligands can affect the stimulation frequency dependent effect of 
nicotine on dopamine release. 
 
The present study investigated the effect of nicotine and dopamine D1 ligands on 
dopaminergic neurotransmission. Studying the role of dopamine transmission can 
be achieved with various methodological approaches. In functional terms, the 
brain is highly spatially and temporally organised. Its function may be studied 
using many different techniques. Basically four main approaches can be 
distinguished, microdialysis, electrophysiology, imaging (e.g. magnetic resonance 
imaging (MRI) or positron emission tomography (PET)) and voltammetry. Each 
method has its advantages and disadvantages, which makes them 
complementary to each other. For example, electrophysiology offers a very high 
temporal resolution but provides only an indirect estimate of dopamine 
transmission and is often not sufficient to identify dopaminergic neurones 
(Margolis et al., 2006). Moreover, the limitations of these techniques are mainly 
based on spatial and temporal sampling constraints. Microdialysis and in vitro 
superfusion techniques are known for their superior selectivity in combination 
with chromatography and suitable detectors. However, they have very poor 
spatial resolution and relatively long sampling times of ca. 10-20 min. The 
technique of fast cyclic voltammetry (FCV) offers high spatial and high temporal 
resolution, which is superior to the other techniques. Moreover, FCV is a less-
invasive technique (compared to e.g. superfusion of microdialysis) which makes it 
suitable for in situ and long term analysis (Bull et al., 1990), and has been 
extensively used to study neurochemistry in vivo and in vitro. A good introduction 
to FCV and other electrochemical methods, including their disadvantages and 
limitations, is given in the book „Electrochemical Methods for Neuroscience‟ 
(Michael and Borland, 2007). 
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The selectivity of the FCV technique for dopamine is extensively discussed in 
previous literature (see introduction Chapter 3). For example, the selectivity of the 
technique for dopamine was examined by oxidation – reduction peak 
characterisation, corresponding dopamine standards, abolishment of signal by 
reserpine, desipramine selectively blocked noradrenaline but not serotonin signal, 
nialamide (a monoamine oxidase inhibitor, MAOi) had no effect, and so 
metabolites did not interfere with the signal (Stamford et al., 1988b; Stamford, 
1990). 
 
FCV is also a versatile method and determinations of various neurotransmitters in 
brain slices using fast-cyclic-voltammetry are described, for example: dopamine 
(Palij et al., 1990; Bull et al., 1990; Kelly and Wightman, 1987), noradrenaline 
(Palij and Stamford, 1992; 1993; 1994), serotonin (O‟Connor and Kruk, 1991; 
Threlfell et al., 2004, 2010), adenosine and adenosine-5 -triphosphate (Swamy 
and Venton, 2007; Cechova and Venton, 2008; Xu and Venton, 2010) histamine 
(Cechova and Venton, 2008), tyramine and octopamine (Cooper and Venton, 
2009), and nitric oxide (Ledo et al., 2005; Cechova and Venton, 2008). The cyclic 
voltammogram produced by FCV contains extensive electrochemical information 
which can be used to identify the individual compounds. By simultaneous 
measurement of both the oxidation and reduction potentials of the analytes it is 
possible to distinguish between chemically related and distinguished compounds. 
Although a great advantage of FCV is to chemically identify compounds by their 
oxidation and reduction potentials, the FCV system as designed by Dr. Julian 
Millar uses a sample and hold device at either the oxidation or reduction peak but 
not simultaneously. This study used a Miller-potentiostat and it was therefore not 
possible to identify compounds using their voltammogram alone. 
 
For the pharmacological validation of the FCV system, the prototypical dopamine 
D2/D3 agonist quinpirole was used. A dopamine D2-like agonist was chosen as 
this receptor is a known autoreceptor which regulates the release of dopamine 
(Palij et al., 1990; Moquin and Michael, 2009). The inhibitory effect of quinpirole 
on dopamine release and pEC50 values found in this study, are in agreement with 
previous literature (O‟Neill et al., 2007). The shift in potency of quinpirole seen at 
a multiple pulse stimulation (4p@1Hz) compared to a single pulse stimulation, 
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could be explained by competition of quinpirole and synaptic available, released 
endogenous dopamine. This is suggested as 4p@1Hz induced twice as much 
dopamine release compared to single pulse stimulation. 
 
Neurotransmission (including the release of neurotransmitters) is highly, but not 
exclusively, dependent on the firing rate of the neurones. The physiological firing 
frequency range of dopaminergic neurones in the brain can be divided into tonic 
(5-10 Hz) and phasic burst-like (20-100 Hz) firing frequencies (Hyland et al., 
2002). This physiological tonic and burst firing can be simulated by electrical field 
stimulation. A bipolar stimulating electrode is positioned in the slice, near the 
recording electrode, and can generate single or multiple electrical pulses at a 
desired frequency. When focussed on multiple pulse stimulation, these results 
showed that a 4p@1Hz gives a larger peak of dopamine release compared to 
5p@10Hz or 5p@100Hz (Figure 3-5 and Figure 3-9). This is likely due to 
accumulation of dopamine release at 4p@1Hz, where the accumulation is less at 
higher stimulation frequencies. 
 
Previous studies on the effect of bath applied nicotine on dopamine release have 
yielded conflicting results. This may be a consequence of the different techniques 
used and the fact that results relate to both in vivo and ex vivo experiments. For 
example, ex vivo superfusion studies using [3H]-dopamine and K+-stimulation 
showed that nicotine increased extracellular dopamine levels. However, studies 
using high-speed dopamine measurement techniques described a bidirectional 
effect of nicotine on dopamine release (Rice and Cragg, 2004; Zhang and Sulzer, 
2004). When stimulating electrically at a low frequency (representing tonic 
release), nicotine decreased dopamine release, which is in contrast to what is 
observed with superfusion studies. When stimulating at high frequency 
(representing phasic release), nicotine increased dopamine release. This latter 
observation is comparable with the findings using [3H]-dopamine and K+-
stimulation suggesting a common phasic dopamine release. Furthermore, 
preferential effects of nicotine on dopamine release within the striatum (i.e. 
between dorsal and ventral) have been reported (e.g. Imperato et al., 1986; Rice 
and Cragg, 2004; Zhang and Sulzer, 2004). 
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A long-held view of psychostimulant addiction (for example by nicotine, cocaine, 
or amphetamine) is that the reinforcing properties are mediated by an increase in 
dopamine levels, especially within the striatum (e.g. Di Chiara and Imperato, 
1988). Paradoxically, it has been reported in human, animal and cell based 
studies, that nicotine administration desensitises nAChRs on dopaminergic 
neurones (Pidoplichko et al., 1997; Zhou et al., 2001) and suppresses striatal 
dopamine release evoked by single action potentials (Zhou et al., 2001). This 
phenomenon was further studied using fast cyclic voltammetry in brain slices and 
determined that nicotine has a preferential, bidirectional effect on dopamine 
release, i.e. nicotine decreases stimulated dopamine release at a single pulse or 
low frequency stimulation, whereas nicotine increased dopamine release at high 
frequency electrical stimulation (Rice and Cragg, 2004; Zhang and Sulzer, 2004). 
The present studies confirmed these findings of the effect of nicotine on 
electrically stimulated dopamine release. 
 
The present study additionally investigated for the first time the pharmacological 
“modification” of nicotine induced “frequency-dependent-signalling” on dopamine 
release. The study examined the effect of the dopamine D1 agonist SKF-38393 
and the D1 antagonist SCH-23390 on nicotine‟s biphasic modulation of dopamine 
release. SKF-38393 or SCH-23390 alone were ineffective in altering electrically 
stimulated dopamine release, which can be explained by the fact that the 
dopamine D1 receptor is localised post-synaptically on GABAergic and 
cholinergic interneurones and therefore may not directly affect dopamine release. 
This finding is also in agreement with previous literature (e.g. Palij et al., 1990; 
O‟Neill et al., 2007). However, it has been reported that SKF-38393 increased 
dopamine release in vivo rat striatum (Walters and Howard, 1990). For the first 
time, this study showed that SKF-38393 and SCH-23390 selectively affect 
nicotine induced frequency dependent dopamine release. It was found that pre-
incubation with either D1 ligand significantly reversed or attenuated nicotine‟s 
effect on single pulse, but not at multiple pulse (high frequency) evoked 
dopamine release. 
When nicotine was pre-incubated before the addition of SCH-23390 to the bath, 
no significant effect of SCH-23390 was observed (Figure 3-11). This could be 
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explained by the low number of experiments (i.e. n = 3) or by (de-) sensitisation 
of nAChRs by nicotine during its pre-incubation time. 
 
It is not yet known how to explain the bidirectional effect of nicotine on dopamine 
release. There are a few hypotheses to explain this phenomenon. For example 
there may be different nAChR subtypes involved in single and multiple-pulse 
release. In vivo single cell recordings in rat VTA indicated that the nAChR 
subtypes  contribute to increased firing rate but not bursting (e.g β2 and α7, 
Schilstrom et al., 2003; Mameli-Engvall et al., 2006). Suggesting from the results 
presented in this thesis, it may be that co-activation or localisation of different 
nAChR subtypes occurs with dopamine D1 receptors. Another concerted 
hypothesis for the nicotinic control of burst firing suggests the rapid and 
preferential desensitisation of nAChRs on dopaminergic neurones (Wooltorton et 
al., 2003; Piccotto et al., 2008). In addition to all of these hypotheses, it must be 
considered if single or multiple nAChR subtypes play this essential and complex 
role in the bidirectional effect of nicotine on dopamine release (Livingstone and 
Wonnacott, 2009). 
 
This phenomenon of preferential or bidirectional effects on neuronal activity at 
different stimulation frequencies is also described in electrophysiology measuring 
firing frequency and is called „frequency dependent signalling‟ or FDS. Further 
research into the quantal neurotransmitter release and frequency relationships is 
needed to evaluate if this phenomenon also applies to functional neurotransmitter 
release. In this study only 5p@10Hz and 5p@100Hz were tested representing 
low and high frequency stimulation respectively. Future experiments should 
assess various stimulation frequencies within the 2 to 100 Hz range and thereby 
creating frequency-response curves. 
 
There are a few reports which studied the effect of behavioural sensitisation on 
ex vivo dopamine release, as measured by FCV. It was shown that there is no 
difference between single pulse stimulated dopamine release in NAc and VTA 
slices from (+)-amphetamine- or quinpirole sensitised groups (Muscat et al., 1993, 
1996), or from caudate and accumbens slices from cocaine sensitised rats 
(Jones et al., 1996; Lee et al., 1998), when compared to vehicle. Dopamine 
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release was enhanced after multiple pulse stimulation (20-50p@5-200Hz) in 
nucleus accumbens and VTA slices from rats sensitised to quinpirole (Muscat et 
al., 1993, 1996). The potency of bath applied quinpirole to inhibit dopamine 
release was decreased in slices containing nucleus accumbens and VTA from 
rats sensitised with quinpirole (Muscat et al., 1993, 1996), and caudate slices 
from cocaine sensitised rats (Jones et al., 1996). In nucleus accumbens and VTA 
slices from (+)-amphetamine sensitised rats, the potency of bath applied 
quinpirole was increased and decreased respectively (Muscat et al., 1993, 1996). 
However, no release experiments following nicotine sensitisation are known and 
future experiments should include the examination of frequency dependent 
release in tissue from chronic nicotine treated animals, to investigate the role of 
frequency dependent signalling in behavioural sensitisation. Many studies have 
shown that the length of time from tissue extraction to analysis is important for 
the effects seen when measuring [3H]-dopamine release ex vivo (e.g. Peris et al., 
1991). This should also be taken in consideration when testing/preparing tissue 
from (chronic) treated animals. 
 
Conclusion 
The present study has shown the effect of only single concentrations of SKF-
38393, SCH-23390 and nicotine on frequency dependent dopamine release. 
However, future experiments should assess various concentrations in order to 
determine the potency (pEC50 values) and efficacy (Emax values) of these 
compounds. The present experiments focused on dopamine release where it 
investigated the role of nicotine on dopamine signalling. However, the extensive 
literature available describing behavioural sensitisation also indicates that many 
different compounds can induce and block behavioural sensitisation. This could 
suggest that more than one mechanism, besides the dopamine system, is 
involved in sensitisation.  
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Chapter 4. Development and in vitro application of a 
method for measuring (cyclic-) nucleotides using 
LC-MS/MS 
 
Abstract. 
OBJECTIVES: Cyclic-adenosine monophosphate (cAMP) plays an important role 
in cell signalling and is widely used as a marker for receptor activation and as a 
molecular target for pharmacological research. This chapter presents the 
development, validation and potential application of a novel method for the 
determination of cAMP and ATP (adenosine triphosphate) and other nucleotides 
in a biological system by combining zwitterionic hydrophilic interaction liquid 
chromatography (HILIC) and tandem mass spectrometry (MS/MS). 
METHODS: The HILIC-MS/MS method was developed for the simultaneous 
quantitative analysis of cAMP and ATP, and was validated by assessment of 
linearity (over a range from 0.5-100 nM for cAMP and 50 nM-50 µM for ATP 
(r2 >0.999)), resolution, limit of detection (0.5 and 50 nM for cAMP and ATP, 
respectively) and reproducibility. 
RESULTS: The method was validated and applied in vitro to determine cAMP 
accumulation in cell cultures and brain tissue samples. The effect of several 
dopamine D2 receptor (partial-) agonists and antagonists on cAMP accumulation 
was assessed by determination of the cAMP/ATP ratio in cells transfected with 
the human dopamine D2L receptor. Furthermore, the method was applied ex vivo 
to determine the effect of a dopamine D1 receptor agonist on cAMP accumulation 
in brain slices. 
CONCLUSIONS: These results demonstrate that the described bioanalytical 
method was robust, fast, sensitive, and selective. Moreover, it showed utility in 
determining cAMP/ATP in biological systems and the ability to study the effect of 
(partial-) agonists and antagonists which makes it a useful tool for drug discovery. 
 
 
 
Keywords: cAMP, ATP, HPLC, MS/MS, HILIC 
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4.1 INTRODUCTION 
 
Cyclic nucleotides (e.g. cAMP and cGMP) are intracellular second messengers 
which play an important role in many physiological processes. cAMP is 
synthesised from ATP by the enzyme adenylate cyclase (AC), and is metabolised 
by the enzyme phosphodiesterase (PDE). cAMP is widely used in biochemical, 
pharmacological and drug research as a marker to screen the activity of 
compounds for specific receptors. Additionally, cyclic nucleotides are used to 
study the activity of PDEs, which play an important role in various 
neuropsychiatric and cardiological diseases. 
 
 
Figure 4-1 Cartoon of dopamine receptor coupled cAMP-pathway  
Activation of the dopamine D1 receptor or D2 receptor will uncouple Gαs or Gαi 
from their heterotrimers (together with Gβ and Gγ subunits), respectively. The 
Gαs subunit can activate the enzyme adenylate cyclase (AC) which catalyzes the 
formation of cAMP from ATP. Gαi can inhibit AC which attenuates cAMP 
formation. 
 
Development of methods for the measurement of (cyclic-) nucleotides has 
received considerable interest in the past few decades, and two major 
approaches for the determination of cAMP accumulation have been developed. 
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Firstly, the classical metabolic labelling method employs tritium-labelled adenine 
as the substrate, followed by anion-chromatographic separation of [3H]-cAMP 
and [3H]-ATP (Solomon et al., 1974; Feenstra et al., 2003). Secondly, the more 
recently developed techniques are based on high throughput, including 
electrochemiluminescence, enzyme complementation, radiometric- and 
luminescence- proximity, fluorimetry, fluorescence polarisation, reporter genes 
(e.g. luciferase and green fluorescent protein) and time-resolved fluorescence 
assays (see Williams, 2004 for review). Although very sensitive, the 
disadvantages of current methods are the requirement of radioactive substrates, 
high false-positive hits and/or the limitation of measuring only one component at 
a time and are highly labour intensive (Williams, 2004). Simultaneous analysis of 
cAMP and ATP, to calculate a cAMP/ATP ratio, is often required to better 
estimate the efficacy (or intrinsic activity) of partial agonists, especially for 
inhibitory coupled receptors like the dopamine D2 receptors. Furthermore, ATP is 
the basic energy source of the living cells and the additional detection of ATP can 
be used as an indicator for cell viability to detect possible cytotoxicity (Kangas et 
al., 1984). 
 
More recently, another analytical method, liquid chromatography – tandem mass 
spectrometry (LC-MS/MS), has gained interest due to its specificity, 
reproducibility and sensitivity (Banoub et al., 2005). Because of the extremely 
polar properties of nucleotides, due to the presence of (multiple-) phosphate 
groups, most LC methods use anion exchange chromatography or reversed 
stationary phases in combination with ion-pairing agents. Unfortunately, both of 
these methods have their drawbacks when used in combination with MS/MS 
analysis (for review see Niessen, 1998). However, hydrophilic interaction liquid 
chromatography (HILIC) is able to separate very polar compounds, without the 
needs of ion-pairing agents, and uses mobile phases which are compatible with 
mass spectrometry analysis. 
 
The involvement and importance of dopamine as an endogenous 
neuromodulator is indisputably in many neuropsychiatric disorders (Marsden, 
2006), and is therefore the key focus of pharmacological research. In numerous 
of cases, studies were designed to specifically screen for dopamine receptor 
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subtype selective ligands. A commonly used method to assess the effect (i.e. 
selectivity, potency and efficacy) of these selective ligands in vitro is to test their 
effect on intracellular cAMP accumulation in cells transfected with specific 
receptor subtypes. 
Although cell based assays have their advantages (e.g. cells can be cultured in 
large amounts for high throughput screening, cells can contain one specific 
receptor subtype), it is still desirable to assess the effect of the compounds in a 
more physiological advanced system. One alternative between in vitro cell based 
assays and in vivo assays is the use of tissue isolated from the animal. Hereafter 
referred to as ex vivo. This can be tissue from non-treated animals or tissue from 
animals (chronically) treated in vivo.  
In the past it was very difficult to examine nucleotides, e.g. cAMP, in rat brain 
slices due to large inter- and intra- assay variation. Hypothetically, like the cell 
based assay, the variation might be caused by the variation in amount of slices 
per sample, and that the level of ATP could be used as a marker for the amount 
of protein. By calculating a cAMP/ATP ratio, a correction could be made for the 
amount of slices in each sample-well, which will reduce variation. 
 
This project initially started with the hypothesis that the radiometabolic labelling 
method for the measurement of [3H]-cAMP and [3H]-ATP, as described by 
Salomon and colleagues (Salomon et al., 1974; Salomon, 1979), could be 
optimised. The optimisation included miniaturisation from 24-well plate cell 
cultures and individual solid-phase-extraction (SPE-) columns to a 96-well plate 
cell culture and online 96-well SPE-filterplates. This optimisation was 
hypothesised to improve the quality of the assay by reducing variation, and 
subsequently improve the ability to measure the effect of compounds with 
reduced efficacy (i.e. partial agonists). Furthermore the miniaturisation would 
increase the robustness, performance and have a higher throughput, which is 
required for future ex vivo studies (later to be discussed in Chapter 5). However, 
miniaturisation of the radioactive assay to 96-well plates did not succeed due to 
radiolabel concentrations reached below limit of detection (data not showed and 
not to be discussed further in this thesis). A second hypothesis was then 
investigated which include the measurement of the two nucleotides of interest (i.e. 
cAMP and ATP) using mass spectrometry. Preliminary studies investigated flow 
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injection analysis (FIA) to quantify cAMP and ATP using the mass separation 
resolving power of the mass spectrometer only. Unfortunately, the limit of 
detection was approximately 1 µM for cAMP, where the expected levels were 
around 1 nM of cAMP. Therefore a hyphenated/hybrid technique by combination 
of liquid chromatography with mass spectrometry was proposed. 
 
The aim of this study was to develop and validate a rapid, sensitive and selective 
method for the simultaneous analysis of cAMP and ATP in biological samples. 
Here, for the first time, we present a method and its application using the 
powerful combination of hydrophilic interaction liquid chromatography and 
tandem mass spectrometry (HILIC-MS/MS) to measure nucleotides. The 
analytical method was applied to in vitro biogenic samples, and the effect of 
several dopaminergic D2 (partial-) agonists and antagonists on intracellular cAMP 
accumulation was assessed. Furthermore, a ratio of cAMP/ATP was calculated 
were ATP was used as a biomarker for cell viability and provide indices of cell 
toxicity and/or cell number which significantly reduced variation. 
To investigate the application of the developed method using brain tissue, slices 
from rat dorsal striatum (caudate putamen) were prepared. The striatum is known 
to contain all different subtypes of the dopamine receptor (i.e. D1-5) (Tarazi and 
Baldessarini, 1999). The dopamine D1-like receptors (i.e. D1 and D5) are 
positively coupled to AC, and activation will lead to an increase of cAMP levels 
(Kebabian and Calne, 1979; Seeman and Grigoriadis, 1987). The dopamine D2-
like receptors (i.e. D2, D3 and D4) are negatively coupled to AC, and activation will 
lead to a decrease of cAMP levels (see Chapter 1). 
 
Dopamine receptors are coupled to adenylate cyclase and subsequently their 
activity can be monitored by the measurement of cAMP accumulation. One of the 
first examples of making the in vitro cell-based experiments possible is the 
dopamine D2 receptor, which was firstly cloned and transfected into cells by 
Bunzow and colleagues (Bunzow et al., 1988). By culturing these cells on a large 
scale it is possible to assess the effect of D2 receptor ligands on receptor binding 
and changes in intracellular pathways such as cAMP, although, the biological 
relevance of transfected cell systems has been questioned. Therefore native 
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systems, like ex vivo slice preparations, remain pivotal to our understanding of 
the complex pharmacological systems within the brain. 
 
Many neuropsychiatric disorders are suggested to be the result of changes in 
dopaminergic function. The basal ganglia, specifically the striatum, are suggested 
to play an important role in modulation of movement and cognitive processes 
involving executive function and reward (for review see, Balleine et al., 2007). 
Especially located in the striatum, the dopamine D1 receptor appears to play a 
pivotal effect in neuropsychiatric disorders (see Chapter 1 and Chapter 2). 
Therefore this chapter also assessed the utility of brain slices to study putative 
changes of intra-cellular (cyclic-) nucleotides in tissue from in vivo disease-
models (e.g. behavioural sensitisation). 
 
HYPOTHESES AND AIMS 
 
Hypotheses: 
- Due to the very polar physical properties of nucleotides, chromatographic 
retention of cAMP and ATP can be achieved using a zwitterionic (ZIC®-pHILIC) 
column. 
- A high throughput cAMP-method is required for the large amount of samples 
from future studies; the development of a 96-well format assay in combination 
with LC-MS/MS will increase throughput and keep simultaneous analysis of 
cAMP and ATP. 
 
 
Aims: 
- Development and analytical validation of the simultaneous analysis of cAMP 
and ATP by using a ZIC®-pHILIC column in combination with electrospray 
ionisation mass spectrometry. 
- Achieve the separation of cAMP and ATP from biological matrices (i.e. cell 
lysate and brain tissue lysate), and validate this method conform generally 
accepted bioanalytic criteria as given by the United States Food and Drug 
Administration (FDA; FDA, 2001). 
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- Development and pharmacological validation of a 96-well format cell based 
assay to measure the effect of compounds on cAMP accumulation. 
- Validation of a 96-well filterplate method for the ex vivo measurement of cAMP 
accumulation in brain slices, to increase throughput in such way that samples 
from multiple treatment groups in vivo can be processed simultaneously. 
-  Pharmacological validation using dopamine D1 and D2 receptor (partial-) 
agonists and antagonists, which can be used for drug discovery, to ensure 
integrity of the assay. 
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4.2 MATERIALS AND METHODS 
 
The described analytical method validation and in vitro pharmacological 
experiments were performed at Abbott Healthcare Products, the Netherlands. 
 
4.2.1. Chemicals 
Adenosine-cyclic-3‟,5‟-monophosphate (cAMP), adenosine-triphosphate (ATP), 
25 % aqueous ammonium hydroxide (NH4OH), ammonium bicarbonate 
(NH4HCO3), D(+)-glucose, forskolin (colforsin), dopamine, (-)-quinpirole, LY-
741626, (±)-SKF-38393, ropinirole, (+)-terguride, haloperidol and (-)-sulpiride 
were purchased from Sigma Aldrich (Zwijndrecht, the Netherlands). Lisuride was 
purchaced from Tocris (Washington, DC, USA). HPLC grade water, LC/MS grade 
acetonitrile (ACN) and calcium chloride (CaCl2) were obtained from Baker 
(Deventer, the Netherlands). 1-Methyl-3-isobutylxanthine (IBMX) from 
Calbiochem (Ontario, Canada). Bifeprunox was synthesised by Solvay 
Pharmaceuticals, the Netherlands. 
 
4.2.2. Liquid chromatography 
High Performance Liquid Chromatography (HPLC) separation was performed 
using an Agilent 1100 liquid chromatography system equipped with a binary 
pump operating at 0.5 mL/min, thermostatic auto sampler and column oven 
(Agilent Technologies, Amstelveen, the Netherlands). The injector was 
maintained at 4 °C and injection volumes were 10 µL. For the separation of 
cAMP and ATP a ZIC®-pHILIC (5 µm polymeric beads, 150 x 4.6) PEEK column 
(SeQuant, AB, Sweden) was used.  
Mobile phase A consisted of 10 mM ammonium bicarbonate buffer adjusted to 
pH 9.4 with ammonium hydroxide in 20 % acetonitrile in HPLC grade water. 
Mobile phase B consisted of 100 % acetonitrile. A linear gradient profile from 
53.7 % B to 0  % B over 1 min followed by a 1 min period of 0 % B and a 3.5 min 
re-equilibration period was used, after which the column was directly ready for 
the next injection. Total run time using pre-sampling was less then 6 min. The 
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column temperature was controlled at 35 °C. The LC system was controlled by 
Chemstation software (Chemstation for LC version 1.4, B.01.01, Agilent 
Technologies, Amstelveen, the Netherlands). 
 
4.2.3. Preparation of standards 
Stock solutions (10 mM of each analyte) were prepared in the HPLC-grade water. 
Calibration standards were prepared by serial dilution ranging from 1 - 100 nM for 
cAMP and 0.1 – 10 µM for ATP. The accuracy (percentage Relative Error, %RE) 
and precision (percentage Relative Standard Deviation, %RSD) of the method 
were determined by replicate analysis of five individual calibration curves. This 
procedure was repeated over five days to get intra- and inter- day variability. 
Quality control samples (QCs) contained 10 nM of cAMP and 1 µM of ATP, and 
were measured in between every 12 samples. Dilutions were made in lysis buffer 
(10 mM NH4HCO3, adjusted to pH 9.4 with 25 % NH4OH solution, in 63 % ACN in 
HPLC grade water). 
 
4.2.4. Mass spectrometry 
In this study, two mass spectrometers were investigated. First, for the 
development of HILIC in combination with a mass spectrometer and the 
subsequent in vitro pharmacological validation, a linear quadrupole ion trap mass 
spectrometer (LTQ10000, Thermo Fisher Scientific /Finnigan, San Jose, CA, 
USA) was used. The HPLC-system, as described above, was coupled to the 
mass spectrometer using an electrospray ionisation (ESI) source. A post-column 
split ratio of 1:5 was applied to reduce fouling of the ion source. After the splitter a 
divert valve directed the column effluent to waste in the period before and after 
elution of the analyte of interest. During effluent diversion, a second Agilent 1100 
isocratic pump delivered a mixture of 50 % (v/v) acetonitrile and water to the 
mass spectrometer to ensure a stable electro spray and to clean the orifice. The 
ion spray voltage was set at 2 kV operating in negative electrospray ionisation 
(ESI). The capillary temperature was set at 300 °C and capillary voltage was set 
to -16 V and -23 V for cAMP and ATP, respectively. Nitrogen flow for sheet- and 
auxiliary- gasses were set at 20 and 15 (arbitrary units) respectively. Sweep gas 
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was not used. The tip of the probe was set off axis to the orifice to ensure system 
robustness (i.e. prevent fouling of the source). Daughter scanning was used as 
the detection mode, as shown in Table 4-1. 
Two segments were used (i.e. m/z 328 for cAMP and m/z 506 for ATP) in the 
negative ESI mode. Before and after the negative ESI segments, segments of 
positive ESI mode were applied using the same conditions for spray voltage and 
gas flow to prevent possible charging of ion lenses of the mass spectrometer. 
Data were acquired with XCalibur v.2.0 SR2 and processed using LCQuan v.2.5 
(Thermo Fisher Scientific/Finnigan).  
 
Table 4-1 Mass spectral conditions for LTQ 10000 
Parent 
(m/z) 
Isolation  
width 
Collision  
energy 
Activation  
time (ms) 
Scan 
(m/z) 
IT time 
(ms) 
XIC 
(m/z) 
328 1.5 38 30 90 - 350 800 134 
506 2.0 25 30 135 - 550 800 408 
IT: Injection time; XIC: Extracted ion chromatogram; ms: milli seconds; m/z: mass 
to charge ratio. Activation type: Collision induced dissociation (CID). 
 
The second mass spectrometer investigated was a triple quadrupole mass 
spectrometer (Quattro PremierTM XE, Micromass, Waters, Milford, MA, USA). The 
HPLC-system was directly coupled to the triple quadrupole mass spectrometer by 
an orthogonal designed electrospray interface (Z-SprayTM-source.) This source 
design improves protection of the mass spectrometry source from fouling, e.g. by 
non-electroactive molecules. Massa spectrometer parameters were optimised by 
flow injection analysis of both compounds (i.e. cAMP and ATP) using auto-tune. 
Two segments were used in the positive ESI mode (i.e. m/z 330 for cAMP and 
m/z 508 for ATP). Data acquisition and analysis were performed with MassLynx 
v.4.1 software (Waters). 
 
4.2.5. Cell culturing 
The human dopamine D2 long splice variant receptor (hD2L) was cloned and 
expressed in Chinese Hamster Ovarian (CHO-K1) cells (Dr. D. Grandy, Vollum 
Institute, Portland, OR, USA). Cells were grown in Dulbecco‟s modified Eagle‟s 
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medium (DMEM; Invitrogen, Breda, the Netherlands) supplemented with 2 mM 
(L)-glutamine and 10 % heat-inactivated foetal bovine serum (FBS; Invitrogen) in 
93 % air/7 % CO2. Cells were cultured twice a week. For the cAMP assay, CHO-
hD2L cells were trypsinisated and transferred into 96-well plates (Nunclon
TM; VWR, 
Amsterdam, the Netherlands), 48 h before the assay to produce a 100 % 
confluent monolayer (ca. 40000 cells/well). 
 
4.2.6. cAMP accumulation assay (cell based) 
In vitro functional adenylate cyclase activation assay 
Test compounds were diluted in a 96-well plate using assay buffer (DMEM, 
containing 1 mM IBMX and 0.3 µM forskolin). Incubations were performed in 96-
well plates at 37 °C for 20 min in a total volume of 100 µL and each condition was 
tested in duplicate. The incubation was initiated by addition of 100 µL assay 
buffer, in the presence or absence of the test compound, to a 96-well plate with 
cultured cells. Additionally for antagonists, the assay buffer also contained 1 µM 
(-)-quinpirole. Prior to nucleotide extraction, adherent cells were rapidly washed 
with water (HPLC grade) to remove the incubation medium and salts, preventing 
fouling of the mass spectrometers orifice and ion suppression. The nucleotides 
were extracted by addition of 100 μL lysis buffer. The plate was cooled at 4 °C for 
a few min and heat-sealed (ThermoSealer Abgene, Thermo Fisher Scientific, 
Breda, the Netherlands). The samples were centrifuged (4000 G, 5 min) and 
stored at 4 °C until analysis.  
In this method, the specific lysis-buffer (pH 9.4 controlled with 63 % ACN in 
HPLC grade water containing 10 mM NH4HCO3) is crucial as pre-validation 
studies showed that other concentrations or reagents will affect subsequent 
analysis (e.g. chromatography and ionisation). 
 
4.2.7. Tissue preparation 
Naïve adult male Wistar Unilever Harlan (WUH) rats, 200-250 g (Harlan, the 
Netherlands) were used and two rats per 96-well filter plate were needed. The 
rats were decapitation, without anaesthetics, using a guillotine and various brain 
regions were dissected (according to Paxinos and Watson, 1998) as quickly as 
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possible. Directly after preparation, the tissue was kept in ice-cold Krebs-Ringer 
Buffer. 3 mM K+ Krebs-Ringer Buffer (KRB, Gibco-Invitrogen, Breda, the 
Netherlands) contained (in mM): 121 NaCl, 2 KCl, 25 NaHCO3, 1.2 MgSO4, 11 D-
(+)-glucose, 1.2 KH2PO4, with modifications as used during whole experiment: 
CaCl2 (1.2 mM) and D(+)-glucose (22 mM). The buffers were freshly prepared on 
each test day, kept at 37 °C and gassed with 5 % CO2/95 % O2 for at least 0.5 h 
before use. 
 
 
Figure 4-2 Schematic of dissected brain area (CPu) 
The pair of vertical lines in the sagittal schematic (top left) indicate the anterior 
and posterior limits of the taken caudate putamen (CPu), coordinates were +1.7 – 
+0.2 mm relative to Bregma (Paxinos and Watson, 1998). CPu indicates the 
region of interest in coronal sections. Diagrams were modified from Paxinos and 
Watson (1998). 
 
The same brain areas from animals within the same group were pooled (i.e. from 
4-6 rats) and sliced together. The fresh tissue was sliced in two directions 
(coronal, 90° apart) using McIlwain tissue chopper (300 μm setting), and 
subsequently washed with three 5-mL aliquots of ice-cold buffer and allowed to 
settle. Then the slices were washed 3x times with warm (37 °C) oxygenated KRB 
followed by one h incubation in 37°C water bath under 5 % CO2/95 % O2 
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atmosphere. The methodology was approved by the animal ethics committee 
(Abbott Healthcare Products, the Netherlands) and is in accordance with all local 
laws. 
 
Methodological considerations 
Variation within in vivo treated groups made it impossible to use only a single rat 
for an n = 1 ex vivo experiment. To overcome this problem the dissected brain 
areas from at least four animals within the same treatment group were pooled. 
This significantly reduced intra-experiment variation. 
An n = 1 experiment consisted of all concentrations conduced in quadruplo in 1 
individual ex vivo experiments using 4 – 8 rats from 1 individual in vivo 
experiment. 
 
4.2.8. cAMP accumulation assay (brain tissue) 
Activation and inhibition of adenylate cyclase activity was monitored by 
measuring levels of cAMP and ATP in 96-well plates by using filterplates (1.2 µm 
Multiscreen-plates, Millipore). Briefly, the slices were washed with three 5-mL 
aliquots KRB followed by taken up in 10 ml warm (37 °C) KRB. After pre-wetting 
the filterplates with 100 μL assay-buffer (KRB with 1 μM Forskolin and 1 mM 
IBMX), constantly suspended slices (100 μL) were transferred to 96-well filter 
plates using large orfice pipette tips. The buffer was removed using vacuum-
filtration (Millipore) and 100 μL of assay-buffer was added to wash the slices. 
After removal of the assay-buffer, 100 μL of the diluted test compounds were 
added. After 30 min the incubation was stopped by vacuum-filtration, slices were 
washed with 100 μL HPLC-grade water and were lysed by the addition of 100 μL 
ice-cold lysis-buffer. After 30 min incubation at 4 °C the plate is vacuum-filtered 
collecting the fraction in a normal 96-well plate. The plate wass heat-sealed 
(Thermosealer, Abgene) and stored at 4 °C till analysis. Heat sealed plates can 
be stored at 4 °C for maximal 2 weeks. Sealed plates could not be stored at -
80 °C, as the acetonitrile would adversely affect the plate seal causing sample 
evaporation  (i.e. freeze-drying). 
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4.2.9. Data analyses 
Chromatographic peak resolution was calculated by Rs = 2 (Rt(a) – Rt(b))/(W(a) + 
W(b)), where Rt is the retention time and W is peak width at peak baseline. 
Complete peak separation is achieved at Rt > 1.5. Calibration curves of cAMP 
and ATP were constructed using linear curve fitting based on the areas under the 
curve of the measured standards. All points were equally weighted and the origin 
ignored. For each biological sample, the cAMP concentration was corrected for 
the ATP concentration by dividing cAMP levels by total amount of nucleotides: 
cAMP/(cAMP+ATP)*100. 
Data represents mean ± s.e.m. from at least four independent experiments, 
conducted in duplicate (in vitro) or quadruple (ex vivo). Values are expressed as 
a percentage of respective control. Curves were fitted by non-linear regression 
using Hill 4 parameter sigmoidal equation. Graphs, pEC50 and Emax values were 
calculated using SigmaPlot (v9.01, Systat, Chicago, IL, USA). Antagonist pA2 
values were calculated according to the Cheng-Prusoff equation (Cheng et al., 
1973). 
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4.3 RESULTS 
 
4.3.1 Analytical Method Development 
For the development of an analytical method to measure cAMP and ATP in cell 
based samples, a linear ion trap mass spectrometer (LTQ, Finnigan) was used as 
this type of mass spectrometer was available at the time. The mass spectrometry 
was coupled to a HPLC system (HP1100, Agilent) with ZIC-pHILIC column 
(SeQuant, Sweden) to achieve temporal separation of the analytes, see below. 
 
Optimisation of HPLC conditions  
In order to optimise the resolution of cAMP and ATP chromatography, the 
resolution was measured at different flow rates (Table 4-2). Although 0.2 mL/min 
gave the best resolution, 0.5 mL/min was chosen as a compromise between the 
resolution and analysis time. At this flow rate the cAMP and ATP peaks are still 
baseline separated. 
 
Table 4-2 Flow rate vs chromatographic resolution of cAMP and ATP 
F  
(mL/min) 
Rt cAMP 
 (min) 
Rt ATP  
(min) 
Rs 
0.2 7.11 9.05 5.84 
0.3 9.94 6.17 4.54 
0.4 3.75 4.79 4.28 
0.5 3.00 3.92 3.98 
0.6 2.42 3.3 3.77 
0.7 2.16 2.97 3.60 
F, flowrate; Rt, retention time; Rs, resolution. 
 
Table 4-3 shows the influence of the pH of mobile phase A on the retention time 
behaviour of cAMP and ATP over a range of pH 8.0 - 10 by adding dropwise 
ammonium hydroxide (25 %). At all tested flow rates the criteria for complete 
peak separation (i.e. Rs > 1.5) was achieved. Experiments were performed at a 
flow rate of 0.5 mL/min. 
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Table 4-3 Influence of pH on the retention times of cAMP and ATP 
pH mobile  
phase A 
Rt cAMP  
(min) 
Rt ATP  
(min) 
8.0 2.87 3.87 
9.4 3.07 4.02 
10.0 3.08 4.03 
Rt, retention time. 
 
With current salt-free buffer composition, chromatographic peaks were relatively 
wide. Therefore the buffer strength of the mobile phase was varied between 1 
and 100 mM ammonium bicarbonate (NH4CO3: a non-volatile salt which can be 
used in combination with ESI-MS) and adjusted to pH 9.4. Peak broadening 
occurred at the 1 mM level and improved with increasing the buffer strength. To 
avoid ion suppression, which occur at high concentrations of ammonium 
bicarbonate, a 10 mM concentration was chosen.  
 
The column temperature was varied between 20 and 50 °C which did not affect 
the retention time of the measured analytes. 
 
Optimisation of mass spectrometric condition 
Preliminary experiments using flow injection analysis (FIA) showed that 
nucleotides (cAMP and ATP) could be identified using mass spectrometry but 
that quantification using FIA is not sufficient due to high background noise; LOD 
~1 nM for cAMP. These preliminary results demonstrate that chromatography is 
needed to concentrate sample and remove contaminations. 
 
Single ion mode (MS) was found to be not sensitive enough and tandem mass 
spectrometry was investigated. Experiments performed with an LTQ (negative 
ESI) showed that MS3 fragment m/z 107 was approximately 1000 times less 
sensitive instead of measuring MS2 fragment m/z 134 (adenine). This result 
shows again no advantage of LTQ above using a triple quadrupole mass 
spectrometer. 
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Under the described conditions the MS-MS fragmentation of cAMP (m/z 328) 
results in the daughter ion m/z 134 which corresponds to the purinylamine part of 
the molecule (i.e. adenine). For ATP (m/z 506) the loss of a phosphate- and a 
water group results in the most intense fragment ion at m/z 408 (see Figure 4-3). 
The fragmentation and tuning of the ion optics for both compounds was optimised 
using the auto tune capabilities of the instrument software. In the acquisition 
method cAMP and ATP were measured in separate segments with a maximised 
injection time to obtain the best possible sensitivity. The lowest calibration 
standard still contained 15 scans to describe the chromatographic peak. A 
tandem mass spectrum (MS/MS) with the selected daughter ions and a proposed 
fragmentation is presented in Figure 4-3. An example extracted ion 
chromatogram is shown in Figure 4-4. 
Using single reaction monitoring (SRM) mode in two separate segments, resulted 
in better sensitivity then simultaneous segments (multiple reaction monitoring, 
MRM) because the mass spectrometer does not have to switch between the two 
mass during the 800 ms interval between ionisation and detection. 
 
Negative ESI was found the most sensitive mode for this assay. Additionally, 
more selectivity was obtained using the negative ESI mode whilst the majority of 
biological molecules in cell lysate were ionised in positive ESI mode.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4 Development and in vitro application of a method for measuring 
(cyclic-) nucleotides using LC-MS/MS 
 
 
80 
 
A      B 
 
Figure 4-3 Mass spectra of cAMP and ATP with their proposed 
fragmentation  
A. MS/MS spectra of cAMP resulting in the main peak at m/z 134. Insert: 
Structure of cAMP with proposed fragmentation m/z 328 > 134. B. MS/MS 
spectra of ATP resulting in the main peak at m/z 408. Insert: Structure of ATP 
with proposed fragmentation m/z 506 > 408. y-axis, relative abundance (%); x-
axis, mass to charge ratio (m/z). 
 
The probe was positioned away from the inlet of the source as far as possible, 
this prevents non-ionic molecules entering the MS. Further settings like collision 
and sheet gas flows, source temperature, and ionisation voltage were optimised 
using the AutoTune function in XCaliber Software (Waters). Another feature to 
reduce fouling of the source of the mass spectrometer was to split post-column 
before the inlet flow to the MS source. Since mass spectrometry is a 
concentration dependent technique, reducing the volume is not of any 
consequence for quantification. Note that the flow rate can have consequences 
for the optimum electrospray, depending on used ESI-probe, ESI-type and MS-
source. By applying a split of 8:2, the contamination was theoretically reduced by 
80%. 
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Figure 4-4 Extracted ion mass chromatogram (XIC) of cAMP and ATP  
Top: XIC of ATP, m/z 506 > 408. Bottom: XIC of cAMP, m/z 328 > 134. y-axis, 
relative abundance (%); x-axis, time (min). 
 
Validation of the LC MS MS method 
The assay was linear over at least the range of 0.5 – 100 nM for cAMP and 50 
nM – 50 µM for ATP. For both components, the use of higher concentrations 
resulted in a non-linear calibration curve. Regression of the calibration curves 
(Figure 4-5) yielded the following for cAMP: slope (s.d.), 0.032 (0.002); y-
intercept, 0.136 (0.346) nM; r2 = 1.000, and ATP: slope, 0.149 (0.003); y-intercept, 
75.639 (14.719) nM; r2 = 0.9999.  
The addition of matrix (i.e. cell lysates) to the calibration curves affected neither 
the accuracy nor the precision of the concentrations within the working range. 
The LOD (3*SD) were at least 0.5 and 200 nM for cAMP and ATP respectively. 
The working range (LLOQ; 5*SD, %RSD < 20 %) was at least 1-100 nM for 
cAMP and 500 – 10000 nM for ATP. 
Carryover was determined by a blank injection after a 10 µM cAMP and 1 mM 
ATP standard and resulted in a carryover of < 0.1 %. 
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Figure 4-5 Calibration curves of cAMP and ATP  
A.) Calibration curve of cAMP in the range of 0.5 – 100 nM. B.) Calibration curve 
of ATP in the range of 50 – 10000 nM. Graphs represent mean ± s.d. of 
measurements from 5 individual days, n = 5. 
 
 
The intra-run accuracy and precision ranged from −8 to 9 % RE and 1 to 17 % 
RSD, respectively, for both of the analytes (Table 4-4). The inter-run accuracy 
and precision ranged from -20 to 8 % RE and 2 to 12 % RSD, respectively, for 
both of the analytes (Table 4). All mean concentrations had an accuracy and 
precision of >85 %, except for LLOQ (>80 %), which is in good agreement with 
FDA guidelines (FDA, 2001). 
 
The robustness of the analysis was monitored by the measurement of quality 
controls (QC) containing 10 nM cAMP/1 µM ATP in lysis buffer. The intra-assay 
variation was assessed by a total of 65 QCs per experiment, i.e. a QC in between 
every twelve biological samples. A typical run contained 65 QCs with RE and 
RSD < 15 % for both cAMP and ATP. 
 
To investigate storage conditions and stability of standards and samples, a 
standard solution of cAMP (10 nM) and ATP (1 µM) was prepared and aliquoted 
in vials. The vials were stored in the refridgerator (4 °C) for a period of 14 days. 
Every day fresh standard solutions were prepared and the stored standard 
solution was measured. No decrease in the concentration of cAMP or ATP was 
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observed. Additionally, the same experiment was performed with CHO-hD2L cell 
lysate; cAMP and ATP were stable for a period of at least 14 days. 
 
Table 4-4 Standard curve statistics for cAMP and ATP 
 Intra-run   Inter-run   
Nominal  
(nM) 
Mean 
(nM) 
RE 
(%) 
RSD 
(%) 
Mean 
(nM) 
RE 
(%) 
RSD 
(%) 
cAMP       
0.5 0.5 3 24 0.7 -41 30 
1 1.1 -5 17 1.3 -20 12 
2 1.8 9 11 2.1 -3 10 
5 5.0 0 3 5.1 -2 4 
10 10.5 -5 1 10.0 0 5 
20 21.5 -8 6 19.4 3 8 
50 50.9 -2 4 49.5 1 3 
100 104.7 -5 7 100.8 -1 5 
       
ATP       
50 144 -188 2 119 -138 19 
100 187 -87 5 162 -62 16 
200 268 -34 3 245 -22 10 
500 536 -7 3 514 -3 5 
1000 1007 -1 3 968 3 4 
2000 1891 5 2 1847 8 3 
5000 4706 6 2 4682 6 3 
10000 10415 -4 2 10120 -1 2 
Statistics indicate nominal concentration (nM), calculated concentration (Mean, 
nM), percentage relative error (%RE), and percentage relative standard deviation 
(%RSD). All curves were regressed using a linear with 1/X fit. n = 5 curves 
analysed for all statistics. 
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Heat sealed 96-well and 384-well plates could be stored in the fridge for a period 
up to 14 days without evaporation of the acetonitrile fraction or decrease of cAMP 
or ATP concentration, which exclude possible adhesion of cAMP or ATP to the 
well plates. 
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4.3.2 Pharmacological validation (cell based assay) 
To verify adenylate cyclase (AC) activity in CHO-cells transfected with the hD2L 
receptor, the effect of the AC activator forskolin on cAMP accumulation was 
assessed. Forskolin produced a concentration dependent increase in cAMP 
accumulation (Figure 4-6). Forskolin was tested in a concentration up to 100 µM, 
as the stimulating effects of higher concentrations were considered to be not 
physiologically relevant, and not necessary for assay development. Because the 
maximal effect was not achieved yet, no pEC50 or Emax values could be calculated. 
Basal cAMP and ATP levels found in 96-well plate cultured CHO-D2L cells (ca. 
40000 cells/well) were between 0.5 - 5 and 1000 - 3000 nM, respectively. ATP 
values lower then 1000 nM/well indicate that no cells were cultured or indicate 
cell toxicity. Cell toxicity is often recognised by a concentration dependent 
decrease of ATP levels caused by the tested drug. Forskolin (0.3 µM) produced 
approximately 20 fold increase over basal levels of cAMP and was used in future 
experiments. 
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Figure 4-6 Effect of forskolin on cAMP accumulation in CHO-hD2L cells  
The AC-activator forskolin stimulated cAMP formation in a dose dependent 
manner. Data presents mean ratio (cAMP/ATP) ± s.e.m. of two individual 
experiments performed in duplicate. 
 
Hypothetically, ratio calculations between cAMP and total nucleotide content 
could make a correction for the relative amount of cells per well/sample, and will 
reduce variation. As proof of concept, the dopamine D2 partial agonist terguride 
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was tested and calculated using only cAMP or the cAMP/ATP ratio. The 
advantage of the cAMP/ATP ratio over cAMP-only for partial agonist terguride 
was tested in a concentration range of 1 pM to 1 µM. When the effect was 
expressed as cAMP levels only, variation was large (Figure 4-7). However, when 
the effect was expressed as the cAMP/ATP ratio, there was a clear concentration 
dependent effect of terguride resulting in a pEC50 of 10.2 ± 0.1 and intrinsic 
activity (Emax) of 35 ± 3 % (Figure 4-7). 
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Figure 4-7 The value of cAMP/ATP ratio calculation  
The effect of terguride on cAMP accumulation was tested and calculated using 
cAMP-only (▲) or cAMP/ATP ratio (□). Calculations using cAMP-only resulted in 
a non-significant effect, with large variations. Calculation using cAMP/ATP ratio 
revealed a significant, partial effect resulting a pEC50 of 10.2 ± 0.1 and Emax of 35 
± 3 %, n = 6. 
 
Effect of dopamine receptor (partial-) agonists on cAMP accumulation 
The quantitative determination of cAMP in cells was further explored to illustrate 
the utility of this method. As a proof of concept the effect of different D2-like 
ligands, including dopamine (endogenous ligand for the dopamine receptor), the 
prototypical agonist quinpirole and ropinirole (selective D2-like agonists), on 
cAMP accumulation in CHO-cells transfected with hD2L receptors was tested. 
Under the conditions used, the application of 10 µM quinpirole reduced forskolin 
(0.3 µM) stimulated cAMP levels by more then 70 %. The potencies of the 
agonists were quinpirole > ropinirole > dopamine (Figure 4-8A, Table 4-5). All 
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compounds were confirmed as full agonists as they were without any effect in 
presence of 1 µM quinpirole (data not shown). 
Furthermore, the dopamine D2 receptor partial agonists terguride, bifeprunox and 
lisuride were tested and showed partial activity on cAMP accumulation under the 
present conditions. The relative efficacies (Emax) of these partial agonists were 
lisuride > terguride > bifeprunox (Figure 4-8B and Table 4-5). The relative 
potencies of terguride, bifeprunox and lisuride were essentially equal to each 
other. 
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Figure 4-8 Effect of D2-like (partial-) agonists on cAMP accumulation  
A. Dopamine (●), quinpirole (○) and ropinirole (■) showed full inhibition of cAMP 
accumulation; B. Terguride (□), bifeprunox (▲) and lisuride (○) showed only 
partial inhibition of cAMP accumulation. See Table 4-5 for pEC50 and Emax values. 
Data are expressed as % maximal forskolin stimulated cAMP inhibition by 1 µM 
quinpirole ± s.e.m. 
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Table 4-5 Functional data of agonists for hD2L receptor in CHO cells 
Compound pEC50 Emax (%) 
Quinpirole 7.8 ± 0.1 98 ± 4 
Dopamine 5.4 ± 0.6 100 ± 2 
Ropinirole 7.1 ± 0.1 89 ± 2 
   
Terguride 10.2 ± 0.1 35 ± 3 
Bifeprunox 10.0 ± 0.2 26 ± 4 
Lisuride 9.9 ± 0.2 68 ± 2 
Functional data represents mean ± s.e.m. (n = 4-12 individual experiments). 
 
 
Effect of dopamine receptor (partial-) antagonists on cAMP accumulation 
The effects of the selective D2-like antagonist LY-741626, and the prototypical 
antagonists haloperidol and (-)-sulpiride on cAMP accumulation were 
investigated. LY-741626, haloperidol and (-)-sulpiride (1 pM – 10 µM) did not 
alter cAMP accumulation and were therefore found as silent antagonists, i.e. 
exhibited neither partial nor inverse agonistic activity at the hD2L receptors in this 
system (data not presented). In order to test antagonism of these ligands, the 
ligands were tested in presence of 1 µM quinpirole. All ligands fully inhibited the 
quinpirole-mediated effect on cAMP accumulation in a dose dependent manner. 
Relative potency: haloperidol > LY-741626 > (-)-sulpiride (Figure 4-9A, and Table 
4-6). 
In order to test the ability of the assay to determine antagonism of partial agonists, 
the partial agonists terguride and bifeprunox were tested in the presence of 1 µM 
quinpirole and partially reversed the effect of quinpirole; relative efficacy (Emax) of 
bifeprunox > terguride, and the relative potency of terguride > bifeprunox (Figure 
4-9B, and Table 4-6). The agonistic and antagonistic effects of the partial 
agonists were found complementary as expected. 
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Figure 4-9 Effect of D2-like partial- and full- antagonists on cAMP 
accumulation 
A. LY-741626 (●), haloperidol (○), and (-)-sulpiride (▲) fully antagonised the 
effect of quinpirole; B. Terguride (□) and bifeprunox (▲) only partially reversed 
the effect of quinpirole. All antagonists were tested in presence of 1 µM of 
quinpirole. See Table 4-6 for pA2 and Emax values. Data are expressed as % 
maximal cAMP inhibition by 1 µM quinpirole ± s.e.m. 
 
Table 4-6 Functional data of antagonists for hD2L receptor in CHO cells 
Compound pA2 Emax (%) 
Haloperidol 9.9 ± 0.1 93 ± 4 
(-)-Sulpiride 8.2 ± 0.1 100 ± 1 
LY-741626 9.2 ± 0.2 102 ± 1 
   
Terguride 9.3 ± 0.1 66 ± 4 
Bifeprunox 8.4 ± 0.2 75 ± 2 
Functional data represents mean ± s.e.m. (n = 2-5 individual experiments). 
 
These results show that the linear ion trap mass spectrometer (LTQ) is suitable to 
measure cell lysate samples, although, the analysis of brain tissue samples 
caused severe contamination of the LTQ and result in loss of sensitivity. Pollution 
of the source of the mass spectrometer was mainly caused by, but not limited to, 
salts and biogenic components in the tissue samples which were extracted by the 
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lysis buffer. At this time, a tandem quadrupole mass spectrometer (Quattro 
PremierTM XE, Micromass) hyphenated with an orthogonal designed electrospray 
interface (Z-SprayTM-source) was available and investigated. The Z-SprayTM-
source protects the mass spectrometer from pollution by unwanted biogenic 
compounds in the tissue samples. The HPLC system as described under 
“Section A: Analytical Method Development” was used, and no future changes on 
the HPLC system were made. 
 
The robustness of the analysis was monitored by the measurement of quality 
controls (QC) containing 10 nM cAMP/1 µM ATP in lysis buffer. A typical run 
contained 41 QCs per experiment, i.e. a QC in between every twelve biological 
samples, and intra-assay variation were RE and RSD < 10 % for both cAMP and 
ATP. 
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4.3.3 Pharmacological validation (brain tissue assay) 
The developed LC-MS/MS method (developed for in vitro cell based assays) was 
applied to ex vivo rat striatal slices (350 x 350 µm) using a new developed filter-
plate assay. To validate the described LC-MS/MS method using striatal tissue, 
the effect of the selective D1-like agonist (SKF-38393) and selective D2-like 
agonist (quinpirole) were tested. 
 
Different concentrations of SKF-38393 were incubated in the presence of rat 
striatal slices for 30 min. A large variation was observed in the measured ATP 
and cAMP levels (Figure 4-10A). When the effect of SKF-38393 was calculated 
based on only cAMP levels, a non-sigmoidal increase was obtained due to large 
variation (Figure 4-10B). However, following correction of the same samples by 
calculation of a ratio between cAMP and ATP, a concentration dependent effect 
was observed with very little variation (Figure 4-10C). 
 
The effect of quinpirole, in presence of 1 µM SKF-38393, on cAMP accumulation 
was assessed. The inter-run variation (i.e. variation between the averages of n = 
4 individual experiments) observed with quinpirole was similar to the effect found 
with SKF-38393, i.e. calculations with cAMP-only demonstrated large variations 
(Figure 4-11A). When calculations were made using a cAMP/ATP ratio, the 
variation was acceptable and a reliable concentration response curve was fit 
(Figure 4-11B). Although final pEC50 values were the same for both cAMP-only 
and cAMP/ATP ratio calculations (8.0 and 8.0 ± 0.1, respectively) the reduction in 
variation is important for the accuracy of the results and calculations of the 
efficacy. 
For validation purposes, also the intra-run data was examined representing the 
variation within an experiment. When the intra-run data was calculated using 
cAMP levels only, very large variation was revealed (Figure 4-11C).  In addition 
to the large variation (%RSD of Figure 4-11C and D: > 30 % and < 14 %, 
respectively), also qualitative pharmacology was affected and in most 
experiments no significant concentration response curve could be obtained when 
using only cAMP levels for calculation (Figure 4-11C). 
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Figure 4-10 Effect of calculations with cAMP levels or cAMP/ATP 
conversion 
SKF-38393 was incubated with rat striatal slices and cAMP and ATP were 
measured. A. Measured ATP and cAMP levels showing large variation. B. The 
effect of SKF-38393 calculated with cAMP levels only. C. Effect when calculated 
using cAMP/ATP conversion. The effect was expressed as mean % ± s.e.m. 
(tested in quadruple), n = 4 individual experiments. 
 
 
 
These experiments demonstrate that quinpirole induced a decreased in SKF-
38393 (1 µM) stimulated cAMP levels in rat striatal slices when cAMP/ATP ratio 
was calculated. 
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Figure 4-11 Effect of calculation with cAMP levels or using cAMP/ATP ratio 
Quinpirole was incubated with rat striatal slices and cAMP and ATP were 
measured. A.) The effect of quinpirole calculated with cAMP levels only, no pEC50 
value could be calculated due to large variation. B.) Effect of calculations using 
cAMP/ATP conversion, pEC50 8.0 ± 0.1. C.) Data from a typical experiment 
representing intra-run data calculated using cAMP levels only. D.) Data from a 
typical experiment, calculated using cAMP/ATP ratio. The effect was expressed 
as mean % of control ± s.e.m. (tested in quadruple), n = 4 individual experiments 
(for A and B). 
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4.4 DISCUSSION 
 
This chapter describes the successful development, validation and application of 
a LC-MS/MS method to determine (cyclic-) nucleotides. The potential applicability 
of the method was evaluated by assessing the utility of measuring cAMP 
accumulation following in vitro (cell based) and ex vivo (rat brain slice) 
experiments with several dopamine receptor ligands. 
 
Due to their extremely polar properties, separation of nucleotides is commonly 
performed using anion-exchange chromatography, although the mobile phase 
compositions are highly incompatible with LC-MS/MS analysis. Another approach 
used is the separation of nucleotides using a reversed phase chromatography, 
however, because of their polar properties the nucleotides are poorly retained on 
a reversed stationary phase and therefore often used in combination with an ion-
pairing reagent (N,N-dimethylhexylamine, Cai, 2001 and Qian et al., 2004; 
hexylamine, Coulier et al., 2006, for review see Werner, 1991) or Hypercarb 
stationary phases combination with diethylamine (Xing et al., 2004). Preliminary 
experiments using the volatile ion-pairing reagent N,N-dimethylhexylamine 
(DMHA) showed a main peak of m/z 130 in the mass-spectrum, originating from 
DMHA, and resulted in poor sensitivity due to substantial background contribution, 
ion suppression, source pollution and possibly other side effects like space 
charging in the ion trap mass spectrometer. Possibly this latter phenomenon will 
not occur in a triplequadrupole mass spectrometer when operating in selective 
reaction monitoring (SRM) mode. Although Lorenzetti and colleagues (2007) 
showed that C18 columns can be used without volatile ion pairing reagents, the 
poor separation of the nucleotides requires good resolving power of the mass 
spectrometer operating in MRM mode to quantify poorly separated peaks. 
However, this method did not have the required sensitivity for our samples. 
 
To avoid the use of ion-pairing reagents, a separation was established using a 
ZIC®-pHILIC column (SeQuant, Sweden). The separation of components was 
performed by a binary gradient elution using acetonitrile (CH3OH)/water (H2O). 
Substitution of acetonitrile by isopropanol (IPA) was possible but increased 
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column pressure due to its higher viscosity compared to acetonitrile. The 
compounds were trapped with acetonitrile and eluted with aqueous buffer, like 
conventional straight phase chromatography (i.e. a polar stationary phase and a 
non-polar, non-aqueous mobile phase). Several chromatographic conditions were 
optimised to achieve a reasonable analysis time without compromising 
chromatographic separation. Addition of 10 mM of ammonium bicarbonate was 
sufficient for separation of the cAMP and ATP. A tenfold higher buffer 
concentration resulted in an even better resolution but was not used to prevent 
ion suppression in the mass spectrometer. A lower (1 mM) buffer concentration 
resulted in poor peak shape. It was found that the flow rate is an important 
parameter in the resolving power of this type of column. The Van Deemter 
equation (van Deemter et al., 1956, i.e. [H = A + (B /u) + C * u]; were A is the 
Eddy diffusion, B/u is the longitudinal diffusion and C*u is the equilibration point) 
for this type of column (4.6 x 150 mm Dp 5 µm) shows an optimum around 200 
µL/min. Higher flow rates result in a loss of theoretical plates affecting the 
resolution. The pH was set to 9.4 and slight variations of ca. 0.1 pH did not affect 
chromatographic behaviour of cAMP and ATP. Changes in temperature within 
the tested range, i.e. 20 – 60 °C, did not affect chromatographic behaviour. A 
temperature of 35 °C was chosen to keep the column at a conditioned 
temperature. 
 Most of the biologically active cyclic nucleotides can behave as zwitterions, due 
to their purine base and phosphate groups, and could potentially be analysed by 
positive- as well as negative- electrospray ionisation (ESI). However, under the 
present conditions, negative ESI was the most sensitive ionisation mode. Good 
chromatographic resolution of both compounds was achieved in separated 
optimised segments providing the best sensitivity for each of the analytes. As 
shown in this study, any mass spectrometer with tandem MS capability and 
sufficient sensitivity may be used for the analysis (e.g. triple quadrupole or ion 
trap machines). Product ions may differ from different types of instruments and 
have to be determined before the analysis. The instrument must be tuned for best 
performance (gasses, temperatures and ion optics). The throughput of the assay 
was improved by the use of 96-well and 384-well plates. Post-column split and 
the use of the mass spectrometer‟s divert valve ensured system robustness by 
preventing source pollution resulting in decreased sensitivity. 
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Although some absolute cAMP and ATP values are presented, one should take 
in account the contribution of matrix effects to the MS signal (e.g. sodium-adduct 
formation). This could have been corrected by using an internal standard.  
 
The described validation study showed intra- and inter- assay variations that are 
in good agreement with The Guidance for Industry, Bioanalytical Method 
Validation (issued by the FDA; FDA, 2001). Although this guidance is aimed at 
the Good Laboratory Practice (GLP) of bioanalytical laboratory, as opposed to 
the pharmacological non-GLP environment the described method was developed 
in, the principles highlighted in this guidance do represent important 
considerations in the development or adaptation of analytical methods. Therefore 
parameters relevant for the current method, i.e. linearity, QCs, accuracy and 
precision of intra- and inter- assay variations, met the FDA guidelines: i.e. The 
mean value was within ±15 % of the theoretical value and precision did not 
exceed 15 % of the CV (except for lower limit of detection where it was allowed 
not to exceed 20 %). 
 
Cyclic nucleotides (e.g. cAMP and cGMP) are biologically important as second 
messengers and are drug targets in their own right. Additionally, cAMP 
accumulation is often used as a marker for determining receptor activity of 
candidate compounds and is a widely used tool in biochemical pharmacological 
research. For this reason, the more recently developed techniques for the 
measurement of cAMP are based on high throughput analysis (see for review 
Williams, 2004). However, these methods remain limited by the measurement of 
only one component at a time and ultimately restrict the quality and increases the 
variation of the data. The described method was developed to measure cAMP 
and ATP simultaneously for two major reasons; I.) ATP can be used as an 
indicator for cytotoxicity, as a large decrease in ATP level is inherent to 
decreased cell viability. This will prevent false-positive results when assessing 
the effect of compounds on inhibitory coupled receptors, as the total cAMP/ATP 
ratio will decrease and not only cAMP levels. II.) By calculating a cAMP/ATP ratio, 
a significant reduction in variation was seen, which significantly improved the 
statistical power. 
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To demonstrate the application of the described method for measuring cAMP in a 
biological system, the method was validated by determination of cAMP 
accumulation in vitro. First, the effect of forskolin, an adenylate cyclase activator, 
was examined. Forskolin showed a concentration dependent increase in cAMP 
accumulation up till the highest concentration tested, i.e. 100 µM, but without 
reaching a plateau. For this reason no pEC50 value could be calculated as the 
Emax value is not available. Higher concentrations were not tested as these are 
not physiologically relevant and might induce cytotoxicity. Furthermore, a 
selection of dopaminergic D2 receptor ligands were tested on cells transfected 
with the human dopamine D2L receptor and cAMP and ATP were measured. 
The dopamine D2L receptor, like other G-protein coupled receptors (GPCR), is an 
important target for psychiatric and neurological disorders, and in particular 
partial dopamine D2 agonists show great therapeutic benefit (Lieberman, 2004; 
Bronzova et al., 2010; Jones et al., 2010). Partial agonists are a challenging class 
of compounds due to their reduced efficacy, and especially partial agonists for 
the dopamine D2L receptor because of the relatively small dynamic window. In 
cAMP functional assays, most biochemical assays have limited resolution to 
distinguish between the degree of intrinsic activity of full and partial agonists 
(Williams, 2004). It is noteworthy that this method is able to detect partial 
agonists (i.e. compounds with reduced efficacy compared to full agonists), even 
for the challenging inhibitory Gαi coupled receptors (e.g. dopamine D2L receptor). 
The pharmacological results shown were in agreement with the literature: the 
ranking, potency and efficacy of all tested compounds were in good correlation 
with quantitative studies using the radiometabolic method (tested in our 
laboratory, Glennon et al., 2006) and other methods (Jordan et al., 2007). 
Although the results are comparable with metabolic labelling, the method showed 
an enlarged induction-factor (or „dynamic window‟) of experiments with forskolin 
and dopamine agonists (e.g. quinpirole and dopamine), when compared to the 
radiolabelling method and several ELISA based kits (data not shown). This 
property, together with the reduced variation by using the cAMP/ATP ratio, 
renders this method ideal for the determination of partial agonists. 
 
The power of this method is the simultaneous measurement of cAMP and ATP. 
Ratio calculations significantly reduce variation and simultaneous ATP 
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measurement provides an index of cellular viability. This feature increases power 
easing the determination of partial agonists. Furthermore, this method uses a 
natural cellular pathway without the use of cellular modification (e.g. luciferase) to 
improve coupling efficiency for signal amplification, which could result in false-
positive results of data misinterpretation (i.e. partial agonists could be detected as 
full agonists or even as antagonists). The HILIC-MS/MS method analyses the 
nucleotides without (radioactive-) pre-labelling, which could be questioned as it 
labels only a certain pool of intracellular nucleotides and metabolites. In addition, 
this novel method is simple, robust and straightforward and does not require 
tedious sample preparation and is therefore applicable for routine analysis. 
 
The present method was also successfully applied in structure-activity-
relationship (SAR) studies (e.g. Brennan et al., 2010) and in other cell systems. 
For example, we have validated cAMP accumulation in CHO-cells transfected 
with the serotonergic 5-HT1A and cannabinoid CB1 and CB2 receptors (e.g. Lange 
et al., 2010). Furthermore, it was showed that the described method can be 
successfully extended for supporting ex vivo cAMP accumulation studies using 
brain slices. Described method was validated using forskolin, dopamine D1 and 
D2 agonists and rat striatal slices. 
Studies over the past decade have pointed to a prominent role for cAMP as a 
second messenger in neural pathways underlying the effects of psychostimulants, 
and previous stimulant administration increases dopamine D1 receptor mediated 
signal transduction (Miserendino and Nestler, 1995; Self and Nestler, 1995; 
Unterwald et al., 1996). The present results showed that the developed method 
can be used to study the effects of dopaminergic ligands on the cAMP pathway. 
 
Future perspectives 
This LC-MS/MS method is able to measure endogenous cAMP and [13C]-labeled 
adenine metabolites (i.e. [13C]-cAMP, [13C]-ATP) simultaneously, and makes it 
possible to study intracellular-compartmentalisation-theories. Preliminary studies 
comparing [3H]-adenine metabolic labelling method (by separation of [3H]-cAMP 
and [3H]-ATP using Dowex-column, Salomon et al., 1974; Salomon, 1979) with 
the described HILIC-MS/MS method showed that 1 µM forskolin increased cAMP 
levels by 4 and 16 times, respectively. The difference in amount of cAMP 
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accumulation could be explained by intracellular-compartmentalisation. However, 
further studies are required. 
When the chromatography was slightly altered by reducing the slope of the 
gradient from organic to aqueous mobile phase, another peak appeared at the 
front of the cAMP peak, with the same unique fragmentation pattern (m/z 328  
134). Preliminary studies (data not shown) revealed that under the LC conditions 
described in the method section, 2‟,3‟-cAMP co-elutes at the front of the 3‟,5‟-
cAMP peak. Thus, the described LC-MS/MS method is able to identify and 
quantify 2‟,3‟-cAMP in the same run as  3‟,5‟-cAMP and ATP. Moreover, the 
measurement of hD2L-CHO-cell lysate showed that < 1 % of the total intracellular 
cAMP content (the sum of the endogenous 3‟,5‟-cAMP and 2‟,3‟-cAMP levels) 
was 2‟,3‟-cAMP. Because separation of these isomers requires an additional 2.5 
min, the 2‟,3‟-cAMP content was neglected during further analysis of cAMP and 
ATP. The role of intracellular 2‟,3‟-cAMP is not clear yet, though using described 
method it is possible to study this subject. 
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Figure 4-12 Chemical structures of cAMP isomers  
Both isoforms of cyclic adenosine monophosphate (cAMP) are endogenously 
present, although, only 3‟,5‟-cAMP is known to be involved in GPCR signalling. 
The present study showed that 2‟,3‟-cAMP is also endogenously present but its 
role is still unknown. 
 
Besides the separation of cAMP (3‟,5‟-cAMP and 2‟,3‟-cAMP) and ATP, the 
method also addresses the separation of other adenosine and guanosine 5‟-
mono-, di- and triphosphates i.e. cAMP, AMP, cGMP, ADP, ATP, GMP, GDP, in 
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respective order of elution at a flow rate of 0.4 mL/min. Especially cGMP is of 
great interest in biomolecular and drug research as cGMP is another second 
messenger which is exclusively coupled to the D1-like receptors in the dopamine 
receptor family. The advantage of yhe described method is the simultaneous 
analysis of both cAMP and cGMP pathways which could contribute to study the 
phenomenon of functional selectivity, also called ligand directed signalling (see 
Gay et al., 2004 for functional selectivity of D2 receptor ligands and review of 
other receptors). 
 
If future studies require additional sensitivity, recent advances using nano-
electrospray might offer a solution. Applying this technique will not alter the 
optimised chromatographic method neither requires special mass spectrometric 
equipment, but using the current method still gain sensitivity. If increased 
throughput is required, this can be achieved by „multiplying‟ or „parallel LC-
MS/MS‟, an approach where two HPLC systems are coupled to one mass 
spectrometer (for example see, Korfmacher et al., 1999). 
 
Conclusion 
In summary, for the first time, the successful development, validation and 
application of a novel, robust and sensitive HILIC-MS/MS method for the 
simultaneous determination of nucleotides in biological samples to study receptor 
activity (e.g. cAMP accumulation) was presented. The simultaneous analysis of 
cAMP and ATP can be applied to deduce a cAMP/ATP ratio with reduced 
variation, making this method ideal for the determination of partial agonistic 
compounds. The method also requires no extensive sample preparation making it 
suitable for routine analysis and is amendable to 96- and 384- well technology. 
Additionally, the method can now be used to investigate putative changes in 
dopaminergic neurotransmission by assessment of cAMP accumulation ex vivo, 
in rat striatal slices of behavioural sensitised animals (see Chapter 5). 
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Chapter 5. Effect of nicotine induced behavioural 
sensitisation on dopamine receptor mediated cAMP 
accumulation in rat striatum 
 
Abstract. 
OBJECTIVES: Chronic intermittent administration of psychostimulants (including 
nicotine) has been shown to induce behavioural sensitisation. Although these 
drugs have diverse molecular targets in the brain, they share the ability of 
increasing the release of dopamine. The aim of the present study was to 
investigate the molecular consequences of nicotine induced behavioural 
sensitisation in rat dorsal striatum. 
METHODS: Behavioural sensitisation in rats was determined by locomotor 
activity following acute or 5 day chronic intermittent nicotine administration. After 
the establishment of sensitisation, rats were withdrawn for a 5 day period 
followed by administration of a nicotine challenge, with or without a pre-challenge 
with SCH-23390 (a dopamine D1 antagonist). Either at 45 min or 24 h post-
challenge the dorsal striatum was isolated and used to assess the effect of a 
selection of dopamine D1 and D2 receptor ligands on intracellular cAMP 
accumulation ex vivo. The cAMP levels were measured using LC-MS/MS. 
RESULTS: The present study showed robust expression of nicotine induced 
behavioural sensitisation in vivo which was significantly blocked by SCH-23390. 
Nicotine induced sensitisation had no effect on forskolin stimulated cAMP 
accumulation, however it increased the efficacy of dopamine for the dopamine D1 
receptor, and decreased the potency of D1 agonists for this receptor. This effect 
was antagonised by the co-incubation with SCH-23390. Also a time dependent 
effect was observed between tissues taken at 45 min or 24 h post-challenge. 
CONCLUSIONS: These results suggest that the dopamine D1 receptor signal 
transduction in the dorsal striatum may play a role in the expression of nicotine 
induced behavioural sensitisation. Furthermore, a connection between the 
behavioural effects of sensitisation and the ex vivo effects on cAMP accumulation 
by dopamine D1 agonists is provided. 
Keywords: cAMP, nicotine, sensitisation, ex vivo, dopamine receptors 
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5.1 INTRODUCTION 
 
It is known that a wide variety of drugs including psychostimulants share the 
ability to induce and express behavioural sensitisation (see Chapter 2). Although 
these different drugs act on different molecular targets (e.g. transporters, receptor 
systems, ion channels and enzymes) they can directly or indirectly activate 
common downstream pathways like cyclic adenosine monophosphate (cAMP) 
and ERK (Nestler, 2001b; Valjent et al., 2006). Previous research has shown that 
behavioural sensitisation is mediated by long-term neuroadaptations that are 
secondary to the pharmacological changes elicited by acute drug administration 
(Wolf, 2003; Niehaus et al., 2010) and studies over the past decade point to a 
prominent role for dopamine and the second messenger cAMP in the neural 
pathways underlying the effects of psychostimulants (Wolf et al., 2003). These 
cyclic nucleotides are powerful signalling molecules, and are hypothesised to 
play a very important role in behavioural sensitisation. An expanding database 
indicates that long-term neuroadaptations underlie the symptoms/pathogenesis of 
neuropsychiatric disorders, more than a consequence of an acute event. 
Behavioural sensitisation is suggested as a model of synaptic plasticity and 
several neurochemical substrates have been proposed to account for 
sensitisation. It is possible that the long-term alterations in dopamine 
transmission, following sensitisation, may be directly mediated by changes in 
striatal activity (Wolf et al., 2004; Nestler, 2005).  
 
Previous research has established that dopamine release is involved in different 
behaviours and it is suggested that dopaminergic neurotransmission plays an 
important role in behavioural sensitisation (Martin-Iverson et al., 1993; see 
Chapter 3). In Chapter 2 of this thesis it is shown that the dopamine D1 receptor 
plays an important role in the expression of nicotine induced behavioural 
sensitisation in vivo. Both of the dopamine D1 and D2 receptor subtypes are 
localised and co-localised on striatal neurones, and both of these receptor 
subtypes regulate cAMP accumulation (Stoof and Verheijden, 1986; Kelly and 
Nahorski, 1987a). Therefore, the enzyme adenylate cyclase is a key component 
of the dopaminergic signalling pathway and it is hypothesised that increased 
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adenylate cyclase activity plays a role in behavioural sensitisation. For example, 
co-administration of cocaine (i.p.) with 7β-deacetyl-7β-[γ-(morpholino)butyryl]-
forskolin (7-DMB-forskolin, intracerebroventricular), an adenylate cyclase 
activator, increased cocaine induced behavioural sensitisation compared to 
cocaine alone. However, chronic 7-DMB-forskolin (intracerebroventricular) alone 
for 7 days did not induce behavioural locomotor sensitisation (Schroeder et al., 
2004). These data suggests that activation of adenylate cyclase affects the 
induction of sensitisation but is not able to induce behavioural sensitisation.  
Dopamine release can be induced by direct or indirect activation of a variety of 
receptors located on dopaminergic cell bodies, terminals and neighbouring 
neurones. The released extracellular dopamine is then able functionally and 
concomitantly to activate dopamine receptors and intracellular pathways like 
cAMP. For example, when rat striatal slices were incubated with the 
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) and exposed to 
different concentrations of the catecholamine-releasing drug amphetamine, this 
produced both a concentration-dependent release of endogenous dopamine and 
accumulation of cAMP in the slices (Kelly and Nahorski, 1987b). In addition to 
cocaine sensitisation it has been shown that acute amphetamine administration 
did not affect the potency of dopamine induced adenylate cyclase activity, as 
measured by radiometabolic labelling of striatal membranes which were taken 25 
min after the in vivo challenge (Barnett et al, 1987). Whereas, chronic 
amphetamine induced behavioural sensitisation (3 mg/kg s.c., for 6 days followed 
by 48 h withdrawal) decreased the potency of dopamine stimulated adenylate 
cyclase activity. Barnett and colleagues used this parameter as an index of 
dopamine D1 receptor activation, and suggest its involvement following chronic 
administration of amphetamine. 
 
As described in Chapter 1, more downstream to adenylate cyclase is the second 
messenger cAMP. cAMP signalling is at the forefront of intense research interest 
because its many effects remain controversial and often contradictory. Although 
much research has been carried out in this area, it is still not clear how 
nucleotides work and their role in behavioural sensitisation and associated 
disorders. It has been suggested that adenylate cyclase is implicated in several 
forms of synaptic plasticity which are also involved in sensitisation and learning 
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and memory. While acute activation of G(i/o)-coupled receptors, for example 
dopamine receptors, leads to the inhibition of adenylate cyclase it was shown that 
chronic activation of these GPCRs produced superactivation or superinhibition, 
as shown by activation of cannabinoid CB1 receptors (Rhee et al., 2000) or mu-
opioid receptors (Nevo et al., 2000). It is well known that sympathetic nerves, 
their neurotransmitters and neuropeptides, act upon the target cells via cAMP, 
which initiates the protein metabolic processes in the cytoplasm, nuclei, 
chromatin (Svenningsson et al., 2003). 
It seems expedient to measure the concentration of intracellular cAMP in the cells 
of the specific brain area in tissue from behaviourally sensitised animals, as a 
measure of neuronal changes. The study described in this chapter examined the 
effect of dopaminergic agonists and antagonists on the accumulation of cAMP in 
dorsal striatal tissue of the rat ex vivo. The cAMP accumulation was assessed in 
tissue from vehicle, acute nicotine, chronic nicotine and chronic nicotine 
antagonised with SCH-23390, treated rats. To assess the effect of the post-
challenge period after which the tissue was dissected for ex vivo studies, tissue 
from every treatment group was taken at 45 min or at 24 h post-challenge, as 
indicated in the text. 
 
HYPOTHESES AND AIMS 
Hypotheses: 
- Dopamine plays an important role in behavioural sensitisation and dopaminergic 
intracellular pathways are affected by the chronic intermittent dosing regime. 
 
Aims: 
- Study putative changes in basal and forskolin-stimulated cAMP levels ex vivo 
following acute- and chronic nicotine administration in vivo compared to tissue 
from vehicle treated groups. 
- Investigate the effect of dopamine D1 and D2 receptor ligands in tissue of the 
different treatment groups. 
- Investigate the effect of a pre-challenge with SCH-23390 in vivo, on ex vivo 
cAMP accumulation in the absence or presence of forskolin or the selected 
dopamine D1 and D2 receptor ligands. 
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5.2 MATERIALS AND METHODS 
 
The described in vivo and ex vivo pharmacological experiments, and the LC-
MS/MS analyses were performed at Abbott Healthcare Products, the Netherlands. 
 
5.2.1. Chemicals 
Adenosine-cyclic-3‟,5‟-monophosphate (cAMP), adenosine-triphosphate (ATP), 
25 % aqueous ammonium hydroxide (NH4OH), ammonium bicarbonate 
(NH4HCO3), D(+)-glucose, forskolin (colforsin), dopamine, (-)-quinpirole, LY-
741626, R-(±)-SCH-23390, SKF-82958 and (±)-SKF-38393 were all purchased 
from Sigma Aldrich (Zwijndrecht, the Netherlands). SB-277011 was synthesised 
by Syncom (Groningen, the Netherlands). HPLC grade water, LC/MS grade 
acetonitrile (ACN) and calcium chloride (CaCl2) were obtained from Baker 
(Deventer, the Netherlands). 3 mM K+ Krebs-Ringer Buffer (KRB) was purchased 
from Gibco-Invitrogen (Breda, the Netherlands), and 1-Methyl-3-isobutylxanthine 
(IBMX) from Calbiochem (Ontario, Canada). Subsequent serial dilutions were 
performed to obtain the desired test concentration, as stated in the text.  
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Figure 5-1 Chemical structure of forskolin  
Forskolin (colforsin) is an activator of adenylate cyclase, which is biologically 
active by catalysing the production of the second messenger cAMP. cAMP 
interacts with proteins such as protein kinase A (PKA) and cyclic nucleotide-
gated ion channels (for review see Cooper, 2003). 
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5.2.2. Animals 
For animals used and description of locomotor activity protocol, see Chapter 2.  
 
5.2.3. Experimental design (in vivo protocol) 
Animals were chronically treated with nicotine and challenged with SCH-23390 
as previously described in Chapter 2. The methodology was approved by the 
animal ethics committee (Abbott Healthcare Products, the Netherlands) and was 
in accordance with all local laws. 
Briefly, one day prior to each experiment (day 0), all animals (n = 8 – 12 
rats/group) were habituated to the activity cages for one hr, followed by a saline 
injection and recording of locomotor activity. On the testing days (days 1 and 5) 
the rats were habituated for 60 min to the test apparatus, before administration of 
either saline (s.c., 2 groups) or (-)-nicotine (0.4 mg/kg, s.c., 1 group). After 
receiving the injections, the rats were directly placed back in the test apparatus 
and locomotor activity was measured for 45 min, in 5 min time epochs. This first 
time dose of nicotine was considered the acute dose. On day 2, 3 and 4 all 
groups received the same treatment as the day before and were directly placed 
back in their home cage. After a 4 day withdrawal period (day 9), all groups 
received a saline injection (s.c.) and locomotor activity was measured to assess if 
the response was context-dependent. On day 10, rats were habituated for 30 min 
to the test apparatus before administration of a pre-challenge of either saline (s.c., 
1 vehicle group and 2 nicotine groups) or SCH-23390 (0.03 mg/kg, i.p., third 
nicotine group). The rats were directly placed back in the test apparatus and 
locomotor activity was measured for 30 min. After 30 min of either saline or SCH-
23390 administration, the Vehicle - Vehicle group was challenged with saline and 
all other groups were challenged with 0.4 mg/kg (-)-nicotine (s.c.). Locomotor 
activity was measured for another 45 min, see Table 2-2 and Figure 5-2 for study 
design. 
A dose of 0.03 mg/kg SCH-23390 (i.p.) was selected as an appropriate dose, as 
it significantly blocked the effect of chronic nicotine challenge (P < 0.01) and at 
this dose had no significant effect on locomotor activity on its own (see Chapter 
2). Locomotor activity was measured 30 min before the pre-challenge with SCH-
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23390 followed by another 45 min following the nicotine challenge, as described 
in Chapter 2.  
 
60 min 45 min 60 min
VEH VEH/
SCH
NIC
DAY 0 DAY 1
Repeated DAY 1 - 5 
45 min 5 days 60 min 45 min 30 min 30 min 45 min or 24 hrs
DAY 9 DAY 10
NICVEH
Termination
 
Figure 5-2 Treatment scheme and termination of the in vivo experiments 
Schematic of the protocol used to determine expression of nicotine induced 
behavioural sensitisation. The in vivo experiments were terminated after either 45 
min or 24 h post-challenge and brain tissue was dissected. Locomotor activity 
was measured as described in Chapter 2. VEH, saline (s.c.); NIC, nicotine (s.c.); 
SCH, SCH-23390 (i.p.). 
 
5.2.4. Tissue preparation 
Brain tissue was prepared as described in the Methods section of Chapter 4, with 
the addition of an extra post-challenge time point. Briefly, rats were given a 
challenge injection (saline or nicotine) and locomotor activity was measured for 
45 min. This was followed by decapitation at 45 min post-challenge or the 
following day at 24 h post-challenge. Both striata were dissected as quickly as 
possible (Figure 5-3) and were kept in ice-cold KRB (for maximal 30 min) until 
brain-slicing using a McIlwain tissue chopper. 
 
5.2.5. cAMP accumulation assay 
See the Methods section of Chapter 4. 
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Figure 5-3 Schematic of dissected brain area 
The pair of vertical lines in the sagittal schematic (top left) indicate the anterior 
and posterior limits of the series of coronal schematics, coordinates were +1.7 – 
+0.2 mm anterior relative to Bregma (Paxinos and Watson, 1998). CPu indicates 
caudate putamen, the region of interest in the coronal sections, and corresponds 
to the dorsal striatum. Diagrams were modified from Paxinos and Watson (1998). 
 
 
5.2.6. Experimental design (ex vivo assay) 
Striatal tissues (both hemispheres) of 4 animals from the same treatment group 
were dissected and pooled. All pooled striatal tissues were sliced together 
resulting in a „homogenous‟ suspension which was divided over the 96-well 
filterplates. Each filterplate contained two controls, i.e. basal and 1 µM forskolin, 
in quadruplo. A single experiment could contain up to twenty 96-well plates and 
at least 1 plate contained a full concentration-response curve of SKF-38393 as 
the reference compound (i.e. positive control). In order to examine the 
pharmacological activity of the test compounds, each concentration of the test 
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compound was tested in quadruplo (4 wells within the same 96-well plate). At the 
end of each experiment, a mean was calculated from the quadruplo values and 
outliers (>2x s.d.) were removed. The calculated mean from this individual 
experiment was considered as n = 1. For example, if stated n = 3 this value is 
taken from 3 means of individual ex vivo experiments after 3 individual in vivo 
experiments. 
 
5.2.7. Sample analyses 
Samples were analysed using LC-MS/MS as described in Chapter 4, with the 
following modifications: The nucleotides were analysed using a different mass-
spectrometer, i.e. triplequadrupole Premier XE (Waters, Breda, the Netherlands) 
in the positive electrospray ionisation mode (ESI-MS/MS). A single ion monitoring 
(SIM) chromatograph was used to only detect the selected mass in the analysis: 
cAMP m/z 330  136, and ATP m/z 508  410. Validation of this method was 
as described in Chapter 4 (data not shown). 
 
5.2.8. Data analyses 
For data analyses of the in vivo experiments see Methods section Chapter 2. For 
data analyses of LC-MS/MS measurements see Methods section Chapter 4. 
Graphs and statistical analyses were performed using PRISM graphing software 
(GraphPad, USA). For each biological sample, the cAMP concentration was 
corrected for the ATP concentration by dividing cAMP levels by the total amount 
of nucleotides: cAMP/(cAMP+ATP)*100. 
Data from ex vivo experiments represent mean ± s.e.m. of at least three 
independent experiments (unless stated otherwise), and were conducted in 
quadruplicate. Values are expressed as a percentage of their respective control. 
The effect of single concentrations of forskolin tested were analysed using a two-
tailed paired t-test. Data with P < 0.05 were considered as significant. 
Concentration response curves were fitted using non-linear regression (i.e. Hill 
three-parameter sigmoidal equation) and mean values were plotted against the 
logarithm of the drug concentration (in molar). The maximal forskolin induced 
stimulated conversion was taken as the maximum value and the maximal 
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inhibition (at 10 µM of the reference compound) as the minimum and these 
values were fixed during the fitting process. This was followed by a calculation of 
pEC50 ± s.e.m. as presented in graphs and tables. EC50 values are defined as the 
concentration that is able to achieve 50 % of the maximally obtained inhibition by 
the compound, and pEC50 is its respective negative logarithm. 
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5.3 RESULTS 
 
5.3.1. Tissue preparation following behavioural sensitisation 
Initially, the behavioural response of the experimental animals to nicotine 
administration was examined in detail to determine the optimal parameters for 
subsequent biochemical studies (see Chapter 2). After the rats were sacrificed by 
decapitation (without the use of anaesthetics) at time point 45 min or 24 h post-
challenge, the dorsal striatum was dissected for ex vivo experiments. Figure 5-4A 
represents a typical locomotor activity measurement, also showing the time of 
injection (t = 0) and time of decapitation at the end of the experiment (t = 45 min 
post-challenge). Figure 5-4B shows the mean locomotor activity of a typical 
sensitisation experiment, illustrating the expression of nicotine induced 
behavioural sensitisation and its inhibition by a pre-challenge with SCH-23390. 
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Figure 5-4 Representative in vivo experiment for ex vivo tissue 
Four groups of rats (n = 8 animals/group) were treated with either saline (2 
groups, vehicle) or nicotine (2 groups) for 5 consecutive days followed by a 
withdrawal period of 5 days. The animals were pre-challenged with either saline 
(3 groups) or SCH-23390 (one of the chronic nicotine treated groups), followed 
by a nicotine challenge. A. Representative experiment showing locomotor activity 
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in 5 min periods following a saline or nicotine challenge. B. Mean ± s.e.m. 
beambreaks after the nicotine challenge [F (3, 28) = 30.37; P < 0.0001]. VEH, 
saline (s.c.); NIC, nicotine (s.c.); SCH, SCH-23390 (i.p.). 
 
The compounds examined in this study were tested at random using tissue from 
13 individual in vivo experiments (Table 5-1). All in vivo experiments showed 
significant behavioural sensitisation to nicotine. 
 
Table 5-1 Overview of in vivo behavioural sensitisation experiments 
Expression of locomotor sensitisation following SCH-23390 challenge and/or 
nicotine challenge. One-way ANOVA followed by post hoc Bonferroni‟s. 
     
Exp 
(No.) 
ANOVA 
(F value) 
post hoc Bonferroni’s 
(P value) 
  VEH-NIC NIC-NIC NIC- SCH+NIC 
     
1. [F (3, 44) = 34.15; P < 0.0001] *** *** ** 
2. [F (3, 44) = 23.58; P < 0.0001] *** *** ** 
3. [F (3, 44) = 54.86; P < 0.0001] *** *** ns$ 
4. [F (2, 21) = 56.79; P < 0.0001] *** *** n/a 
5. [F (2, 20) = 26.28; P < 0.0001] * *** n/a 
6. [F (2, 21) = 84.49; P < 0.0001] *** *** n/a 
7. [F (2, 21) = 56.78; P < 0.0001] *** *** n/a 
8. [F (3, 27) = 22.01; P < 0.0001] *** *** ns$ 
9. [F (2, 23) = 63.90; P < 0.0001] *** *** n/a 
10. [F (2, 23) = 33.09; P < 0.0001] * *** n/a 
11. [F (2, 23) = 38.85; P < 0.0001] *** *** n/a 
12. [F (2, 21) = 125.9; P < 0.0001] *** *** n/a 
13. [F (3, 28) = 30.37; P < 0.0001] *** *** * 
     
ns, not significant; n/a, not available; $, see discussion for comments. VEH, 
vehicle; NIC, nicotine; SCH, SCH-23390. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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5.3.2. Effect of forskolin on cAMP accumulation 
To examine the effect of in vivo nicotine induced behavioural sensitisation on 
basal and forskolin stimulated cAMP accumulation, the dorsal striatum was 
dissected following the final nicotine challenge and the slices were incubated with 
forskolin. As a positive control, basal and 1 µM forskolin stimulated cAMP 
accumulation were tested in every plate. All cAMP data are presented as a 
percentage of forskolin, which represents the viability of the physiological system 
at that time and circumstances. Forskolin did significantly increased cAMP 
accumulation within all treatment groups (paired t-test, *** P < 0.001, Figure 5-5). 
However, behavioural sensitisation did not affect basal or forskolin stimulated 
cAMP accumulation, as there was no significant difference observed between the 
treatment groups, basal [F (3, 19) = 1.408; P = 0.2712] and forskolin [F (3, 19) = 
0.3484; P = 0.7907]. 
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Figure 5-5 Effect of behavioural sensitisation on basal and forskolin (1 µM) 
stimulated cAMP accumulation in rat striatal slices  
Groups (pre-treatment + challenge): Vehicle (saline + saline), acute nicotine 
(saline + nicotine), chronic nicotine (nicotine + nicotine) or chronic nicotine + SCH 
(nicotine + SCH-23390/nicotine). Data of n = 6 different 96-well plates from a 
single ex vivo experiment representing the effect of basal and forskolin stimulated 
cAMP accumulation and intra-assay variation. Paired t-test, *** P < 0.001. 
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Forskolin was also tested in a concentration range from 1 nM to 0.1 mM to 
determine its potency. Forskolin increased cAMP formation in a concentration 
dependent manner (Figure 5-6A), which is in agreement with results shown 
above using a single 1 µM concentration. Theoretically no pEC50 value can be 
calculated as the highest concentration forskolin tested (i.e. 0.1 mM) did not 
produce a maximal effect or plateau. Estimated pEC50 values, calculated using 
PRISM software when Emax values were given, are showed in Table 5-2. 
Nonetheless, the results show that there is no change in potency following 
chronic nicotine treatment compared to vehicle (Figure 5-6A), and that in vivo 
pre-challenge with SCH-23390 before the nicotine challenge also did not affect 
the potency of forskolin stimulated cAMP accumulation (Figure 5-6B). 
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Figure 5-6 Effect of forskolin on cAMP accumulation in rat striatal slices 
Effect of forskolin on cAMP accumulation in striatal slices from vehicle and 
chronic nicotine treated rats (A) and chronic nicotine animals pre-treated with 
SCH-23390 (B). Tissue was dissected 45 min after the nicotine challenge. n = 4 
individual experiments, from 4 individual in vivo experiments. 
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Effect of after 24 h post-challenge 
The results above were obtained using tissue prepared 45 min post-challenge. 
To investigate the putative time-response effect of the post-challenge period 
before dissection of the brain tissue, the striata of animals from the same 
treatment group were dissected 24 h after the challenge injection. Forskolin 
stimulated cAMP accumulation in a concentration dependent manner, 
comparable to the results seen with tissue taken 45 min post-challenge (Figure 
5-7). No difference in time-response effect was observed for either treatment 
group (Table 5-2). 
 
A 
-10 -9 -8 -7 -6 -5 -4 -3
0
500
1000
1500
2000
2500
3000
Vehicle
Chronic Nicotine
Log [forskolin] (M)
%
 o
f 
c
o
n
tr
o
l
 
B 
-10 -9 -8 -7 -6 -5 -4 -3
0
500
1000
1500
2000
2500
3000
Chronic Nicotine + SCH-23390
Log [forskolin] (M)
%
 o
f 
c
o
n
tr
o
l
 
Figure 5-7 Effect of forskolin on cAMP accumulation in rat striatal slices 
prepared 24 h post-challenge  
The effect of forskolin on cAMP accumulation in striatal slices from vehicle and 
chronic nicotine treated rats (A) and chronic nicotine animals pre-challenged with 
SCH-23390 (B). Tissue was dissected 24 h after the final nicotine challenge. n = 
4-5 individual experiments, from 4 individual in vivo experiments which all 
showed significant behavioural sensitisation. 
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Table 5-2 Effect of forskolin on cAMP accumulation in rat striatal slices  
Values are pEC50 mean ± s.e.m. n-number is given between parentheses and Emax 
values (%) between brackets. 
  
VEH-VEH 
 
VEH-NIC 
 
NIC-NIC 
 
NIC-SCH+NIC 
 
45 min post-challenge 
   
Forskolin* 4.8 ± 0.2 (4) 
[2462] 
4.5 ± 0.2 (4) 
[2170] 
4.6 ± 0.2 (4) 
[2488] 
4.8 ± 0.1 (4) 
[2024] 
 
24 h post-challenge 
   
Forskolin* 4.5 ± 0.2 (5) 
[2385] 
4.5 ± 0.3 (4) 
[2298] 
4.5 ± 0.2 (4) 
[2352] 
4.5 ± 0.2 (3) 
[2715] 
     
VEH, vehicle; NIC, nicotine; SCH, SCH-23390. * Note: The highest concentration 
tested (100 µM forskolin) did not produce a maximal effect or plateau; therefore it is 
theoretically not possible to calculate a pEC50 value. However, when the fitting 
software (PRISM) estimates the maximal value at 0.1 mM, the pEC50 values are 
calculated. 
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5.3.3. Effect of dopamine on cAMP accumulation 
It is hypothesised that dopamine, the endogenous ligand for the dopamine 
receptor, would have equal affinity for both dopamine D1-like and dopamine D2-
like receptor subtypes and therefore would have no effect on cAMP accumulation. 
When the effect of dopamine was tested at a concentration up to 0.1 mM, a small 
but concentration dependent increase in cAMP production in dorsal striatal slices 
was observed. Dopamine produced a maximum stimulation of cAMP production 
of 167 ± 28 % over basal levels in the dorsal striatum of saline administrated 
animals (Figure 5-8A). Specific antagonism of the dopamine D2 receptor subtype, 
by co-incubation of dopamine with LY-741626, increased the potency of 
dopamine (pEC50 dopamine 4.4 ± 0.2 vs. dopamine + LY-741626 co-incubated 
5.6 ± 0.4, Figure 5-8C and Table 5-3). In contrast to the results observed with a 
dopamine D2 antagonist, co-incubation of dopamine with the dopamine D1 
antagonist SCH-23390 inhibited the effect of dopamine and as a result prevented 
stimulation of cAMP accumulation (pEC50 < 5.0, Figure 5-8E).  This is in 
agreement with the in vivo behavioural sensitisation observations which are also 
blocked by SCH-23390. 
 
In addition to the examination of dopaminergic ligands on cAMP accumulation in 
tissue from naïve animals, the effect of these ligands was investigated in tissue of 
animals sensitised to nicotine by chronic administration. It was found that 
behavioural sensitisation did not affect dopamine stimulated cAMP accumulation 
(Figure 5-8A). However, a large increase in the Emax value of dopamine was 
found in tissue from sensitised animals, when the dopamine D2 component was 
blocked by co-incubation with LY-741626 (Emax vehicle 162 % vs. chronic nicotine 
213 %, Figure 5-8E). Co-incubation of dopamine with SCH-23390 did not 
increase cAMP accumulation in tissue from sensitised rats (pEC50 < 5.0, Figure 
5-8E).  
 
The effect of dopamine on cAMP accumulation in tissue from sensitised animals 
which were additionally pre-challenged with SCH-23390 prior to the nicotine 
challenge was investigated. The Emax value of dopamine in tissue from these 
animals was strongly reduced (Figure 5-8B). The increase in Emax value of 
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dopamine in the presence of LY-741626 following behavioural sensitisation was 
also reduced by an in vivo pre-challenge with SCH-23390 (Figure 5-8D). As 
expected from the results observed above, no increase was seen by dopamine in 
the presence of SCH-23390 (pEC50 < 5.0, Figure 5-8F). 
 
Co-incubation of dopamine with the selective dopamine D3 antagonist SB-277011 
(1 µM) completely blocked the effect of dopamine on cAMP accumulation (pEC50 
< 4.0). This antagonism by SB-277011 was not affected by in vivo challenge of 
nicotine or SCH-23390 (Table 5-3). 
 
This study also investigated the time-response effect when tissue was taken 24 h 
post-challenge. When striata from animals of the same treatment-group were 
dissected 24 h after the last nicotine challenge, no effect of dopamine on cAMP 
accumulation was observed (pEC50 < 5.0, n = 3 for vehicle and chronic nicotine 
treated groups, see Table 5-3).  
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Figure 5-8 Effect of dopamine on cAMP accumulation in rat striatal slices  
The effect of dopamine on cAMP accumulation in striatal slices from vehicle and 
chronic nicotine treated rats (A) and chronic nicotine treated animals pre-
challenged with SCH-23390 (B). The effect of dopamine in the presence of 1 µM 
LY-741626 (C, D). The effect of dopamine in the presence of 1 µM SCH-23390 
(E, F). Tissue was taken 45 min post-challenge. n = 4-6 individual ex vivo 
experiments from individual in vivo experiments. 
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Table 5-3 Effect of dopamine on cAMP accumulation in rat striatal slices 
Values are pEC50 mean ± S.D. n-number is given between parentheses and Emax 
values (%) between brackets. 
  
VEH-VEH 
 
VEH-NIC 
 
NIC-NIC 
 
NIC-SCH+NIC 
     
45 min post-challenge    
Dopamine 
 
4.4 ± 0.2 (6) 3.8 ± 0.1 (4) 4.7 ± 0.2 (6) 3.8 ± 0.1 (4) 
Dopamine + 
LY-741626 (1µM) 
5.6 ± 0.4 (4) 
[162] 
5.9 ± 0.3 (4) 
[172] 
5.8 ± 0.3 (4) 
[213] 
4.3 ± 0.4 (4) 
[166] 
Dopamine + 
SCH-23390 (1µM) 
<4.0 (4) <4.0 (3) <4.0 (4) <4.0 (4) 
Dopamine + 
SB-277011 (1µM) 
<4.0 (3) <4.0 (3) <4.0 (3) <4.0 (3) 
     
24 h post-challenge    
Dopamine 
 
<5.0 (3) n/a <5.0 (3) n/a 
Dopamine + 
LY-741626 (1µM) 
n/a n/a n/a n/a 
Dopamine + 
SCH-23390 (1µM) 
n/a n/a n/a n/a 
Dopamine + 
SB-277011 (1µM) 
n/a n/a n/a n/a 
     
n/a, not available; VEH, vehicle; NIC, nicotine; SCH, SCH-23390. 
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5.3.4. Effect of dopamine D1 ligands on cAMP accumulation 
The dopamine D1 agonists SKF-38393 and SKF-82958 showed a concentration 
dependent increase in cAMP accumulation using striatal slices from saline 
treated animals (Figure 5-9A and C, respectively). When SKF-82958 was tested 
at higher concentrations (i.e. 10 µM and 100 µM), the simultaneously measured 
ATP levels were strongly decreased indicating toxicity. 
The effect of the dopamine D1 agonists was tested in tissue from sensitised 
animals (tissue taken at 45 min post-challenge). The potency of both dopamine 
D1 agonists was reduced after acute and chronic nicotine administration, i.e. 
SKF-38393 also showed a shift in potency of cAMP accumulation in vehicle 
(pEC50 7.2 ± 0.2) versus acute (pEC50 6.7 ± 0.2) and chronic (pEC50 6.0 ± 0.2) 
nicotine treated animals. SKF-82958 showed also a shift in potency; Vehicle 
(pEC50 7.7 ± 0.2), acute (pEC50 7.3 ± 0.4) and chronic nicotine (pEC50 6.2 ± 0.2). 
Moreover, the effect of in vivo pre-challenge with SCH-23390 on SKF-38393 and 
SKF-82958 stimulated cAMP accumulation was examined. Interestingly the in 
vivo SCH-23390 pre-challenge increased the potency of SKF-38393, back to the 
level of vehicle and thus abolished the effect of the sensitisation on cAMP 
accumulation (Figure 5-9B). The same effect, although to a lesser extent, was 
observed with SKF-82958 (Figure 5-9D). Furthermore, the maximal effect (Emax) 
of SKF-82958 was decreased. 
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Figure 5-9 Effect of dopamine D1 receptor agonists on cAMP accumulation  
A. Effect of chronic saline and nicotine (A) and chronic nicotine with SCH-23390 
pre-treatment (B) on SKF-38393 (A and B) or SKF-82958 (C and D) stimulated 
cAMP accumulation. Tissue taken 45 min post-challenge. See Table 5-4 for 
pEC50 and Emax values, n-numbers and data for acute nicotine treatment. 
 
 
This study also assessed the effect of the dopamine D1 antagonist SCH-23390 
on cAMP accumulation. Previous research showed that dopamine D1 antagonists 
have no intrinsic activity on the dopamine D1 receptor and as a result have no 
effect on cAMP accumulation. This was confirmed by this study where the 
dopamine D1 antagonist SCH-23390 had no effect on cAMP accumulation in 
striatal slices (Figure 5-10A). When the dopamine D1 agonist SKF-38393 (1 µM) 
was tested in combination with SCH-23390 its effect on cAMP accumulation was 
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abolished, i.e. antagonised by SCH-23390 (Figure 5-10C). The same effects 
were found for SCH-23390 alone or in presence of SKF-38393 in tissue following 
chronic nicotine administration (Figure 5-10B and D). It was found that in vivo 
behavioural sensitisation, with or without a SCH-23390 pre-challenge, did not 
affect the lack of activity of SCH-23390 (Figure 5-10A and B). 
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Figure 5-10 Effect of dopamine D1 receptor antagonist SCH-23390 on cAMP 
accumulation  
The effect of SCH-23390 alone (A) or in the presence of SKF-38393 (C) on 
cAMP accumulation in striatal slices from vehicle and chronic nicotine treated rats. 
The effect of SCH-23390 alone (B) or in the presence of SKF-38393 (D) following 
chronic nicotine with SCH-23390 pre-treatment. Tissue taken 45 min post-
challenge. See Table 5-4 for pEC50 and Emax values, n-numbers and data for 
acute nicotine treatment. 
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This study also investigated the effect of dopamine D1 ligands on cAMP 
accumulation following a longer post-challenge period, using the striata of vehicle 
treated rats which were dissected 24 h after the last challenge. A concentration 
dependent effect of dopamine D1 agonist SKF-38393 on cAMP accumulation was 
observed (Figure 5-11A) with a pEC50 of 6.9 ± 0.1. This result is comparable to 
the results obtained using tissue from non-treated animals (see Chapter 4) and 
tissue taken 45 min post-challenge (7.2 ± 0.2, Table 5-4). In contrast to results 
seen using tissue taken at 45 min post-challenge, the in vivo nicotine induced 
sensitisation did not alter the potency of SKF-38393 on cAMP accumulation when 
tissue was taken 24 h post-challenge (Figure 5-11A). Also no difference in 
potency was observed following a pre-challenge with SCH-23390 (Figure 5-11B). 
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Figure 5-11 Effect of dopamine D1 agonist SKF-38393 on cAMP 
accumulation, 24 h post-challenge 
A. Effect of SKF-38393 on tissue from vehicle and chronic nicotine treated 
animals taken 24 h after the final nicotine challenge. B. Effect of SKF-38393 
following chronic nicotine and pre-challenged with SCH-23390. See Table 5-4 for 
pEC50 and Emax values, n-numbers and data for acute nicotine treatment. 
 
 
The other dopamine D1 receptor agonist SKF-82958 showed the same effect 
when using tissue taken 24 h post-challenge, compared to tissue which was 
taken 45 min post-challenge. Also, behavioural sensitisation did not affect the 
potency of SKF-82958 stimulated cAMP accumulation (Figure 5-12A) in contrast 
to results seen with tissue taken 45 min post-challenge (see Table 5-4). Moreover, 
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the effect of the partial dopamine D1 agonist SKF-77434 was examined. Unlike 
the dopamine D1 agonists SKF-38393 and SKF-82958, SKF-77434 did not 
increase cAMP accumulation and no difference was seen between vehicle and 
chronic nicotine treated rats (pEC50 <5.0, Figure 5-12B). 
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Figure 5-12 Effect of dopamine D1 receptor agonists on cAMP accumulation, 
24 h post-challenge 
Effect of SKF-82958 (A) and SKF-77434 (B) on tissue from saline or chronic 
nicotine treated animals, taken 24 h after challenge. SKF-82958, n = 7 and SKF-
77434, n = 4 from individual ex vivo experiments from individual in vivo 
experiments. See Table 5-4 for pEC50 and Emax values, n-numbers and data for 
acute nicotine treatment. 
 
 
The dopamine D1 receptor antagonist SCH-23390 was tested using tissue taken 
24 h post-challenge and did not show any effect on cAMP accumulation (i.e. 
pEC50 < 5.0 for both vehicle and nicotine sensitised groups) which is in 
agreement with previous observations using tissue taken 45 min post-challenge 
or non-treated animals (see Table 5-4). The effect of SCH-23390 in the presence 
of SKF-38393 was examined and showed a concentration dependent inhibition 
with potency comparable to tissue taken 45 min post-challenge. In vivo chronic 
nicotine and chronic nicotine with SCH-23390 pre-challenge did not affect this 
concentration dependent effect (Figure 5-13, Table 5-4). 
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Figure 5-13 Effect of SCH-23390 in presence of SKF-38393 on cAMP 
accumulation, 24 h post-challenge 
A. Effect of SCH-23390 in the presence of SKF-38393 (1 µM) using tissue from 
vehicle and chronic nicotine treated animals taken 24 h after nicotine challenge. 
B. Effect of SCH-23390 in the presence of SKF-38393 (1 µM) following chronic 
nicotine pre-challenged with SCH-23390. See Table 5-4 for pEC50 and Emax 
values, n-numbers and data for acute nicotine treatment. 
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Table 5-4 Effect of D1 ligands on cAMP accumulation in rat striatal slices   
Values are pEC50 mean ± S.D. n-number is given between parentheses and Emax 
values (%) between brackets. 
  
VEH-VEH 
 
VEH-NIC 
 
NIC-NIC 
 
NIC-SCH+Nic 
     
45 min post-challenge    
SKF-82958 
 
7.7 ± 0.2 (4) 7.3 ± 0.4 (3) 6.2 ± 0.2 (4) 7.6 ± 0.3 (3) 
SKF-38393 
 
7.2 ± 0.2 (5) 6.7 ± 0.2 (3) 6.0 ± 0.2 (5) 6.4 ± 0.2 (4) 
SKF-77434 
 
n/a n/a n/a n/a 
SCH-23390 
 
<5.0 (3) <5.0 (3) <5.0 (3) <5.0 (3) 
SCH-23390 + 
SKF-38393 (1µM) 
8.2 ± 0.3 (5) 8.4 ± 0.2 (5) 7.9 ± 0.5 (5) 7.9 ± 0.2 (4) 
     
24 h post-challenge    
SKF-82958 
 
7.7 ± 0.4 (7) 
[202] 
7.2 ± 0.5 (2) 
[165] 
7.4 ± 0.5 (7) 
[179] 
n/a 
SKF-38393 
 
6.9 ± 0.1 (8) 
[218] 
7.0 ± 0.3 (4) 
[197] 
7.0 ± 0.2 (6) 
[208] 
6.9 ± 0.3 (3) 
[209] 
SKF-77434 
 
<5.0 (4) n/a <5.0 (4) n/a 
SCH-23390 
 
<5.0 (3) n/a <5.0 (3) n/a 
SCH-23390 + 
SKF-38393 (1µM) 
8.4 ± 0.2 (4) 8.3 ± 0.1 (3) 8.1 ± 0.3 (4) 8.1 ± 0.3 (3) 
     
n/a, not available; VEH, vehicle; NIC, nicotine; SCH, SCH-23390. 
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5.3.5. Effect of nicotine on cAMP accumulation 
The effect of nicotine on cAMP accumulation in the striatum of non-treated 
animals was investigated. Nicotine was tested in a dose range from 0.01 to 10 
µM without any effect on cAMP accumulation and the pEC50 values for nicotine in 
vehicle and chronic nicotine tissue were both < 5.0 (n = 3). Furthermore, the 
effect of nicotine on SKF-38393 stimulated cAMP accumulation was investigated 
using tissue from non-treated animals. The presence of 10 µM nicotine did not 
alter the potency or efficacy of SKF-38393 in rat striatal slices (Figure 5-14). 
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Figure 5-14 Effect of nicotine on the effect of SKF-38393 stimulated cAMP 
accumulation 
The effect of SKF-38393 on cAMP accumulation was tested in the absence (■) or 
presence (▲) of nicotine (10 µM). Tissue taken from non-treated animals, n = 2. 
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5.3.6. Effect of dopamine D2 ligands on cAMP accumulation 
The dopamine D2-like full agonist quinpirole showed an inhibition of cAMP 
accumulation with a pEC50 of 9.2 ± 0.5. The potency of quinpirole was decreased 
following sensitisation using tissue taken 45 min post-challenge (pEC50 8.4 ± 0.5, 
Figure 5-15A). An in vivo pre-challenge with SCH-23390 did not affect the results 
of the nicotine challenge on cAMP accumulation and quinpirole showed a pEC50 
of 8.2 ± 0.6 (Figure 5-15B). The selective dopamine D2 antagonist LY-741626 did 
not affect cAMP accumulation when tested alone (pEC50 < 5.0) and was not 
affected by either behavioural sensitisation with or without a SCH-23390 pre-
challenge (Figure 5-15C and D). 
 
The selective dopamine D3 antagonist SB-277011 was tested and did not affect 
cAMP accumulation when tested alone (pEC50 < 5.0). Furthermore, its effect was 
not affected by either behavioural sensitisation with or without a SCH-23390 pre-
challenge (Table 5-5). 
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Figure 5-15 Effect of dopamine D2 receptor ligands on cAMP accumulation 
Effect of the dopamine D2 agonist quinpirole on striatal slices from vehicle and 
chronic nicotine treated rats (A) and chronic nicotine treated animals pre-
challenged with SCH-23390 (B). Effect of the dopamine D2 antagonist LY-741626 
in slices from vehicle and chronic nicotine treated rats (C) and chronic nicotine 
treated animals pre-challenged with SCH-23390 (D). Tissue was taken 45 min 
post-challenge. For pEC50 values and n-numbers see Table 5-5. 
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To investigate dopamine D1/D2 synergism, the dopamine D2-like full agonist 
quinpirole was tested in the presence of the dopamine D1 receptor agonist SKF-
82958. When quinpirole was co-incubated with SKF-82958 (1 µM) in tissue from 
non-treated animals, the pEC50 of quinpirole decreased compared to when 
quinpirole was tested alone (i.e. pEC50 8.1 ± 0.2 and 9.2 ± 0.5, respectively). 
When quinpirole was co-incubated with SKF-82958 and tissue taken 45 min post-
challenge from either vehicle, acute or chronic nicotine treated rats, no difference 
in potency was seen (Figure 5-16). This is in contrast when quinpirole was tested 
alone, and suggests that dopamine D1 receptor activation does have an effect on 
dopamine D2 receptor mediated signalling. No significant effect of quinpirole was 
seen in tissue (taken 24 h post-challenge) from either vehicle or chronic nicotine 
treated rats (Table 5-5). This might be explained by the high concentration of 
SKF-82958 used (i.e. 10 µM) and therefore the stimulation of cAMP accumulation 
is too strong to be reversed by 10 µM quinpirole. 
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Figure 5-16 Effect of dopamine D2 receptor agonist in presence of a D1 
agonist on cAMP accumulation 
The effect of quinpirole in the presence of SKF-82958 (1 µM) on cAMP 
accumulation in tissue from vehicle or chronic nicotine treated, behaviourally 
sensitised animals. Tissue was taken 45 min post-challenge, n = 4. For pEC50 
values see Table 5-5. 
 
 
The effect of quinpirole on tissue taken 24 h post-challenge was also investigated. 
Quinpirole inhibited cAMP accumulation in saline treated animals (VEH) and 
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resulted in a lower pEC50 value compared to tissue taken 45 min post-challenge 
(i.e. pEC50 8.4 ± 0.3 vs. 9.2 ± 0.5). Tissue from sensitised animals resulted in a 
pEC50 of 7.9 ± 0.5 and therefore there was no effect of behavioural sensitisation 
observed on the effect of quinpirole when tissue was taken 24 h post-challenge. 
When quinpirole was tested in combination with SKF-38393, it showed a 
concentration-dependent decrease of cAMP levels in tissue from vehicle (pEC50 
8.1 ± 0.2) as well as chronic nicotine treated rats (pEC50 7.8 ± 0.3) when tissue 
taken 24 h post-challenge. No experiments of quinpirole in combination with SKF-
38393 were performed at 45 min post-challenge. 
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Figure 5-17 Effect of quinpirole alone and in presence of SKF-38393 on 
cAMP accumulation 
The effect of quinpirole on tissue from vehicle or chronic nicotine treated animals 
(A) or chronic nicotine pre-challenged with SCH-23390 (B). The effect of 
quinpirole in the presence of 1 µM SKF-38393 (C). Tissue taken 24 h post-
challenge. 
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Table 5-5 Effect of D2 ligands on cAMP accumulation in rat striatal slices 
Values are pEC50 mean ± S.D. n-number is given between parentheses. 
  
VEH-VEH 
 
VEH-NIC 
 
NIC-NIC 
 
NIC-SCH+NIC 
     
45 min post-challenge    
Quinpirole 
 
9.2 ± 0.5 (3) 8.2 ± 0.3 (3) 8.4 ± 0.5 (3) 8.2 ± 0.6 (3) 
Quinpirole + 
SKF-38393 (1µM) 
n/a n/a n/a (1) 
Quinpirole + 
SKF-82958 (1µM) 
8.1 ± 0.2 (4) 7.9 ± 0.4 (2) 8.1 ± 0.4 (4) (1) 
Quinpirole + 
SKF82958 (10µM) 
n/a n/a n/a n/a 
LY-741626 
 
<5.0 (4) <5.0 (4) <5.0 (4) <5.0 (4) 
SB-277011 <5.0 (4) <5.0 (4) <5.0 (4) <5.0 (4) 
24 h post-challenge    
Quinpirole 
 
8.4 ± 0.3 (3) 8.9 ± 0.3 (3) 7.9 ± 0.5 (3) 8.2 ± 0.2 (3) 
Quinpirole + 
SKF-38393 (1µM) 
8.1 ± 0.2 (5) 8.2 ± 0.1 (2) 7.8 ± 0.3 (5) n/a 
Quinpirole + 
SKF-82958 (1µM) 
n/a n/a n/a n/a 
Quinpirole + 
SKF82958 (10µM) 
<5.0 (4)* <5.0 (1) * <5.0 (4) * n/a 
LY-741626 
 
n/a n/a n/a n/a 
SB-277011 
 
n/a n/a n/a n/a 
n/a, not available; *, Weak effect, only 10-20%. pEC50 ca. 7.0. VEH, vehicle; NIC, 
nicotine; SCH, SCH-23390. 
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5.4 DISCUSSION 
 
The data presented herein provide further insights into the pharmacological 
characteristics of striatal cells possessing dopaminergic receptors and 
demonstrate that the functionality of the dopamine receptor is altered following 
the expression of behavioural sensitisation. It is shown that the dopamine D1 
receptor plays a role in the expression of nicotine induced behavioural 
sensitisation. Moreover, this study demonstrated for the first time a direct 
connection between the involvement of the dopamine D1 receptor in behavioural 
sensitisation and the changes in dopamine receptor mediated cellular responses 
following sensitisation. 
 
Cyclic adenosine monophosphate or cAMP is an important intracellular second 
messenger and plays a major role in cell signalling. Furthermore, it helps 
understanding molecular modulations and is therefore a standard assay in the 
development of new neuropsychiatric drugs. The use of individual techniques has 
been shown to be insufficient and more multidisciplinary approaches are required. 
Therefore, the current study combined in vivo and ex vivo approaches to achieve 
maximal efficacy in an attempt to identify and pharmacologically characterise 
behavioural sensitisation. In line with this strategy, the present study used in vivo 
behavioural and ex vivo cAMP accumulation assays. 
 
Initial locomotor activity experiments showed that the effect of nicotine returned to 
basal activity levels after 45 min (Figure 5-4A) and therefore the first time point to 
terminate the in vivo experiment was selected at 45 min after the last nicotine 
challenge.  
As indicated in Table 5-1, two behavioural experiments examining the effect of a 
pre-challenge with SCH-23390 on sensitisation did not reach significance, 
although both experiments did show significant sensitisation to nicotine. In 
experiment number 3, the nicotine sensitised group showed a relative high 
locomotor response (697 beambreaks/45 min) which should normally read 
between 550 and 650 beambreaks/45 min. In experiment number 8, the nicotine 
sensitised group showed a relatively low locomotor response (502 
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beambreaks/45 min). There were no individual outliers, as defined by the criteria 
of values higher or lower than the mean ± two times the standard deviation. 
Moreover, the variation within the groups was small, i.e. s.e.m. < 9%. As stated in 
the methods, tissues from all animals were used regardless of their behavioural 
response. Tissues from animals within the same treatment group were pooled 
and test compounds were randomised and tested across tissue from at least 
three individual in vivo experiments (unless stated otherwise). 
 
Forskolin, a diterpene derivative (Figure 5-1), can directly activate the catalytic 
subunit of adenylate cyclase thereby elevating intracellular cAMP levels. The 
involvement of adenylate cyclase in the development of behavioural sensitisation 
has been suggested after repeated co-administration of forskolin and cocaine, 
which significantly enhance the development of behavioural sensitisation to 
cocaine (Schroeder et al., 2004). In an attempt to further characterise the role of 
cAMP signalling in sensitisation, this experiment used forskolin as a tool to 
investigate the relationship between nicotine induced alterations in behaviour and 
brain cAMP levels. Forskolin showed a concentration dependent increase in 
cAMP accumulation (Figure 5-6A) and was active at concentrations as low as 
0.01 µM. The highest concentration tested (100 µM) gave a relatively high 
response, and the Emax is expected to be close to this estimated concentration. 
Therefore an estimated Emax was used to calculate pEC50 values for forskolin. 
Forskolin increased cAMP accumulation, however neither acute nor chronic 
nicotine administration (i.e. nicotine induced behavioural sensitisation) affected 
basal or forskolin stimulated cAMP levels. 
The actual percentage of stimulation by forskolin compared to basal can differ 
greatly between the individual ex vivo experiments. Therefore, for comparison of 
the effect of forskolin between experiments (Figure 5-5), the effect of forskolin 
was expressed as the cAMP:ATP ratio. 
 
The low potency of dopamine on cAMP accumulation (i.e. pEC50 4.4 ± 0.2, Table 
5-3) might be explained by the breakdown of dopamine during the incubation. 
This could be prevented by addition of an anti-oxidant (e.g. ascorbic acid/Vitamin 
C) to the incubation buffer, although the anti-oxidant can also affect the binding 
kinetics and therefore is not recommended (see Chapter 6). The low potency of 
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dopamine is in contradiction to the reported high affinity binding of dopamine at 
the dopamine receptor (see Chapter 6 for discussion). It could be suggested that 
this effect is due to the non-selectivity of dopamine for dopaminergic receptor 
subtypes, i.e. dopamine will activate both the dopamine D1-like and D2-like 
receptors. As the D1-like and D2-like receptors are respectively stimulatory and 
inhibitory coupled to adenylate cyclase, it could be suggested that the net effect 
of dopamine on cAMP accumulation could be zero. However, Mottola and 
colleagues showed that dopamine decreased forskolin stimulated cAMP 
accumulation when tested on its own (Mottola et al., 2002). In the present study 
dopamine stimulated cAMP accumulation (Figure 5-8). It should be noted that 
dopamine produced a maximum stimulation of cAMP production of 167 ± 16 % 
over basal levels (at 0.1 mM), at which point it had not reached a plateau. An 
estimated pEC50 value was calculated (as described above for forskolin). The low 
potency observed could also suggest a relative low affinity for the dopamine 
receptor subtypes. 
Dopamine was tested in presence of the selective dopamine D2 receptor 
antagonist LY-741626, the selective dopamine D3 receptor antagonist SB-277011, 
or the selective dopamine D1 receptor antagonist SCH-23390. It was proposed 
that the dopamine D2 antagonist would prevent dopamine D2 receptor induced 
inhibition, and keep the dopamine D1 receptor available for dopamine stimulation. 
The present data showed that the dopamine D1 component of dopamine is 
revealed when dopamine was tested in combination with the dopamine D2 
antagonist LY-741626 (Figure 5-8C), which is in agreement with previous data 
(Barnett et al., 1987). When rats were sensitised with nicotine, an increase in 
potency to stimulated cAMP accumulation was found. This is in contrast with 
previous data (Barnett et al., 1987) which showed a decrease in dopamine 
stimulated adenylate cyclase activity after chronic amphetamine administration, 
were dopamine was used as an index for dopamine D1 receptor activation. 
However, the present results of the dopamine induced D1 receptor activation 
were observed in the presence of D2 receptor blockade. A dopamine D1/D2 
receptor “(de-) activation synergy” could explain the discrepancy between the two 
studies. 
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The scientific literature is contradictory, for example, repeated cocaine 
administration produced no persistent changes in dopamine stimulated adenylate 
cyclase activity in either caudate putamen or nucleus accumbens ex vivo 
(Mayfield et al., 1992). Although acute administration of a high dose of 
amphetamine (5 mg/kg) or methylphenidate (50 mg/kg), but not with lower doses, 
resulted in the desensitisation of dopamine stimulated adenylate cyclase activity, 
which occurred within 25 min but recovered rapidly within 90 min (Barnett et al., 
1986). It might be possible that the decrease of dopamine D1 agonist (SKF-38393 
and SKF-82958) stimulated cAMP accumulation, seen in the present study after 
45 min but not after 24 h post-challenge, might be due to desensitisation of the 
dopamine D1 receptor. Future studies should investigate tissue taken at 
additional time points between the 45 min and 24 h post-challenge, in order to 
fully evaluate the temporality of the effect. 
 
These data suggests that chronic nicotine administration can affect the 
functionality of the dopamine D1 receptor. No conclusions can be made about the 
dopamine D2 receptor as dopamine does not seem to be the right tool to monitor 
dopamine D2 receptor activity by cAMP accumulation.  
 
Behavioural sensitisation experiments in the present study have shown that 
nicotine sensitisation can be antagonised by the dopamine D1 antagonist SCH-
23390, suggesting a role for the dopamine D1 receptor in behavioural 
sensitisation. It is hypothesised that nicotine induced behavioural sensitisation 
will subsequently affect the dopamine D1 receptor cAMP pathway. Previous 
literature showed that activation of the dopamine D1 receptor increases cAMP 
levels in rat striatum (Mottola et al., 2002; see also Chapter 4). This study 
examines the effect of the dopamine D1 agonists SKF-38393 and SKF-82958 on 
cAMP accumulation in the striatum following nicotine induced behavioural 
sensitisation. 
The dopamine D1 agonists SKF-38393 and SKF-82958 increased cAMP 
formation by stimulation of the dopamine D1 receptor, as the D1 receptor is 
positively coupled to adenylate cyclase through the Gs-protein, and the effect 
was blocked by a dopamine D1-like antagonist SCH-23390 (Figure 5-10). In this 
study, SKF-38393 was found to be a full D1 agonist, although this compound has 
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been described as a partial agonist in the literature. For example, using a specific 
antibody, dopamine and the selective dopamine D1 receptor agonists SKF-81297 
and SKF-82958 behaved as high-efficacy agonists (Emax 100 %) in stimulating 
[35S]-GTPγS (guanosine-5‟-O-(3-[35S]-thio)-triphosphate, a non-hydrolysable G-
protein activating analogue of GTP) binding to Gs in L-cells over-expressed with 
the human dopamine receptor subtype 1 (D1), whereas SKF-38393 displayed 
partial agonist properties (Emax 70 %; Cussac et al., 2004). Other examples 
include the examination of adenylate cyclase activity in rat striatal membranes, 
and dopamine D1 receptor over-expressed in C6-glioma cells, where SKF-38393 
displayed an efficacy of only 30–40 % relative to dopamine (O‟Boyle et al., 1989; 
Lewis et al., 1998). The discrepancy between these different assays is probably 
reflecting a difference in density of dopamine D1 receptors in the cell systems 
used, i.e. a low receptor density would results in a very poor efficacy whereas a 
high receptor density would result in full agonistic properties. The present study 
used intact striatal cells measuring intracellular cAMP accumulation instead of the 
described indirect methods or in vitro cell cultures. 
 
The present study showed that the potency of dopamine D1 receptor agonist 
stimulated cAMP accumulation was decreased following nicotine sensitisation. 
Although this is in contrast to previous reports, this might be explained by the 
different treatment protocols used. For example, the sensitivity of dopamine and 
SKF-82958 on adenylate cyclase activity was increased following 14 days of 
chronic cocaine treatment, but not after acute or 7 days treatment (Unterwald et 
al., 1996). This study also showed that the maximal effect produced by dopamine 
or SKF-82958, as well as the pEC50 of SKF-82958 were increased. However, 
Unterwald and colleagues measured the adenylate cyclase activity using [3H]-
cAMP membrane binding and tissue was taken 30 min post-challenge, and 
because of these methodological differences the results from the present study 
might not be comparable. SCH-23390 was tested in a wide concentration range 
from 1E-11 to 1E-05 M, to assess putative high and low affinity sites as proposed 
by receptor binding experiments (see Chapter 6). 
Considering all the experimental evidence, it is quite conceivable that changes in 
cAMP-modulation are only seen 45 min after challenge injection, and not after 24 
h, as cAMP is a relatively fast acting second messenger as over time (>24 h) 
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more downstream signalling molecules will get activated. Moreover, changes in 
dopamine D1 agonist mediated cAMP accumulation are seen after chronic as well 
as acute nicotine administration. This study does not show a difference between 
acute and chronic nicotine administration, and is not sufficient to make 
conclusions about long term changes. 
It was shown that the stimulating effect of dopamine D1 agonists on ex vivo cAMP 
is affected by behavioural sensitisation and can be reversed by in vivo pre-
treatment with a dopamine D1 antagonist; this increases the predictive validity of 
the hypothesis that the induced cAMP accumulation is related to behavioural 
sensitisation. Moreover, this suggests that the dopaminergic pathway plays a role 
in behavioural sensitisation. 
 
The present study observed only an effect of dopamine D1 agonist stimulated 
cAMP accumulation when tissue was taken 45 min post-challenge, but not 24 h 
post-challenge. It might be suggested that there is still nicotine left in the tissue 
taken 45 min after the challenge injection and no nicotine present 24 h post-
challenge. The nicotine still present could then affect the dopamine D1 stimulated 
cAMP accumulation, maybe due to the desensitisation of the nAChRs or 
dopamine receptors. 
The shift in potency seen with SKF-38393 after chronic nicotine treatment is in 
agreement with the given hypothesis (i.e. dopaminergic receptors are involved in 
chronic nicotine induced behavioural sensitisation), the potency shift seen after 
acute nicotine administration did not agree with the hypothesis. It could be 
suggested that there is still nicotine present in the tissue after in vivo 
administration. This is supported by the fact that the shift is only seen 45 min and 
not 24 h after the last injection. However, the extensive washing and stabilisation 
time of the tissue before testing ex vivo contradicts this possibility. Therefore the 
effect of nicotine on cAMP was investigated, and no significant effect of nicotine 
was seen (data not shown). To exclude the putative interference of nicotine, if still 
present in the slices after in vivo administration, the effect of SKF-38393 in 
combination with nicotine (10 µM) was examined. Co-incubation with nicotine did 
not affect the potency or efficacy of SKF-38393. 
The present results showed that nicotine does not have any effect on cAMP 
accumulation in tissue of naïve animals. Neither does nicotine affect the potency 
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or efficacy of SKF-38393 stimulated cAMP accumulation. Taken together, these 
results suggest that the putative presence of nicotine in the tissue after in vivo 
nicotine administration (0.4 mg/kg, s.c., tissue dissected 45 min after the 
challenge), likely does not interfere with the observed cAMP results, and that this 
does not explain the effects seen after acute nicotine administration. However, a 
full concentration curve of nicotine should be performed to achieve a more 
physiologically relevant concentration, which might act differently on nAChRs and 
subsequently cAMP levels. 
 
It has been shown that dopamine D2 receptor antagonists do not block 
behavioural sensitisation (Vezina and Stewart, 1989; Drew and Glick, 1990) and 
therefore it was hypothesised that nicotine induced behavioural sensitisation 
would not affect dopamine D2-like receptors or cAMP accumulation. The present 
results show that both acute as well as chronic nicotine administration slightly 
decrease the potency of quinpirole on cAMP accumulation. Futhermore, the in 
vivo pre-challenge of SCH-23390 did not affect this.  
When quinpirole was tested in the presence of SKF-82958 (1 µM), the pEC50 
value of quinpirole was lower than without the SKF-82958, and in its presence 
there was no effect of the in vivo nicotine treatments on quinpirole. In the 
presence of 10 µM SKF-82958 there was no effect of quinpirole observed, which 
could be explained by assuming that the increasing effect of the dopamine D1 
agonist on cAMP accumulation was too strong for quinpirole to compete with. 
Furthermore, as observed with the dopamine D1 ligands, there was no effect of 
the nicotine treatment on quinpirole in tissue taken 24 h post-challenge. 
 
Not investigated in this study, but important to include in further studies is a group 
chronically treated with nicotine and challenged with saline. It would be 
interesting to know if chronic nicotine pretreatment does change dopamine 
stimulated adenylate cylcase activity in the absence of nicotine challenge, or 
rather lowered the dose threshold for the nicotine induced desensitisation of 
dopamine stimulated adenylate cyclase. 
 
Schroeder and colleagues showed that activation of adenylate cyclase affects the 
induction of sensitisation but is not able to induce behavioural sensitisation on its 
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own (Schroeder et al., 2004). These experiments however, did not show whether 
adenylate cyclase activation is necessary for behavioural sensitisation. This can 
be investigated using knock-out animals for specific adenylate cyclase isomers, if 
available, or by using spectific inhibitors (e.g. SQ-22536) in combination with a 
psychostimulant. Although the 7-DMB-forskolin treatment did not produce a long 
lasting effect, i.e. no effect on the expression of cocaine sensitisation (Schroeder 
et al., 2004), adenylate cyclase activation and cAMP production still might be 
necessary for the expression of sensitisation. Future studies should investigate 
the effect of adenylate cyclase inhibitors (e.g. SQ-22536) on the development 
and expression of behavioural sensitisation.  
 
The present study investigated the role of dopamine D1 and D2 receptor subtypes. 
However, previous literature also suggests a role for the dopamine D3 receptor in 
behavioural sensitisation (Le Foll et al., 2003a; 2003b; Harrison and Nobrega, 
2009 and references therein). In could be hypothesised that not the selectivity of 
the dopaminergic ligands for one specific receptor but the synergy (i.e. co-
activation) of multiple dopamine receptor subtypes is required to achieve optimal 
efficacy. For example, simultaneous activation of dopamine D1/D3 or dopamine 
D2/D3 or dopamine D1/D2 receptor subtypes. In the present study it was shown 
that quinpirole on its own had a pEC50 of 9.2 and quinpirole in the presence of 
SKF-82958 (1 µM) a pEC50 of 8.1. This preliminary data suggests an interaction 
of the two receptor subtype ligands and needs further studying. 
 
Conclusion 
The data presented here provides biochemical evidence that dopamine receptors 
exist on cells in the striatum that possess receptors for neuromodulators known 
to be important in regulating basal ganglia activity, and inducing or antagonising 
locomotor activity sensitisation. This information from behavioural and 
subsequent ex vivo biochemical studies shows a direct connection between the 
behavioural effects of sensitisation and the ex vivo effects on cAMP accumulation 
by dopamine D1 agonists. Furthermore, the ex vivo biochemical assay was able 
to monitor the in vivo reversal of sensitisation by the dopamine D1 agonist SCH-
23390. 
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Chapter 6. Effect of chronic nicotine induced 
behavioural sensitisation on ex vivo receptor 
binding pharmacology 
 
Abstract. 
OBJECTIVES: It has been shown that the intermittent administration of 
psychostimulants can induce behavioural sensitisation and is associated with 
changes in dopaminergic neurotransmission in the striatum. Psychostimulants 
(including nicotine) are known to increase dopamine release in the striatum which 
subsequently can bind to dopamine receptors. The objective of this study was to 
investigate if nicotine induced behavioural sensitisation affect the dopamine D1 
receptor binding pharmacology in rat striatum ex vivo.  
METHODS: Rats were administered with saline or nicotine (0.4 mg/kg, s.c.) for 5 
consecutive days followed by a 5 day withdrawal period. After the withdrawal 
period rats were decapitated after 24 h following the final nicotine challenge 
injection, and dorsal striatum was dissected and frozen on dry-ice. Radioligand 
binding using [3H]-SCH-23390 was performed to determine the dopamine D1 
receptor occupation in membrane homogenates of dorsal striatum from vehicle 
and behaviourally sensitised rats. A selection of dopaminergic (D1-like) ligands 
was assessed using a newly established 96-well filterplate method. 
RESULTS: Behavioural sensitisation was verified by increased intensity of 
horizontal locomotor activity and it was observed that nicotine significantly 
induced expression of sensitisation. However, the nicotine induced behavioural 
sensitisation did not affect the affinity (Kd) of dopamine, apomorphine, SKF-
38393, SKF-82958, SCH-23390, or butaclamol for the dopamine D1 receptor. 
CONCLUSIONS: Nicotine induced behavioural sensitisation does not affect the 
affinity of the tested dopaminergic ligands for the dopamine D1 receptor. However, 
functional studies have now shown that behavioural sensitisation only has an 
effect on tissue taken 45 min post-challenge and further binding studies should 
include this additional time point. Also, the presence of high and low affinity 
dopaminergic binding sites is argued. 
Keywords: Receptor binding, behavioural sensitisation, nicotine, [3H]-SCH23390 
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6.1 INTRODUCTION 
 
It is hypothesised that behavioural sensitisation is caused by an excess of 
dopamine release in the midbrain. This synaptically available, released dopamine 
is than able to bind to dopaminergic receptors. Receptor binding is the interaction 
of a ligand binding to form a complex with a biological protein. The ligand can be 
endogenous or exogenous and upon binding to a receptor, it can alter the 
structural conformation of the receptor. Subsequently, the functional state of the 
receptor can be changed which can trigger a physiological response like 
activation of intracellular signalling cascades and subsequent release of 
neurotransmitters.  
 
In humans, psychostimulant dependence (for example by cocaine, 
methamphetamine, and also alcohol or opioids) is associated with lower 
availability of the dopamine D2 receptor in the striatum, which is suggested to be 
a result of increased dopamine release (Volkow et al., 2001; Zijlstra et al., 2008). 
Moreover, a significant correlation between the duration of (poly) drug use and 
striatal dopamine D2 receptor availability has been shown (Zijlstra et al., 2008). In 
nicotine dependent smokers, significantly less available dopamine D2/D3 
receptors within the putamen and nucleus accumbens were observed (Fehr et al., 
2008). In contrast, the there was no difference in dopamine D2 receptor binding in 
the caudate or nucleus accumbens of sensitised rhesus monkeys, two weeks 
after repeated cocaine injections (Farfel et al., 1992). This suggests a specific 
role for the dopamine D1 receptor and the same study showed that the densities 
of the dopamine D1 receptor binding sites in the caudate, but not nucleus 
accumbens, of the sensitised monkeys were significantly decreased two weeks 
after repeated cocaine injections (Farfel et al., 1992). 
In rats, behavioural sensitisation to psychostimulants is correlated with 
supersensitivity to dopamine agonists (Robinson and Becker, 1986; Robinson 
and Berridge, 2000), however, it is still unclear if the sensitisation by dopamine 
agonists is primarily dependent on dopamine D1 receptor activation (Vezina, 
1996) or D2 receptor activation (Ujike et al., 1990). In rats exhibiting behavioural 
sensitisation following daily cocaine administration (10 mg/kg, i.p.), the 
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occupation of dopamine D1 and D2 receptors by dopamine (as measured by 
EEDQ) was increased by approximately 100 % (Burger and Martin-Iverson, 
1994). Despite the increased occupation of dopamine D1 and D2 receptors 
following daily cocaine administration, this occupancy of striatal dopamine 
receptors does not appear to be related to behavioural sensitisation as this 
increase was observed following either intermittent or continuous cocaine 
treatment regimes (see for review Martin-Iverson and Burger, 1995; and Chapter 
2 for the discussion of different treatment regimes and behavioural sensitisation). 
This is in agreement with work published by Claye and colleagues who showed 
that the affinity (Kd) of the radioligands and the density (Bmax) of striatal dopamine 
D1 ([
3H]-SCH-23390) and D2 ([
3H]-spiperone) binding sites remained unchanged 
when measured after 3 days of withdrawal following 14 days of chronic 
intermittent cocaine administration (Claye et al., 1995). And in agreement with 
work published by Mayfield and colleagues who observed no differences in 
dopamine D1 receptor density and affinities for either [
3H]-SCH-23390 or [3H]-
dopamine, in the nucleus accumbens or dorsal striatum, following cocaine 
induced behavioural sensitisation (Mayfield et al., 1992). 
 
In addition to the classical receptor binding hypothesis it is reported that certain 
receptors, including the dopamine receptors, have two different affinity binding 
sites in vitro, i.e. a high and a low affinity binding site. The high-affinity state is 
considered to be the physiologically functional state (George et al., 1985) and, for 
example, the high affinity binding site of the dopamine D2 receptor (D2
High) is 
suggested to be involved in diseases like schizophrenia and psychosis (Seeman 
et al., 2005, 2006). The high affinity binding site is also suggested to play a role 
in behavioural sensitisation, for example following amphetamine induced 
sensitisation the proportion of dopamine D2
High is increased, as measured by 
dopamine in competition with [3H]-domperidone (Seeman, 2009) or [3H]-PHNO 
[(+)4-propyl-9-hydroxynaphthoxazine] (Seeman et al., 2007). A 2-4 fold elevation 
in the proportion of dopamine D2
High receptors was observed following 
behavioural sensitisation (Seeman et al., 2002; see for review Seeman et al., 
2006). Although the dopamine D2 receptor availability may be lower in 
psychostimulant abusers, the proportion of the D2
High versus D2
Low receptors is 
likely to be elevated, in accord with the clinical observation that such individuals 
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are dopamine supersensitive (Volkow et al., 2001). Furthermore, it has been 
shown that the proportion of dopamine D1
High receptor affinity state by dopamine 
in competition with [3H]-SCH-23390 is increased following methamphetamine 
sensitisation (Shuto et al., 2008). 
 
In principle, the high affinity state of the dopamine receptor can be labelled by 
low concentrations of various radioactive dopamine ligands (Richfield et al., 
1989). However, it should be noted that literature describing the determination of 
high and low affinity sites of dopaminergic receptors is not always consistent. For 
example, the dopamine D1
High receptor affinity state is not always observed in 
striatal membranes (e.g. [3H]-SCH-23390, Leonard et al., 2006 and Schulz et al., 
1985), although other groups show that [3H]-SCH-23390 in the presence of 120 
mM NaCl and 4 mM MgCl2 can detect the two binding sites in the striatum (Shuto 
et al., 2008; Sumiyoshi et al., 2005) and might be dependent on the presence of 
other metals (e.g. sodium, lithium and magnesium; Gottberg et al., 1989). 
 
The aim of this study was to investigate the effect of nicotine induced behavioural 
sensitisation on the binding affinities of dopamine D1 receptor ligands for the 
dopamine D1 receptor. For this purpose, saturation curves and competition 
experiments were performed using membrane preparations of rat dorsal striatum. 
Furthermore, the proportion of the high and low affinity binding sites was 
investigated. 
 
 
HYPOTHESES AND AIMS 
 
Hypotheses: 
Dopamine D1 receptors are not up-regulated following behavioural sensitisation 
and behavioural sensitisation will not affect the affinity (Kd) of dopamine D1 
receptor ligands. 
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Aims: 
- Investigate if the dopamine D1 receptors are up- or down-regulated following 
behavioural sensitisation by measuring the density of dopamine D1 receptors by 
determining the Bmax. 
- Investigate putative changes in the affinity (Kd) of dopaminergic (D1–like) 
receptor ligands using a competition experiment with [3H]-SCH-23390 (D1-like 
binding). 
- Identify and quantitate the high and low affinity receptor states in the striatal 
membrane preparations and determine if behavioural sensitisation has an effect 
on their proportions. 
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6.2 MATERIALS AND METHODS 
 
The described receptor binding experiments were performed at Abbott 
Healthcare Products, the Netherlands. 
 
6.2.1. Chemicals 
The following drugs were ordered from Sigma (Zwijndrecht, the Netherlands): (+)-
butaclamol, (R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H- 
benzazepine-7-ol ((R)-(+)-SCH-23390), (-)-sulpiride, 2,3,4,5,-tetrahydro-7,8-
dihydroxy-1-phenyl-1H-3-benzazepine ((±)-SKF-38393), dopamine, 3-allyl-6-
chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF-82958), 
apopmorphine, and salts, Tris-HCl, ethylenediaminetetraacetic acid (EDTA), 
sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2), 
magnesium chloride (MgCl2). All buffers were made using purified water (MilliQ, 
Waters, Milford, MA, USA). 
 
[3H]-SCH-23390 (N-methyl-3H, specific activity of 2.7047 TBq/mmol) was 
purchased from Perkin Elmer (Waltham, Massachusetts, USA), see Figure 6-1. 
N CH
3
*
Cl
OH
 
 
[3H]-SCH-23390  
Figure 6-1 Chemical structure of radiolabelled [3H]-SCH-23390  
Chemical structure of the selective dopamine D1 receptor antagonist [
3H]-SCH-
23390. *, indicates the position of the tritiated isotope ([3H]) according to the 
manufacturer (Perkin Elmer). 
 
6.2.2. Animals 
For animals used and description of locomotor activity protocol, see Chapter 2. 
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6.2.3. Experimental design (in vivo protocol) 
Animals were chronically treated and challenged with nicotine as previously 
described in Chapter 2. The methodology was approved by the animal ethics 
committee (Abbott Healthcare Products, the Netherlands) and was in accordance 
with all local laws. 
Briefly, one day prior to each experiment (day 0), all animals (n = 8 – 12 
rats/group) were habituated to the activity cages for one h, followed by a saline 
injection and recording of locomotor activity. On the testing days (days 1 and 5) 
the rats were habituated for 60 min to the test apparatus, before administration of 
either saline (s.c., 2 groups) or (-)-nicotine (0.4 mg/kg, s.c., 1 group). After 
receiving the injections, the rats were directly placed back in the test apparatus 
and locomotor activity was measured for 45 min, in 5 min time epochs. This first 
time dose of nicotine was considered the acute dose. On day 2, 3 and 4 all 
groups received the same treatment as the day before and were directly placed 
back in their home cage. After a 4 day withdrawal period (day 9), all groups 
received a saline injection (s.c.) and locomotor activity was measured to assess if 
the response was context-dependent. On day 10, rats were habituated for 30 min 
to the test apparatus before administration of a pre-challenge of saline (s.c., all 
groups). The rats were directly placed back in the test apparatus and locomotor 
activity was measured for 30 min. After 30 min of the pre-challenge, the Vehicle - 
Vehicle group was challenged with saline and all other groups were challenged 
with 0.4 mg/kg (-)-nicotine (s.c.). Locomotor activity was measured for another 45 
min, see Table 2-1 and Figure 2-1 for study design. 
 
6.2.4. Tissue preparation 
The male Wistar rats were decapitated at 24 h after the last challenge, without 
anaesthetics and the brains were rapidly removed. The brain areas of interest 
were dissected according to Paxinos and Watson (1998) and directly frozen on 
dry-ice. The samples were stored at -80 °C until membrane preparation. 
Frozen rat striatal samples were weight and homogenised in ice-cold Tris buffer 
(50 mM Tris-HCl, pH 7.4, 1 mM EDTA) using GentleMax tissue homogeniser 
(protocol RNA.01.01, for 30 s.; Miltenyi Biotec, Germany). The membranes were 
precipitated by centrifugation at 10,000 x g for 10 min at 4 °C and washed by re-
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homogenisation using the GentleMax. This was followed by centrifugation at 
50,000 x g for 10 min at 4 °C. The final pellet was re-homogenised (GentleMax, 
15 s.) in incubation buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, containing 120 
mM NaCl, 5 mM KCl, with or without 1.5 mM CaCl2 and 4 mM MgCl2, as stated in 
the text, and Table 6-1) to obtain the required membrane concentration. The 
tissue was kept at room temperature for 30 min before starting the incubation. 
 
Methodological considerations 
Variation between animals within the same in vivo treatment group made it 
impossible to use tissue from only a single rat for an n = 1 ex vivo experiment. To 
overcome this problem the dissected tissue from at least four animals within the 
same treatment group were pooled and homogenised together. This protocol 
significantly reduced the intra-experiment variation. 
 
6.2.5. Radiolabel 
The actual radioligand concentration was determined in order to calculate the 
exact radioligand concentration. A stock concentration of the radiolabel was 
obtained by dilution of 5 µL [3H]-SCH-23390 in 1600 µL incubation buffer. Of this 
stock, 10 µL was transferred to a volume of 10 mL scintillation liquid (UltimaGold 
XR, Perkin Elmer) in duplicate and radioactivity disintegrations per minute (DPM) 
were determined using a liquid scintillation analyser (Perkin Elmer). To correct for 
the degradation (half-life) of the radiolabel, the current activity was calculated by: 
 
 Activity (KBq) = Rad Conc Current (MBq/mL) * 0.1 * stock volume (mL) 
 
The actual stock concentration was calculated by: 
 
 Conc (nM) = activity (KBq) /volume (mL) * specific activity (GBq/mmol) 
 
If required, the stock solution was diluted by the following dilution-factor: 
 
 Conc (nM) = Conc (nM) /10 * Kd (nM) 
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This stock is 10 times concentrated as the label will be 10 times diluted at the 
start of the incubation (as described in the next section). 
 
6.2.6. Receptor binding 
Incubations were performed in a total incubation volume of 200 µL using 
MultiScreen®HTS 96-well filterplates (1.0 µm Glass Fiber Type B Filter, cat.no. 
MSFBN6B50, Millipore, Billerica, MA, USA). Compounds were diluted in 
incubation buffer (Table 6-1) and were tested in triplicate. To each well was 
added 20 µL test compound, 20 µL tritiated label, and the incubation was started 
upon addition of 160 µL tissue homogenate. The plates were shaken using a 
well-plate shaker (TeleShake, Variomag, Thermo, MA, USA) and incubated for 2 
h in a well-plate incubator at 25 ºC. The incubations were terminated by rapid 
filtration through the MultiScreen®HTS filterplates using a vacuum unit (Millipore), 
followed by washing the filterplates rapidly three times with 100 µL ice-cold 50 
mM Tris-HCl/1 mM EDTA buffer. After air drying the filterplates, each well 
received 35 µL scintillation cocktail (MicroScint-OTM, Perkin-Elmer) and the 
filterplates were sealed. After 24 h equilibration, radioactivity was determined 
using a beta scintillation counter (MicroBeta, Perkin-Elmer). 
 
Saturation experiments 
Tissue saturation experiments were constructed by the incubation of different 
concentrations of tissue homogenate with 0.8 nM [3H]-SCH-23390 in the absence 
or presence of 10 µM (+)-butaclamol (a non-selective dopamine antagonist) to 
determine total and non-specific binding, respectively.  
 
To determine the Kd and Bmax of [
3H]-SCH-23390 in rat striatum, saturation 
experiments were performed by the incubation of striatal homogenate (5 mg/mL) 
with different concentrations of [3H]-SCH-23390 (final concentrations ranging 
from 0.05 – 8 nM). In these experiments, the non-specific binding was defined 
using 1 µM (+)-butaclamol.  
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Competition experiments 
Competition experiments were performed by incubation of different 
concentrations of test compound with [3H]-SCH-23390 (0.8 nM) and 5 mg/mL 
striatal membranes. Non-specific binding was defined by the binding in the 
presence of 1 µM (+)-butaclamol. 
 
Table 6-1 Buffer compositions  
All buffers were adjusted to pH 7.4. 
 
Salt 
 
Conc. (mM) 
 
Normal 
 
w/o Mg2+, Ca2+ 
 
Only TRIS 
     
TRIS.HCl 50 + + + 
EDTA 1 + + + 
NaCl 120 + +  
KCl 5 + +  
CaCl2 1.5 +   
MgCl2 4 +   
     
 
6.2.7. Data analyses 
For the saturation experiments, raw data (expressed in counts per minute, cpm) 
represent radioligand binding at the membrane preparation and the filterplate. 
Incubations with only radioligand and membranes represent the total binding, and 
radioligand and membranes in the presence of 10 µM (+)-butaclamol represent 
non-specific binding. The specific binding was defined as total binding minus 
binding in the presence of 10 µM (+)-butaclamol (i.e. non-specific binding). 
Binding isotherms were analysed by non-linear regression, using PRISM 
graphing software (Graphpad software, San Diego, CA, USA) to yield IC50 values. 
The Scatchard plots, i.e. Bound/Free versus Bound plot (Scatchard, 1949), were 
calculated as followed: 
 
 Bound [B] (dpm) = Total (dpm) – non-specific binding 
 Free, [F[ (dpm) = Total (dpm) – specific activity (dpm = cpm*3) 
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Competition receptor binding 
Raw data (cpm) representing total radioligand binding (i.e. the sum of specific 
and non-specific binding) are plotted as a function of the logarithm of the molar 
concentration of the competitor (i.e. test or reference compound). Non-linear 
regression of the normalised raw data (i.e. percent radioligand binding compared 
to that observed in the absence of test or reference compound) was performed 
with PRISM graphing software using the built-in three parameter logistic model 
describing ligand competition binding to radioligand-labelled sites:  
 
 y = bottom + [(top-bottom)/(1 + 10x pIC50)] 
 
were bottom equals the residual radioligand binding measured in the presence of 
10 μM reference compound (i.e. non-specific binding) and top equals the total 
radioligand binding observed in the absence of competitor. The pIC50 (i.e. the 
negative logarithm of the ligand concentration that inhibits the specific radioligand 
binding by 50 %) is estimated from the data and used to obtain the inhibition 
constant (Ki) by applying the Cheng-Prusoff equation (Cheng and Prusoff, 1973):   
 
 Ki = IC50/(1 + [ligand]/Kd)  
 
where [ligand] equals the radioligand concentration (nM) and dissociation 
constant (Kd) equals the affinity constant of the radioligand for the target receptor 
(nM). 
 
The actual concentration of the radiolabel at the time of the experiment was 
calculated by: 
 
 nM = dpm /0.02 * 60 * 10 * specific activity (GBq/mmol) 
 
The activity (in dpm) was measured in triplo at the day of the experiment, using a 
liquid scintillation counter. 
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6.3 RESULTS 
 
6.3.1. Saturation experiments 
The following saturation experiments were performed to determine the optimum 
tissue concentration for the binding experiments. The experiments were 
performed at equilibrium (i.e. 2 h incubation at 25 °C) with 8 different 
concentrations of rat dorsal striatal membranes. The various concentrations of rat 
striatal membranes (0-10 mg/mL) were incubated with 0.8 nM [3H]-SCH-23390. 
The maximum specific binding (Btot – Bnon-specific = Bspecific) observed under the 
described conditions was 49 % (Figure 6-2). A wet tissue concentration of 5 
mg/mL was used for all future experiments as this concentration gave a robust 
response, maximal specific binding and the results are in agreement with 
previous literature (e.g. Schulz et al., 1985; Leonard et al., 2006). 
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Figure 6-2 Saturation experiment of striatal membranes ([3H]-SCH-23390) 
A. The binding isotherm of [3H]-SCH-23390 at different concentrations of dorsal 
striatal membranes. B. Specific binding (%) of 0.8 nM [3H]-SCH-23390 at different 
concentrations of striatal membranes (0 - 10 mg/mL). Tissue taken from non-
treated animals, n = 1. 
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In order to determine the binding constants of [3H]-SCH-23390, saturation 
experiments were performed using 12 different concentrations of [3H]-SCH-23390 
to determine the Kd and Bmax values. Rat striatal membranes (5 mg/mL) were 
incubated with various concentrations of the radioligand ranging from 0 to 8 nM 
for 2 h at 25 °C. A typical binding isotherm was observed with a parabolic curve 
equation for total and specific binding and a linear curve equation for non-specific 
binding (Figure 6-3A). The Bmax value was determined at 8 nM (highest 
concentration tested) and the Kd value for [
3H]-SCH-23390 was determined at 1.0 
± 0.3 nM. 
 
A maximum of 73 % specific binding was found at a concentration of 0.4 nM [3H]-
SCH-23390 (Figure 6-3B). The specific binding of [3H]-SCH-23390 was < 50 % at 
concentrations lower then 1 nM. The radioligand concentrations for competition 
experiments were chosen 0.8 nM at which it achieved ca. 70 % specific binding. 
 
The calculated Scatchard plot, i.e. Bound/Free versus Bound plot (Scatchard, 
1949), of the saturation curve resulted in two lines indicating the presence of two 
different binding sites (Figure 6-3C). However, due to the large variation between 
the different concentrations tested, no Kd values could be calculated. 
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Figure 6-3 Saturation experiment of [3H]-SCH-23390 (striatal membranes) 
A. Representative binding isotherm of different concentrations [3H]-SCH-23390. B. 
Specific binding (%) in striatal membranes, n = 3 (5 mg/mL). C. Scatchard plot. B, 
bound; F, free (dpm). Non-specific binding was determined using 10 µM (+)-
butaclamol. Tissue was taken from non-treated animals. Data represents mean ± 
s.e.m., of three individual experiments performed in triplicate. 
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6.3.2. Biphasic high and low affinity site 
The effect of the alkali cations sodium (Na+) and potassium (K+), magnesium 
(Mg2+) and calcium (Ca2+) on the high and low affinity agonist state of [3H]-SCH-
23390 binding site were investigated. This was performed by competition 
experiments using dopamine as the endogenous substrate to antagonise the 
receptor binding. Three different incubation buffers were prepared and 
investigated, containing TRIS/EDTA (“Only TRIS”), TRIS/EDTA + NaCl + KCl 
(“w/o Mg2+, Ca2+”), and TRIS/EDTA/NaCl/KCl + MgCl2 + CaCl2 (“normal”). 
 
The competition experiments with the endogenous agonist dopamine did not 
reveal the presence of a high affinity (Kh) binding site. 
 
 
 
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0
20
40
60
80
100
120
Normal
w/o Mg2+, Ca2+
Only TRIS
Log [Dopamine] (M)
%
 o
f 
c
o
n
tr
o
l
 
 
Figure 6-4 Influence of salt concentration on receptor affinity states  
The inhibition of specific [3H]-SCH-23390 binding to dorsal striatal membrane 
preparations by dopamine (at 16 concentrations) using three different incubation 
buffers. The results shown are from a representative experiment. 
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6.3.3. Competition experiments 
To investigate putative changes in binding affinity of the dopamine D1 receptor 
following chronic nicotine treatment, the affinities of a selection of dopaminergic 
ligands was tested in competition experiments against [3H]-SCH-23390. 
 
The non-selective dopamine receptor agonists dopamine and apomorphine, the 
selective dopamine D1 receptor agonists SKF-38393 and SKF-82958, the 
selective dopamine D1 receptor antagonist SCH-23390 and the non-selective 
dopamine receptor antagonist butaclamol, all concentration dependently 
antagonised the [3H]-SCH-23390 binding (Figure 6-5A to F, respectively). There 
was no effect of chronic nicotine treatment on the potency or efficacy of these 
ligands for dopamine D1 receptor binding. 
 
Competition experiments were performed using buffer without Mg2+ or Ca2+ (see 
methods), and in each case a two-site model was considered, however, a single 
binding site equation showed a significantly better fit according to the F-test (P < 
0.05, PRISM software). 
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Figure 6-5 Effect of dopaminergic ligands on dopamine D1 receptor binding 
Membrane preparations from vehicle treated or nicotine sensitised rats were 
incubated with [3H]-SCH-23390 and increasing concentrations of dopamine (A), 
apomorphine (B), SKF-38393 (C), SKF-82958 (D), SCH-23390 (E) or butaclamol 
(F). Without Mg2+ or Ca2+ (see methods). For pIC50 values see Table 6-2. Data 
represent mean ± s.e.m. of n = 1 - 4 independently performed experiments. 
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Table 6-2 Affinity of dopaminergic ligands for dopamine D1 receptor  
[3H]-SCH-23390 receptor binding in rat dorsal striatal membranes. Values are 
pIC50 mean ± s.e.m. n-number is given between parentheses. 
  
VEH-VEH 
 
VEH-NIC 
 
NIC-NIC 
    
24 h post-challenge    
SKF-38393 6.4 (1) n/a 6.4 (1) 
    
SKF-82958 7.3 (3) n/a 7.3 (3) 
    
SCH-23390 9.4 (3) n/a 9.3 (3) 
    
Apomorphine 5.3 (3) n/a 5.4 (3) 
    
Dopamine 4.3 (1) n/a 4.4 (1) 
    
Butaclamol 7.0 (3) n/a 6.9 (4) 
    
n/a, not available 
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6.4 DISCUSSION 
 
The present study showed that, under the given conditions, nicotine induced 
behavioural sensitisation did not affect the affinity of dopamine, apomorphine, 
SKF-38393, SKF-82958, SCH-23390, or butaclamol for the dopamine D1 
receptor (Figure 6-5).  
Prior to the pharmacological study, a MultiScreen®HTS 96-well filterplate-based 
receptor binding technique was established, using vacuum-filtration instead of the 
classical harvesting method. The advantages of this method are the high 
reproducibility, small variation, less chemical waste production, high throughput, 
and suitablility for tissue homogenates. Prior to the described rat brain tissue 
experiments, the filterplate based method was first developed using Chinese 
hamster ovarian (CHO) cells transfected with the human dopamine D2L receptor 
(data not shown). However, the in vitro cell based receptor binding using 
transfected cells is a very artificial system making translation and predictive 
validity to animal models very difficult. Therefore more advanced and 
physiologically relevant experimental systems, such as brain slices (ex vivo) are 
required. For example, dopamine D1 and D2 receptor binding in striatal brain 
slices has been positively correlated to the effect of amphetamine seen in PET 
and SPECT studies (Gifford et al., 2000). After the validation in vitro, this assay 
was successfully applied to ex vivo rat brain tissue. The whole assay is 
performed in a single 96-well filterplate and is using only a small volume (i.e. 200 
µL format), which requires less tissue and reagents although still showing high 
specific binding (i.e. > 70 % in this study). 
 
The present study used a dose of 0.03 mg/kg, i.p. of SCH-23390 to antagonise 
the nicotine induced behavioural sensitisation. This was found both behaviourally 
the most effective dose (Chapter 2) as well as on receptor occupancy where the 
dopamine D1 receptor occupancy following systemic administration of SCH-
23390 was evident as an inverted U-shaped dose-dependent effect, with the 
greatest occupancy observed at the intermediate dose of 0.3 mg/kg i.p 
(Neisewander et al., 1998). 
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In the present study the tissue used was taken only at 24 h post-challenge. As 
discussed in previous chapters, the time of dissection of the tissue following the 
last challenging dose of nicotine in vivo might be crucial to observe effects ex 
vivo. It has been shown that the time frame of dissection can be critical for 
functional assays (Chapter 5; Kleven et al., 1990) and herein is also suggested to 
be crucial for binding assays. Further studies should include tissue taken at 45 
min post-challenge as tissue taken at this time point, but not at 24 h post-
challenge, showed changes in cAMP accumulation (Chapter 5). The present 
study only investigated tissue from vehicle and nicotine behavioural sensitisised 
animals. Further studies should also include tissue from acute nicotine treated 
animals, although no effect is expected as both vehicle and chronic nicotine 
treatments did not affect dopamine D1 receptor binding (Table 6-2). 
 
In this study SKF-38393 and SKF-82958 were considered as selective dopamine 
D1 receptor agonists and SCH-23390 as a selective dopamine D1 receptor 
antagonist (O‟Boyle and Waddington, 1984). [3H]-SCH-23390, a selective 
antagonist of dopamine D1-like receptors, is the prototypical ligand to determine 
dopamine D1 receptor binding parameters (Faedda et al., 1989), however also 
has affinity for the serotonin 5-HT2 receptor (see General Discussion). 
 
The absence of high and low affinity binding sites in competition with dopamine 
might be an experimental artefact due to fast degradation of dopamine by 
oxidation. This degradation could be prevented by the presence of an anti-
oxidant (e.g. ascorbic acid or vitamine C, cystein and formic acid, etc.). In the 
present study no ascorbic acid was used as this was reported to compete with 
dopamine for dopaminergic receptors (Tolbert et al., 1979; 1992; Wiener et al, 
1989). Additionally, it has been shown that treatment of membranes with ascorbic 
acid could distinguish and visualise the high and low affinity binding sites of 
dopamine, but not SKF-38393, when competing with [125I]-SCH-23982 (Kimura 
and Sidhu, 1994). The increase and decrease of high and low affinity binding 
sites, respectively, is suggested to be the result of the anti-oxidant properties of 
ascorbic acid preventing the oxidation of dopamine in the in vitro system. This 
was also supported by the finding that ascorbic acid induced inhibition of 
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dopamine D1 antagonist binding which was prevented by addition of EDTA 
through an unknown mechanism (Kimura and Sidhu, 1994). 
 
A review of the literature suggests that the high and low binding sites can only be 
determined in specific brain areas (or under certain incubation conditions) 
suggesting a specific role for these binding sites. For example, [3H]-SCH-23390 
can distinguish between the two affinity binding sites in the hippocampus and 
amygdale but only in the absence of MgCl2. Whereas Mg
2+ does not have any 
effect in striatum, where only 1 affinity site can be detected (Leonard et al., 2006). 
Furthermore, it has been shown that [3H]-SCH-23390 can have preferential 
effects between different brain areas and even within brain structures like 
striatum (i.e. different effects between dorsal and ventral striatum, Savasta et al., 
1986). Therefore further studies should include different brain areas and using 
more advanced techniques look at the distribution of binding sites within the 
dorsal striatum. 
 
The high affinity state of the dopamine D2 receptor is postulated to be functionally 
responsible for its signal transduction. At present, only a few experiments have 
been carried out to selectively measure dopamine D2
High affinity states in humans 
and were limited by using [11C]-(+)-PHNO, as no other useful in vivo method 
exists to selectively measure dopamine D2
High affinity states in humans (Willeit et 
al., 2006). However, following a dual-radiotracer experiment with [11C]-(+)-PHNO 
and [3H]-raclopride, which label the high affinity state and both affinity states 
respectively, there was no proof of a distinct high affinity state measured in vivo 
(McCormick et al., 2008). This cast some doubt on the in vivo applicability of the 
dopamine D2 two-state model, as described by in vitro binding experiments. 
Numerous reports have been published concerning high and low affinity binding 
sites, although their occurance in dopaminergic receptors is still susceptible. For 
example, the homogenate as used by Seeman and colleagues was not washed, 
centrifuged or pre-incubated (Seeman et al., 1984; Seeman et al., 2007), which 
can be argued as a crude preparation where non-specific binding can explain the 
two binding sites. 
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Another receptor binding parameter which might be important in behavioural 
sensitisation is the ratio of dopamine D1 receptor versus D2 receptor signalling. It 
is suggested that changes in the ratio of D1R:D2R could contribute to 
psychostimulant induced behavioural plasticity (Thompson et al., 2010). 
To study the effect of behavioural sensitisation on dopamine D2 receptor binding, 
a receptor binding protocol using [3H]-domperidone was tested. This specific 
dopamine D2 receptor radiolabel was chosen as it is reported to distinguish 
between the dopamine D2 receptor high and low affinity binding states (Seeman 
et al., 2003). Although the assay was performed exactly according to the protocol 
as described by Seeman and colleagues (e.g. Seeman et al., 2002; 2007; 2009), 
no high affinity binding site could be observed (data not shown). Therefore, only 
dopamine D1 receptor binding using [
3H]-SCH-23390 was investigated. Another 
key note to be made is, although specific ligands bind to the specific dopamine 
receptor subtypes not every compound is suitable for performing a receptor 
binding assay. For example, quinpirole is a prototypical selective dopamine D2-
like receptor agonist. Quinpirole has a 250-fold selectivity for dopamine D2-like 
receptors over dopamine D1-like receptors (Seeman and Schaus, 1991), however 
due to its high dissociation constant of ca. 5 nM it is vulnerable to inhibition by 
endogenous dopamine. Moreover, radiolabelled quinpirole showed high non-
specific binding, indicating that this compound binds to other unidentified binding 
sites as well. Other radiolabels which have been used to selectively label the 
dopamine D2 receptor include [
3H]-NPA (agonist, only high affinity state), [3H]-
spiperone (antagonist, high and low), [3H]-raclopride (antagonist, high and low), 
[3H]-domperidone (antagonist, only high), and [3H]-PHNO (agonist, only high). 
However, their commercial availability is often limited. [3H]-domperidone is found 
the best label to measure dopamine D2 receptor binding and determine high and 
low affinity binding sites. However, the present research was limited by patent 
issues of [3H]-domperidone for this type of research (Seeman, 2005). Additionally, 
preliminary experiments of the present study showed very low specific binding 
and high variation when using [3H]-domperidone (data not shown), and therefore 
these experiments were discontinued. 
 
Conclusion 
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The high and low affinity binding site hypothesis it is a very interesting theory with 
potential to better understand the receptor binding kinetics of a ligand, although, 
many attempts, including this study, failed to visualise the high and low affinity 
binding sites. Nicotine induced behavioural sensitisation does not affect the 
affinity of the tested dopaminergic ligands for the dopamine D1 receptor. However, 
functional studies have now shown that behavioural sensitisation only has an 
effect on tissue taken 45 min post-challenge and further binding studies should 
include this additional time point.  
 
 
 
 
 Chapter 7 
 
 
165 
 
Chapter 7. General Discussion 
 
Abstract. 
OBJECTIVES: The present study focussed on the behavioural, neurochemical 
and receptor alterations of the dopaminergic system as a consequence of 
nicotine induced behavioural sensitisation to gain a better understanding of its 
neurobiology. Herein it is hypothesised that understanding the mechanism 
underlying the phenomenon behavioural sensitisation can help to elucidate the 
responsible mechanism(s) underlying different neuropsychiatric disorders, and 
eventually could lead to improved (pharmaco) therapies. The present study 
investigated the working hypothesis that the dopamine receptor, specifically the 
dopamine D1 receptor subtype, plays an important role in the mechanism 
underlying behavioural sensitisation. 
CONCLUSIONS: The present study showed that selective antagonism of the 
dopamine D1 receptor blocks the expression of nicotine induced behavioural 
sensitisation in vivo. From a mechanistic perspective, the results suggest that 
sensitisation induced by chronic nicotine administration occur as a result of 
neuroadaptations, i.e. the enhanced response of neurones in the dorsal striatum 
to dopamine D1 receptor activation. Information from genetics, neuropathology, 
brain imaging, and basic neuroscience has provided insights into understanding 
the aetiology of neuropsychiatric disorders, however remains still not fully 
understood. This thesis presents a successful multidisciplinary approach which 
resulted in more information about the mechanism underlying behavioural 
sensitisation and showed an important role for the dopamine D1 receptor. 
Furthermore, the described approach provides a successful framework to study 
behavioural sensitisation which also can be used for future studies and ultimately 
the elucidation of the mechanism(s) underlying neuropsychiatric disorders. 
 
 
 
 
Keywords: cAMP, LC-MS/MS, nicotine, behavioural sensitisation, dopamine, 
release, voltammetry, receptor binding 
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7.1 DISCUSSION 
 
Basic biomedical research is mainly directed toward the understanding of 
neurobiological mechanism(s) behind diseases. Better understanding of the 
neurobiology can improve drug discovery and eventually could lead to improved 
medications. Herein it is hypothesised that understanding the mechanism 
underlying the phenomenon behavioural sensitisation can help to elucidate the 
responsible mechanism(s) underlying many neurpsychiatric disorders. The 
present study investigated the working hypothesis that the dopamine receptor, 
specifically the dopamine D1 recpetor subtype, plays an important role in the 
mechanism underlying behavioural sensitisation. 
 
Among other reasons, acute animal models do not resemble, nor correlate with 
the clinical efficacy observe because the clinical symptoms are developed over a 
longer period of time (i.e. years). Therefore this study used a chronic treatment 
model and examines the expression of behavioural sensitisation. The used dose 
of nicotine (i.e. 0.4 mg/kg, s.c.) was chosen as the representative that was shown 
to be behaviourally active in rats and produced a maximal response (Clarke and 
Kumar, 1983; Ksir et al., 1985; Ksir et al., 1987) and in our own laboratory it was 
observed that higher dose (i.e. 0.6 mg/kg, s.c.) resulted in what is believed 
„clenching‟ of the peritoneal musculature (data not shown). Moreover, the 0.4 
mg/kg dose is used in other reported nicotine induced behavioural locomotor 
studies (e.g. Domino, 2001) and which therefore can be used for comparison with 
other literature. The present study showed that behavioural sensitisation to 
intermittent nicotine administration was developed within 5 days and reaching a 
plateau (Figure 2-2). This is in agreement with the complex pharmacokinetics of 
nicotine. Intermittent nicotine administration in the rat (0.03 mg/kg) showed 
increased brain concentrations of nicotine and its major metabolites (i.e. cotinine 
and nornicotine) by 2-, 12-, and 9- fold, respectively, reaching a plateau following 
the fifth injection (Ghosheh et al., 2001). 
Dopamine D1-like agonists (e.g. A-68930, dihydrexidine) suppress acute 
locomotor activity and amphetamine induced hyperlocomotor activity, an effect 
which can be selectively reversed by dopamine D1-like, but not D2-like, receptor 
antagonists (Isacson et al., 2004). This antagonism of hyperactivity produced by 
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amphetamine is traditionally interpreted as a sign of potential antipsychotic 
properties suggesting clinical implications for the dopamine D1 receptor in the 
treatment of schizophrenia. 
This study provides evidence that a dopamine D1 antagonist can block the 
expression of nicotine induced behavioural sensitisation. From a perspective of 
therapeutics, it could imply that the dopamine D1 receptor might be a valid target 
for treatment of neuropsychiatric disorders related to the behavioural sensitisation 
model. 
 
The measurement of cAMP accumulation is a very robust and simple method 
with a high reproducibility and very usefull screen compounds for a certain 
receptor regarding their functional effect on a molecular level, altough, the 
physiological relevance compared to the in vivo situation is often very low. 
Receptor binding and cAMP accumulation as targets to study dopaminergic 
medications offers only modest predictive validity of in vitro to in vivo 
extrapolations. Especially for GPCR targets other than dopamine the predictive 
validity is very low. Therefore, one should know its limitations and the search for 
more advanced in vitro assays with high predictive validity, in order to predict 
efficacy in vivo, still goes on. 
 
The potency of the dopaminergic ligands was determined by assessing their 
effect on cAMP accumulation. The agonists did increase cAMP accumulation 
whereas antagonists had no effect on cAMP accumulation. The potency of the 
agonists was decreased following chronic nicotine treatment in vivo, although 
examination of the antagonist (in the presence of 1 µM agonist) did not show any 
effect on potency. 
The measured locomotor behaviour related to hyperdopaminergic activity was 
accompanied by changes in cAMP levels. It has been reported that 
methamphetamine administration does not change striatal cAMP levels directly, 
but systemic co-administration of rolipram (a cAMP phosphodiesterase type IV 
inhibitor) has been shown to antagonise methamphetamine induced behavioural 
changes and sensitisation (Iyo et al. 1995, 1996). This is in agreement with the 
findings of the present study where no changes on basal cAMP accumulation 
were observed and changes were only observed following cAMP stimulation by 
dopamine D1 receptor agonists. 
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Dopamine D1 receptors are generally coupled to Gs and can activate cAMP 
signalling, however in vitro and ex vivo studies have shown that they can also 
affect other pathways. For example the phosphatidyl inositol (IP) cascades which 
activate protein kinase C (PKC, EC 2.7.11.13, Von Euler and Von Euler, 1991; 
Undie and Friedman, 1990, 1992; Zhen et al., 2005). Therefore it should be 
noted that the effects of ligands observed cannot simply be explained by a single 
pathway or route. Additionally, the results of the present study, together with 
previous research, suggest an important role of cAMP in behavioural 
sensitisation. However, cAMP is likely not the only player in the field, and 
additionally cGMP might be involved as well. The novel LC-MS/MS method 
presented in Chapter 4, was also validated to measure other nucleotides like 
cGMP (data not shown). The involvement of the dopamine D1 receptor in 
behavioural sensitisation, together with the fact that the dopamine D1 receptor 
(but not the D2 receptor) is able to alter cGMP accumulation, suggests that this is 
an important area which needs to be further explored. 
 
cAMP and cGMP are very important intracellular second messengers and 
moreover, they are also important extracellular neurotransmitters. Considering 
the effect of behavioural sensitisation on their intracellular accumulation, future 
research should investigate the role of these nucleotides in the extracellular 
space following behavioural sensitisation. The presently developed LC-MS/MS 
method and described pharmacological assays provides an excellent framework 
to asses the extracellular involvement of (cyclic) nucleotides. Preliminary 
experiments during the present study already identified their extracellular 
presence (data not shown). 
 
Elucidation of the responsible intracellular pathways between the receptor protein 
and cAMP accumulation might include research into RGS (regulators of G-protein 
signalling), G-protein coupling, adenylate cyclase activity, and phospho-
diesterases (PDE) activity. In the present study, the effect of basal and adenylate 
cyclase activation on cAMP accumulation was investigated. It was shown that 
behavioural sensitisation did not affect basal nor forskolin stimulated cAMP 
accumulation, suggesting adenylate cyclase was not affected by behavioural 
sensitisation. Furthermore, the ex vivo cAMP accumulation assay was performed 
in the presence of a high concentration IBMX, a non-selective PDE inhibitor. This 
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PDE inhibitor prevents the metabolism of cAMP into AMP. Although the present 
experiment cannot exclude a putative role of PDE in sensitisation, at least it can 
be concluded that if PDE is involved, it is not the only player. 
Another player in the intracellular signalling networks is the accessory protein 
regulating G protein-coupled receptors (RGS). RGS inhibits GDP dissociation 
from the Ga subunit in a receptor independent manner, which returns the G-
proteins back to their inactive form, and exert regulatory functions on intracellular 
effectors (Natochin et al., 2000). It has been shown that dopaminergic receptor 
ligands also can regulate RGS, the study showed that dopamine D1 receptor 
ligands (SKF-82958 and SCH-23390) and D2 receptor ligands (quinpirole and 
haloperidol) can regulate the five most abundant RGS in the striatum (Taymans 
et al., 2003). This study also showed a specific link between dopamine D1-RGS2-
cAMP and between dopamine D2-RGS4-cAMP, and proposed a distinct function 
of RGS in dopaminergic signalling. Little is known about RGS in behavioural 
sensitisation, although Rahman and colleagues observed that RGS9-2 was 
increased following chronic cocaine administration (Rahman et al., 2003) and 
Schwendt and McGinty showed that RGS4 was decreased in rat dorsal striatum 
and nucleus accumbens following the expression of amphetamine induced 
behavioural sensitisation (Schwendt and McGinty, 2007). Targeting RGS may 
introduce new possibilities of fine tuning the effects of GPCR activation by, for 
example, dopaminergic receptor ligands, although, future studies are required. 
Furthermore, in addition to RGS, the identification of activator of G protein 
signalling (AGS) proteins as receptor-independent activators of G-protein 
signalling reveals unexpected mechanisms for the regulation of heterotrimeric G-
protein activation and has opened up new areas of research related to the role of 
G proteins as signal transducers (Blumer et al., 2005). Activator of G protein 
signalling 3 (AGS3) has been shown to play a putative role in the expression of 
cocaine induced sensitisation (Bowers et al., 2004). 
 
The affinity of the ligands was measured by radioligand (antagonist) binding. The 
agonists as well as antagonists both inhibited [3H]-antagonist binding. No change 
in potency of either agonist or antagonist was observed following chronic nicotine 
treatment in vivo (Chapter 6). On a molecular receptor level, the effect of an 
antagonist in the presence of 1 µM agonist is the result of a competition between 
these two ligands for a specific binding-pocket. The use of an agonist radioligand 
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instead of an antagonist radioligand could provide additional information about 
the putative changes in receptor conformation following behavioural sensitisation. 
 
The lack of effect on receptor binding following behavioural sensitisation, together 
with the data showing changes in cAMP accumulation, could suggests that 
behavioural sensitisation impaires specifically the intracellular functionality. 
However, as mentioned before, the lack of effect on the receptor binding could be 
due to the fact that only tissue taken 24 h post-challenge was used and not tissue 
taken 45 min post-challenge. However, it appears that changes in the dopamine 
D1 receptor mediated signal transduction can occur in the presence or absence 
of changes in dopamine receptor number (Unterwald et al., 1994). 
 
It has been reported that dopamine D2 agonists alone do not block or reverse 
behavioural sensitisation (Li et al., 2000). In this same study, Li and colleagues 
suggest that a combination of a dopamine D2 agonist with a NMDA antagonist is 
sufficient. However, dopamine D2 partial agonists have been shown to block the 
expression of nicotine induced sensitisation (McCreary et al., unpublished data). 
Partial agonists are drugs that bind and fully occupy the receptor, yet have sub-
maximal capacity to activate its associated functional signal transduction 
mechanisms. By binding to dopamine receptors, the partial agonist will modulate 
dopamine function by acting as an antagonist preventing binding of endogenous 
dopamine. But, in comparison to full antagonists, will not completely block 
dopamine transmission. It should be noted that considering the overall binding-
affinity profile of current available „selective‟ dopamine D2 partial agonists, 
activation or blockade of other receptors could account for the observed effects 
as well. It could be proposed that strong activation of the dopamine D2 receptor is 
not sufficient, but at the same time full receptor occupation is required to achieve 
maximal efficacy. Furthermore, major drawbacks of using dopamine agonists are 
the risk of overdose effects such as respiratory depression and overstimulation of 
the mesolimbic reinforcement system (or reward pathway), which is the prime 
driver behind eurphoria, craving and loss of control seen in addiction. The partial 
agonist thus decreases the unwanted symptoms of withdrawal, euphoria and 
respiratory depression. 
An analogous hypothesis is the potential for compounds which possess the right 
dopamine D1/D2 receptor affinity ratio. This bi-directional control of 
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neuroadaptation might be crucial for potential drug therapies for neuropsychiatric 
disorders. Maggio and colleagues hypothesis that the antipsychotic actions of 
“partial agonists” may not reflect inefficient stimulation of dopamine D2 and/or D3 
receptors, but block D2/D3 receptorhetrodimers that are “weakly” coupled to 
transduction mechanisms of the dopaminergic pathway (Maggio et al., 2008). 
 
This thesis focussed on the dopamine D1 receptor, although there is evidence to 
suggest that other receptor subtypes, for example the dopamine D2 receptor, also 
do play a role in behavioural sensitisation. An increasing body of evidence 
suggests that the dopamine D1 and D2 receptor families interact functionally in 
ways that may be of potential importance in the pharmacotherapy of 
neuropsychiatric disorders (Braun et al., 1997 and references herein; for review 
see Pollack, 2004).  
The dopamine D1 and D2 receptor are colocalised on the striatal neurones and 
where they both regulate cAMP accumulation (Stoof and Verheijden, 1986; Kelly 
and Nahorski, 1987a). Dopamine D1-like and D2-like receptors have been defined 
traditionally by their opposing effects on adenylate cyclase (Stoof and Kebabian, 
1981), although, their effect on signalling systems other than adenylate cyclase 
have been confirmed, including voltage-activated calcium channels, potassium 
channels, and phosphatidylinositol hydrolysis (Jaber et al., 1996). It has been 
shown that dopamine D1 and D2 receptor co-activation can activate a novel 
Phospholipase C (PLC) -mediated pathway (Lee et al., 2004; Pollack, 2004), 
possibly required for heterooligomer formation (George and O‟Dowd, 2007; Hasbi 
et al., 2010). Many effects resulting from dopamine D2 receptor stimulation are 
manifest only when the dopamine D1 receptor is stimulated. Dopamine D1 
receptor stimulation by administration of a selective D1 receptor agonists (e.g. 
SKF-38393) significantly increased the functional effects of selective dopamine 
D2 agonists (e.g. quinpirole), as shown by electrophysiological and behavioural 
(stereotypy) effects (Hu and White, 1994). These qualitative and quantitative 
forms of dopamine D1 and D2 receptor synergism are abolished by chronic 
dopamine depletion which is suggested a result of supersensitivity of either D1 or 
D2 receptors, or the combination of both. This heterologous regulation of 
dopamine D2 receptor sensitivity by dopamine D1 receptors may be related to 
uncoupling of functional D1 and D2 synergism. For example, cocaine self 
administration is also suggested to be result of specific differential alterations in 
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functional dopamine D1 and D2 receptors, and their ability to modulate cocaine 
behaviour (Edwards et al., 2007). 
It could be proposed that behavioural sensitisation is a result of impaired 
dopamine D1 and D2 receptor synergism in the dorsal striatum, which is 
hypothesised to be a functional filter for neurotransmitter signalling. Therefore, 
further studies should include the examination of compounds having different 
affinity combinations for dopamine D1 and D2 receptor on functional activity, for 
example, determining cAMP accumulation or dopamine release. In addition to the 
example of synergism between dopamine receptors, many other receptors are 
suggested to play a role in behavioural sensitisation and could putatively depend 
on the dopamine D1 receptor activity.  
 
Three important aspects involved in the pathophysiology of neuropsychiatric 
disorders have been proposed. The first is cell migration, the second is 
unbalanced excitatory-inhibitory networks, and the third is synapse formation and 
pruning. This all can be shorten to synaptic plasticity. Synaptic plasticity, the 
ability of a synapse to change in strength, can be intrinsic (i.e. as a result of its 
own activity) or extrinsic (i.e. induced by activity in another pathway). 
Mechanisms underlying synaptic plasticity include changes in neurotransmitter 
release and the efficacy of cells responding to these neurotransmitters. 
Behavioural sensitisation is putatively a result of synaptic plasticity as differences 
have been observed between nicotine induced sensitisation in adolescent (still 
developing) and adult rats (Schochet et al., 2004; Belluzzi et al., 2004). Long-
term potentiation (LTP) is a persistent increase in synaptic strength following 
high-frequency stimulation of a chemical synapse. Studies of LTP are often 
carried out in slices of the hippocampus, an important organ for learning and 
memory. Previous literature suggests that this form of synaptic plasticity is 
facilitated by D1/D5 dopamine receptors (e.g. Huang and Kandel, 1995; 
Otmakhova and Lisman, 1996). Activation of phosphatases is a key reaction in 
both long-term depression (LTD) and depotentiation (i.e. the reversal of LTP) 
(Mulkey et al., 1994; O‟Dell and Kandel, 1994; Staubli and Cheun, 1996), and 
there is a well established pathway by which cAMP activates PKA and 
subsequently inhibit the activity of protein-phosphatase-1 (PP1). This suggests 
that dopamine, which can modulate the cAMP pathway, could affect the storage 
of information that arrives before dopamine (Otmakhova and Lisman, 1998). 
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It was shown that dopamine D1 receptor agonists increased cAMP accumulation 
in a concentration response manner. Moreover, in addition to this concentration 
dependent effect, a time-dependent effect was observed depending on the time 
of tissue preparation post-challenge, i.e. only an effect was seen after 45 min but 
not after 24 h post-challenge. This is in agreement with nicotine impaired long-
term potentiation of GABAergic synapses (Niehaus et al., 2010). 
 
The pharmacological tools used in the present studies have been widely used to 
characterise the functional role of the dopamine D1 receptor, both in vitro as well 
as in vivo paradigms (O‟Boyle et al., 1989; Gessa et al., 1991; Lewis et al., 1998). 
The used prototypical compounds might not be superior to other current available 
ligands, although, these compounds can easily be compared to the ones used in 
the existing literature. In addition to their selectivity for receptor subtypes, 
agonists can also be selective for different intracellular signalling pathways 
coupled to a single receptor subtype. This process is know as „functional 
selectivity‟ (Berg and Clarke, 2006; Urban et al., 2007) and should be taken in 
consideration when interpretating results from in vitro functional data. 
In the literature, SKF-38393 is often referred to as a partial agonist for the 
dopamine D1 receptor. However, signal amplification of second messengers (like 
adenylate cyclase) could also be responsible for the observation of partial 
agonism. It is previously reported that greater receptor occupancy is necessary to 
achieve half-maximal activation of G proteins compared to that of downstream 
effectors, such as described for the adenosine receptor A2C-Gi-adenylyl cyclase 
and the serotonin receptor 5-HT2C-Gq- phospholipase C signalling pathways (in 
CHO cells, Umland et al., 2001; Cussac et al., 2002a,b). Taken together, these 
results suggest that SKF-38393 could probably exhibit full agonist properties at 
the level of adenylyl cyclase in our cell (tissue) system. 
As the adenylate cyclase isozymes differ in the parameters that define their 
stimulation and inhibition characteristics, and as various tissues, brain areas, and 
cell types are known to vary in their repertoire of adenylate cyclase isozyme 
populations (Mons and Cooper, 1995), it is likely that dopamine could have 
different regulatory effects on adenylate cyclase activity depending on the tissues 
examined. 
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As previously discussed in Chapter 2, SCH-23390 is generally used as a 
prototypical „selective‟ dopamine D1 receptor antagonist. However, it also has 
high affinity for the serotonin 5HT2 receptor and was found agonist using [
3H]-
phophotidylinositol (PI) accumulation (Ki 9.3 nM, EC50 2.6 nM, Millan et al., 2001). 
The serotonin 5HT2 receptor is functionally coupled to PLC and will results in 
diacylglycerol activation, arachidonic acid and inositol synthesis, but not directly 
to cAMP synthesis. In consensus with previous literature, the serotonin 5HT2 
agonist DOI (2,5-dimethoxy-(4-chlorophenyl)-isopropylamine) was tested in the 
present study and had no effect on cAMP accumulation in the striatum (data not 
shown). Therefore present study is not able to make conclusions about the 
involvement of the serotonin 5HT2 receptor, however showed that SCH-23390 is 
a dopamine D1 antagonist and that the potency of dopamine D1 agonists is 
altered after nicotine sensitisation. This suggests a role for the dopamine D1 
receptor in behavioural sensitisation. Nonetheless, this selectivity fact cannot be 
neglected, as activation of serotonin 5HT2 receptors by SCH-23390 may 
contribute to its functional properties both in animals and in humans, and 
therefore need further research. 
 
Nicotine induced behavioural sensitisation is a complex phenomenon which 
occurs as a consequence of neuroadaptive changes in a number of brain 
systems. Historically, research into behavioural sensitisation was focused solely 
on adaptive changes in dopamine and dopamine receptor signalling. Recent 
literature showed that the behavioural effects of cocaine are a result of the impact 
of cocaine on many different neural receptor systems (i.e. opiodergic, GABAergic, 
serotonigeric, glutamatergic). Furthermore, evidence suggests that the cocaine 
induced changes in behaviour also result from the cocaine‟s impact on many 
ubiquitous intracellular neuronal molecules. 
The present study focused on the dopaminergic system and showed that 
dopamine receptors play an important role in behavioural sensitisation. However, 
additional systems might be necessary to support the dopamine system in its role. 
In particular, but not limited to, the serotonergic system is involved in 
dopaminergic neurotransmission. For example in frontal cortical regions were 
less dopamine transporters are available or in striatal areas were less 
dopaminergic neurones are present as a result of neuropathological disorder (e.g. 
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Parkinson‟s disease), the serotoneric and noradrenergic systems play a key 
regulatory role in dopaminergic neurotransmission. 
Activation of NMDA receptors, localised on dopaminergic cell bodies in the 
ventral tegmental area, may play an important role in the development of 
behavioural sensitisation (Karler et al. 1991; Wolf et al. 1994; Kalivas, 1995; 
Cador et al. 1999). The behavioural changes induced by amphetamine and its 
development of behavioural sensitisation mainly occur via pre and/or post-
synaptic dopaminergic systems (Robinson and Becker 1986; Kalivas and Stewart 
1991; Wolf et al. 1994). FK506 is a potent calcineurin (Proteinphosphatase2B, 
PP2B) inhibitor and acts on these dopaminergic systems. It can enhance 
dopamine release by inactivating calcineurin, which inhibits dopamine release at 
presynaptic sites by inactivating synapsin I (Iwata et al. 1997; Snyder et al. 1998). 
Moreover, it was shown that FK506 attenuated the development of 
methamphetamine induced sensitisation (Tsukamoto, 2001). Additionally, chronic 
nicotine administration produced functional upregulation of ionotropic glutamate 
receptors mediating striatal dopamine release (Risso et al., 2004). 
 
The present findings that SCH-23390 shows a differential effect on nicotine 
induced dopamine release (Figure 3-11) correlates with the in vivo data showing 
SCH-23390 blocks nicotine induced behavioural sensitisation (Figure 2-6). In vivo 
voltammetry and microdialysis are two complementary methods, and both 
methods can even be combined in the same animal (Yang and Michael, 2007). 
However, in some cases in vivo voltammetry is the only or at least the best option 
to answer the questions related to the effects of drugs or their mechanisms of 
action. Furthermore, the combination of simultaneous in vivo voltammetry with 
locomotor activity measurements to study behavioural sensitisation can provide 
more information about the real-time activation pattern of the different 
neurotransmitters and in different brain areas during the different stages of 
behavioural sensitisation (i.e. development, withdrawal and expression). 
 
The FCV technique also has been proven successfully in a wide range of species, 
e.g. rats, mice, guinea pigs, (for review see Michael and Borland, 2007), 
zebrafish (Njagi et al., 2010), and humans (Paul Garris et al., unpublished data). 
It could therefore also be applied to investigate the effect of dopamine following 
behavioural sensitisation in one of these species which will give more insight in 
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the variety and differences in behavioural sensitisation and role of dopamine 
between species. Also a correlation can be made between the role of dopamine 
in preclinical (i.e. animal) and clinical (i.e. human) sensitisation. 
However not described in this thesis, in parallel a novel FCV system (PGSTAT) 
was developed by the author of this thesis in collaboration with EcoChemie B.V. 
(Utrecht, the Netherlands). Recently, the development and validation of the 
PGSTAT within Abbott was finished (manuscript in preparation). Details of this 
system will not be discussed here, however it is noteworthy that the novel 
PGSTAT system has many advantages compared to the currently available 
systems. Therefore, future pharmacological experiments as suggested in this 
thesis should be considered to be performed using this new system. 
 
Methodological considerations 
In vivo locomotor activity showed that there is a certain natural variation within 
the same treatment group. As seen in ex vivo cAMP experiments, it was 
impossible to use only a single rat for an n = 1 ex vivo experiment. To overcome 
this issue, the dissected brain areas from at least four animals within the same 
treatment group were pooled. However, using ex vivo FCV this is not possible as 
only a single brain slice from one animal can be measured at the time. One 
solution to overcome this issue is to challenge and measure locomotor activity of 
one animal at the time. 
 
Herein it is hypothesised that the dorsal striatum is a functional, multidimentional, 
frequency-dependent, signalling filter which, in the case of a disordered system 
(e.g. a neuropsychiatric disorder or behavioural sensitisation), becomes 
imbalanced. Secondly, it is hypothesised that the dopaminergic system is 
necessary in behavioural sensitisation, and moreover, that its mechanism is not 
limited to a specific dopamine receptor subtype but underlies receptor synergy 
(e.g. dopamine D1/D2 or D1/D3 combinations). Thirdly, behavioural sensitisation 
affects the frequency-dependent filtering of the striatum, resulting in a dopamine 
release deficiency and receptor synergism.  
One challenge of investigating behavioural sensitisation in humans is the very 
difficult diagnosis of (early) development of behavioural sensitisation in the clinic, 
as the symptoms are just to become visual when sensitisation is already 
developed. To date, there are no biomarkers for the development of behavioural 
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sensitisation available yet. Therefore we are currently limited to treatment of 
symptoms and therefore this study focused on the expression of sensitisation.  
Recent evidence suggests that the cognitive symptoms of nicotine withdrawal 
and the cognitive symptoms of attention deficit hyperactivity disorder (ADHD) 
may share neural correlates. One could suggest that therapeutics ameliorates 
ADHD symptoms may also ameliorate nicotine induced withdrawal symptoms. 
This hypothesis suggests they share a common mechanism, putatively 
behavioural sensitisation. It is suggested that behavioural sensitisation might be 
the trigger of the hypofunctionality of the mesolimbic dopamine system (ventral 
tegmental area  nucleus accumbens) following chronic psychostimulant 
administration and can be used as a model for (drug) addiction. A better 
understanding of behavioural sensitisation could then improve anti-addiction 
therapies and improve drug discovery by excluding addictive properties of new 
medications. Moreover, investigating changes that persist after drug 
discontinuation could be fundamental to understand the mechanisms underlying 
craving, relapse and withdrawal symptomes.  
Preclinical data suggested a putative role for dopamine D1 receptor mediated 
medication, however, when considering potential dopaminergic drug therapies for 
neuropsychiatric disorders a major concern is the liability for abuse of these 
pharmacotherapies by themselves. Besides that behavioural sensitisation can 
help to understand several disorders, it also could improve current medications. 
For example, the current treatment of Parkinson‟s disease is based on chronic L-
DOPA administration. It is known that after a few years the L-DOPA will induce 
dyskinesia. In rodents, chronic L-DOPA treatment has been shown to induce 
behavioural sensitisation (e.g. Kalda et al., 2009) and affects the cAMP pathway 
by increasing cyclic AMP response element-binding (CREB) protein 
phosphorylation in striatal neurones (Cole et al., 1994; Oh et al., 2003). By 
understanding the mechanism underlying behavioural sensitisation, also currently 
used pharmacotherapies can be improved and negative side effect can be 
excluded. 
It is hypothesised that sensitisation to life events is the core feature of depressive 
disorders (Patten, 2008; Myin-Germeys et al., 2005). This could be explained by 
the phenomenon of cross-sensitisation. Previous literature showed that cross-
sensitisation can occur when a challenge is give by a compound different to the 
compound by which the sensitisation was developed, i.e. other factors can trigger 
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the „disorder‟. This is also suggested in case of life events triggering depression 
and therefore, it is extremely difficult to target the original cause(s). 
 
Neuropsychiatric disorders like schizophrenia, psychosis, depressive disorders, 
and bipolar disorders are major health and socioeconomic problems. Despite the 
extensive research and drug discovery efforts currently available (pharmaco-) 
therapies offer only modest efficacy. The main difficulty challenging drug 
discovery is the unknown mechanism(s) responsible for these neuropsychiatric 
disorders. Psychostimulants, for example amphetamine, cocaine and 
methylphenidate, are widely used as pharmacotherapies in medical treatments 
and abused as recreational drugs. The chronic administration of these drugs are 
known to cause addiction, psychosis and other neuropsychiatric disorders, as will 
be described in more detail below. Moreover, many of the currently used 
medicines also induce behavioural sensitisation and the development of severe 
side effects including addiction. However, these medicines are still in use as no 
better medication is available at this time. A few examples of these prescript 
clinical medicines are amphetamine for the treatment of attention deficit 
hyperactivity disorder or ADHD, traumatic brain injury, and narcolepsy, 
methylphenidate (Ritalin) for the treatment of ADHD, morphine as an analgesic, 
methamphetamine for the treatment of obesity and depression. Moreover, 
chronic treatment with for example, classical antipsychotic agents (i.e. dopamine 
receptor antagonists, used to treat diseases like schizophrenia and Parkinson‟s) 
has been associated with the undesirable complication of tardive dyskinesia (an 
involuntary hyperkinetic syndrome) and anhedonia (a mood disorder like 
depression) and withdrawal from the treatment often results in incurring relapse 
psychosis. 
The many research efforts over the last few decades to elucidate the 
mechanisms underlying neuropsychiatric disorders are pointing towards a 
common mechanism called behavioural sensitisation. Behavioural sensitisation is 
hypothesised to underlie many neuropsychiatric disorders including, but not 
limited to, Pakinson‟s disease (PD), schizophrenia, psychosis and mania (Segal 
et al., 1981; Fibiger, 1991; Post, 1992), stimulant induced psychosis (Angrist, 
1983; Tadokoro and Kuribara, 1986), dyskinesia, attention deficit hyperactivity 
disorder (ADHD), obsessive compulsory disorder (OCD: Szechtman et al., 2001), 
bipolar disorders (Post, 1992), depressive disorders (Patten, 2008), (emotional-) 
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pain, and drug addiction (Robinson and Berridge, 1993). While behavioural 
sensitisation is of great interest, its mechanism of action is not yet fully 
understood. 
 
7.2 CONCLUSION 
 
Information from genetics, neuropathology, brain imaging, and basic 
neuroscience has provided insights into understanding the aetiology of 
neuropsychiatric disorders, however remains still not fully understood. After the 
discussion of the neurochemical, behavioural and clinical perspectives the overall 
conclusion suggests a putative common mechanism with behavioural 
sensitisation. The integration of methodologies from multiple disciplines such as 
behavioural neuroscience, molecular pharmacology, and neurochemistry, 
enables a powerful approach for investigating complex neuropsychiatric disorders. 
This thesis presents a successful multidisciplinary approach which resulted in 
more information about the mechanism underlying behavioural sensitisation and 
showed an important role for the dopamine D1 receptor. Furthermore, the 
described approach provides a successful framework to study behavioural 
sensitisation which also can be used for future studies and ultimately the 
elucidation of the mechanism(s) underlying neuropsychiatric disorders. 
 
The data presented here provides biochemical evidence that dopaminergic 
receptors exist on cells in the dorsal striatum that possess receptors for 
neuromodulators known to be important in regulating basal ganglia activity, as 
inducing and antagonising locomotor activity sensitisation. This information from 
behavioural and subsequent ex vivo biochemical studies, combined with clinical 
pharmacological studies might ultimately be useful in describing a role for 
dopaminergic neurones in behavioural sensitisation and their relation to disease 
states resulting from basal ganglia dysfunction. To the extent that behavioural 
sensitisation reflects underlying neuroadaptations that are related to 
neuropsychiatric disorders, present findings suggest that pharmacotherapies 
using dopamine D1 ligands could be effective in the treatment of behavioural 
sensitisation related diseases as, for example, psychosis, bipolar diseases and 
schizophrenia. 
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In conclusion, the present results suggest that selective antagonism of dopamine 
D1 receptors can block the expression of nicotine induced behavioural 
sensitisation. From a mechanistic perspective, the results of the present study 
suggest that sensitisation induced by chronic nicotine administration occurred as 
a result of neuroadaptations, the enhanced response of neurones in the dorsal 
striatum to dopamine D1 receptor activation. This suggests that the mechanism 
involved in the expression of behavioural sensitisation to nicotine is the same to 
those involved in amphetamine or cocaine induced behavioural sensitisation. 
However, additional studies will be required to examine other putative 
neuroadaptations and elucidate the exact mechanism. The results of the present 
study, along with previous literature, suggest that a dopamine D1 ligand 
pharmacotherapy has potential utility in the treatment of neuropsychiatric 
disorders. Although the exact mechanism is still not fully understood, the 
accumulating findings will elucidate the exact molecular mechanism of 
behavioural sensitisation. 
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